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Abstract 
 
Atheromas contain hypoxic areas which upregulate HIF1α expression, promoting angiogenesis 
and unstable lesion formation. Simvastatin stabilises atheromas through preventing rupture and 
neovascularisation. Atheromas express matrix metalloproteinase 14 (MMP14) which degrades 
matrix proteins and promotes neovascularisation. MMP14 is upregulated by hypoxia and 
contains Hypoxic-Inducible Factor (HIF) recognition sequences (5’-RCGTG-3’). My project sought 
to investigate if HIF1α interacts with the MMP14 promoter to enhance MMP14 expression, and 
whether simvastatin attenuates this effect, inhibiting angiogenesis.  
 
Immunostaining of atheromas identified MMP14 and HIF1α localisation. Protein-DNA binding 
assays were performed on human umbilical vein endothelial cells (HUVECs) and showed HIF1α 
bound to the MMP14 promoter in hypoxia, which was significantly decreased by simvastatin. To 
assess gene regulation, a human MMP14 promoter-firefly luciferase reporter construct was 
transfected into C166 endothelial cells alongside HIF-overexpression plasmids and mutations of 
the MMP14 promoter region at HIF recognition sequences. Overexpression of HIF1α and HIF1β 
increased MMP14 activity which was abolished by introducing the mutations and diminished by 
simvastatin in a HIF-dependent manner. Immunoblots, flow cytometry, scratch assays and 
bromodeoxyuridine incorporation showed HIF1α knockdown and simvastatin significantly 
attenuated hypoxia upregulated MMP14 expression, migration and proliferation in a HIF1α-
dependent manner.  
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Angiogenesis was assessed using in vivo sponge angiogenesis assays and ex vivo aortic ring 
assays cultured in hypoxia or normoxia, with or without 0.1µM simvastatin, and MMP14 
inhibitor, utilising HIF1αfl/flTie1Cre+ and wildtype littermates. Simvastatin perturbed 
angiogenesis through decreasing MMP14 expression in a HIF1α-dependent manner.  
 
The results show hypoxia upregulates MMP14 through HIF1α interaction with the MMP14 
promoter. Simvastatin attenuates MMP14 upregulation which reduces HIF1α:MMP14 promoter 
interaction. HIF1α knockdown and simvastatin treated HUVECs show less migration and 
proliferation, equivalent to that of MMP14 inhibition. Simvastatin inhibits neovascularisation in 
a HIF1α-dependent manner. These results suggest simvastatin may stabilise atheromas through 
inhibiting MMP14 driven angiogenesis which may have further implications in the treatment of 
atherosclerosis.  
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1. Introduction 
1.1 The Vascular System 
 
The cardiovascular system is composed of the heart, vasculature, and the blood and is vital for 
transporting nutrients and oxygen to target tissues, removing metabolic waste products, and 
delivering immune responses to affected areas of the body 1. The vasculature is a closed loop 
consisting of the arteries, veins and capillaries, which continually circulate blood throughout the 
body 1. The different types of vessel are classified by their size and location within the 
vasculature 2.  
 
The cardiovascular system is divided into the pulmonary and systemic circulation. The 
pulmonary circulation transports deoxygenated blood from the heart to the lungs via the 
pulmonary arteries, where the blood is oxygenated and returned back to the heart through the 
pulmonary veins. The systemic circulation carries oxygenated blood from the heart to the cells, 
tissues and organs of the body.  
 
The aorta is the largest artery and originates from the left ventricle, from here it branches into a 
network of arteries, which once at their target tissue branch into the smallest arterioles 2.  
Capillaries link the arterioles to venules which take the deoxygenated blood from the tissues 
and merge into small veins, delivering deoxygenated blood to the venous side of the circulation. 
The small veins merge into larger veins until ultimately they converge into the two largest veins, 
the venae cavae, where they empty into the right atrium of the heart 2. 
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Both the venous and the arterial blood vessels have the same basic structure, with an outer 
layer known as the tunica externa, a middle layer or tunica media, and an inner layer known as 
the tunica intima. However the size and organisation of these layers differs between these 
types of vessels (Fig. 1).  
 
The tunica externa, also known as the tunica adventitia, is comprised almost entirely of fibro-
elastic connective tissue which provides structural support to the vessel 3. The predominant 
structural proteins are collagen and elastin fibres which allow for the strength and elasticity that 
the vessels require. Longitudinal smooth muscle cells are also commonly located in this layer.  In 
the larger of the arteries and veins the tunica adventitia contains its own blood supply, the vasa 
vasorum, which provides nutrients to cells that would be too far from for the nutrients and 
gases to move via diffusion. The difference between veins and arteries arises from the relative 
thickness of the tunica externa in relation to the overall diameter of the vessel. In veins and 
venules this layer comprises the majority of the vessel wall, whereas in arteries and arterioles it 
represents approximately half of the overall thickness 2. 
 
The tunica media is the muscular layer of the vessel and is comprised, in large, of smooth 
muscle cells which are arranged circularly around the lumen of the vessel, as well as elastin 
fibres which allow the vessels to stretch. The tunica media tends to be more highly organised 
and thicker in larger arteries as they play a vital role in the transport of large quantities of blood 
3. The external elastic laminar coats the thick layers of smooth muscle cells and provides 
structural support 3. The medial layer within the venous circulation is a lot thinner and less 
organised than the arterial vessels, leading the veins to have thinner, less rigid walls which allow 
them to hold a larger proportion of circulating blood 2.  
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Fig. 1 – Schematic showing the basic structure of the arteries and veins. Adapted from Servier 
Medical Art 4 
 
Arteries contain a further band of elastic fibres which wraps the innermost layer, the tunica 
intima. The tunica intima is the thinnest layer of the vasculature and is characterised by its 
single endothelial cell layer which lines the lumen of the vessel and is mounted onto the basal 
lamina 3. Beneath the basal lamina is a network of fibro-elastic connective tissue which allows 
support and flexibility of the endothelial cells 3. The veins differ from the arteries as they 
contain valves, which protrude into the lumen of the vessel and prevent the backflow of blood 
(Fig. 1).  
 
The vascular endothelium forms the innermost layer of the entire vasculature in both blood 
vessels and lymphatic vessels 2. It plays an important role in many physiological functions, 
including controlling vasomotor tone, trafficking of blood cells, angiogenesis, formation of 
connective tissue, and in innate and adaptive immunity 5, 6. 
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1.2 Endothelial Cells  
 
Endothelial cells are a highly metabolically active cell type that provide a semipermeable barrier 
between the blood and the vessel wall which is vital for the transport of nutrients and 
regulating the tissue fluid balance.  They are especially important in allowing the transfer of 
macromolecules and fluid between the interstitial space as loss of function can lead to 
inflammation 7.  
 
Endothelial cells are typically flat, with a thickness which varies from less than 0.1µm in 
capillaries and veins to 1µm in the aorta 5. They are a heterogeneous cell population in that they 
differ in morphology and function depending on their location in the vascular system. This can 
be seen by comparing endothelial cells in the smallest arterioles and venules, where the 
endothelial cells are longer and narrower in the arterioles in comparison to the venules 2. They 
are heterogenous in both a structural and a molecular sense with evidence showing that 
different proteins are expressed in different vascular beds 5,8. An example of this can be seen in 
the expression profile of von Willebrand Factor (vWF) which has low expression in capillaries 
and high expression in the aorta 8.   
 
The function between arterioles and venules also differ in that the arteriolar endothelial cells 
major role is controlling vascular tone, whereas endothelial cells from post-capillary venules are 
the primary site of leukocyte trafficking 2. It has been shown that endothelial cells cultured from 
different locations throughout the vasculature have different permeabilities. The lowest 
permeability is attributed to the arterial endothelial cells, with the highest seen in the 
microvessels, followed by the venule endothelial cells 7. There are several molecules known to 
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increase blood vessel permeability including thrombin, bradykinin, and oxidants. In addition to 
this there are molecules that stabilise endothelial cell junctions, therefore decreasing 
permeability. These molecules include angiopoietin-1 and sphingosine-1-phosphate.  
 
As well as having a role as a permeable and physical barrier the endothelial cells also have roles 
in endocrine regulation with the ability to produce and release a host of growth factors 
including nitric oxide, endothelin and prostaglandins. The endothelial layer is able to sense 
changes in the bloods flow rate, blood pressure and concentration of humoral substances. This 
allows the quick release of vaso active substances that can respond to dynamic changes in the 
blood 9.  
 
The vascular endothelium is supported by the extracellular matrix (ECM) which provides an 
essential scaffold for organising endothelial cells into blood vessels. The ECM is a dynamic 
structure which has multiple roles in cell support, adhesion and signalling and influences on cell 
migration, proliferation, differentiation, polarity and survival 10. The ECM is comprised of many 
structural proteins including the collagens, laminins, fibronectins, nidogen, proteoglycans and 
elastins.   
 
Endothelial cell adhesion to the ECM is required for proliferation, migration, morphogenesis, 
survival, and ultimately the stability of the vasculature 11.  A disruption to the normal 
physiological functioning of the endothelium can lead to the development of a number of 
pathological conditions including cancer and cardiovascular disease. 
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1.3 Cardiovascular Disease 
 
Cardiovascular diseases (CVD) comprise the major disorders of the heart and the arterial 
circulation 12 and remain the leading cause of death worldwide, with over 17.3 million deaths in 
2008 being attributed to CVD 13. They are a major public health concern globally with impaired 
quality of life, loss of independence and high mortality rates 12. In the UK the burden of CVD on 
the economy exceed £30 billion per annum, with NHS costs alone being higher than £14 billion, 
and predicted to rise further 14. It is predicted by the World Health Organisation that by 2030, 
almost 23.3 million people will die from CVDs and they will remain the single leading cause of 
death globally 15. 
 
There are several risk factors that are associated with the likelihood of developing CVD. The 
major risk factors for developing CVD include tobacco use, high blood pressure, raised blood 
glucose levels, physical inactivity, obesity and abnormal lipid levels 16. Most of these risk factors 
can be incurred due to behavioural choices and can be remedied through altered lifestyle 
choices. However, other factors, such as ethnicity, gender and age are acquired or inherited, in 
turn influencing our response to environmental risk factors. Sex and age are major risk factors 
with CVD mortality. Incidence and prevalence rates are increasing steeply, roughly doubling 
each decade, with males likely to develop CVD ten years younger than females 14.  
 
Cardiovascular diseases affect the heart and blood vessels and include hypertensive disorders, 
ischaemic heart disease, cerebrovascular disease and peripheral vascular disease 13. Most CVDs 
are the result of reduced blood flow to the heart, brain or peripheral tissues caused by the 
formation of fatty plaques, or atheromas, which silently build up in different arteries during 
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adult life (Fig. 2).  The atheromas begin as fatty streaks, composed of fat-loaded blood cells, 
which gradually progress, becoming larger and more complex, turning into intermediate lesions, 
which in turn, form a fibrous plaque. This multifactorial process is known as atherosclerosis and 
can be caused by impaired endothelial cell function, increase in LDL-cholesterol, inflammation 
of vasculature, and influx of leukocytes into the vessel wall 17. The atheromas eventually cause 
obstructions and narrowing of the arteries and can trigger a local thrombosis, completely 
blocking the blood flow, resulting in a heart attack, stroke or ischaemic leg 14. The thrombus can 
develop in two ways, either on the surface of the plaque, due to endothelial cell degradation, or 
within the plaque itself after plaque rupture 18. 
 
 
Atherosclerosis has a major impact on society and is responsible for a large proportion of CVDs. 
In 2008, out of the 17.3 million cardiovascular deaths, heart attacks were responsible for 7.3 
million deaths and strokes were responsible for 6.2 million deaths 13. As discussed above, there 
are several risk factors which lead to the progression of atherosclerosis including the use of 
 
Fig. 2 – Photomicrographs of non-diseased (A) and atherosclerotic carotid arteries (B) The 
disease vasculature is characterised by the formation of the fatty plaque, indicated by the red 
arrows (Adapted from Agrogiannis et al., 2013) 19  
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tobacco, an unhealthy diet, diabetes, physical inactivity, poverty, obesity, the male gender and 
genetic disposition 13. Unhealthy behaviours can lead to metabolic and physiological changes 
including hypertension, obesity, diabetes and dyslipidaemia, which in turn, induce endothelial 
dysfunction through mechanisms including free radical oxidation and haemodynamic strain 20 
causing damage to the blood vessels due to the progression of atherosclerosis 13. 
 
 
1.4 Formation of the Plaque 
 
During atherogenesis there is a defined series of morphological and biological changes within 
key players including inflammatory cells, low density lipoprotein (LDL), cholesterol, and smooth 
muscle cells 17. These changes contribute to the formation of the plaque which gradually 
enlarges, with increased inflammation, and leads to blockage of the vessel (Fig. 3).   
 
 
 
 
Fig. 3 – The progression of atherosclerosis. As inflammation increases the plaque thickens 
leading to almost complete obstruction of the vasculature. Adapted from Servier Medical Art 4 
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The endothelium is a cell monolayer which allows the transport of nutrients between the blood 
and the tissues. A force that is acting on the endothelial cells is fluid shear stress, which affects 
the morphology of the cells. It has been seen that cells in the tubular regions of arteries, where 
the fluid shear stress is weaker, are ellipsoid in shape and aligned in the direction of the blood 
flow. When the blood flow is disturbed, for example at branch points in the artery, endothelial 
cells tend to be more polygonal in their shape without a particular orientation 17. The 
endothelium in this area is weakened and becomes increasingly permeable to lymphocytes and 
monocytes. This happens, for example, when there is an increase in LDL cholesterol and other 
macromolecules, making the area vulnerable for lesion formation 13. The extent of effect from 
differences in shear stress tension can be seen clearly in the regulation and expression of genes 
where it has been shown that in a porcine model 764 genes are differently expressed in low 
shear stress regions compared to high stress regions 21. The differently expressed genes have 
key roles in apoptosis and senescence, and have been shown to contribute to the formation of 
atherosclerosis 22.  
 
One of the factors contributing to the formation of atherosclerotic plaques are autoimmune 
responses involving cholesterol and heat shock proteins (HSP), particularly HSP60 23. HSP60 is 
upregulated in response to infection, and activates both the innate and adaptive immune 
systems. Under stressful conditions, endothelial cells translocate HSP60 to the cell surface. A co-
expression of both adhesion molecules, such as intercellular adhesion molecule 1 (ICAM-1) and 
vascular cell adhesion molecule 1 (VCAM-1) 24, and HSP60 leads to a reaction for attachment 
and destruction of endothelial cells by the immune system against HSP60. Following this, 
intimal infiltration by mononuclear cells leads to the plaque formation 23.  
 
P a g e  | 24 
 
Activated T cells, in particularly CD4, are the first cells to infiltrate into the arterial intima and 
this occurs early on in the formation of the lesion 23. Following this, macrophages invade into 
the vessel wall which is a primary event toward the eventual formation of the atheroma 25. The 
phagocytes engulf LDL via endocytosis and convert into foam cells with cytoplasmic, membrane 
bound lipid droplets 26. The uptake of LDL particles by macrophages is mediated by a group of 
receptors that recognize a wide array of ligands 17. Foam cell formation is mediated by acyl-
coenzyme A:cholesterol-acyltransferase (ACAT) which esterifies cholesterol and allows more 
efficient transport into macrophages 27. In addition to esterification the formation of foam cells 
requires the LDL to be highly oxidised by reactive oxygen species (ROS) which are produced by 
endothelial cells and macrophages as well as several enzymes.  Oxidised LDL is less susceptible 
to degradation by the lysosome of macrophages and therefore a foam cell is formed 20. Even 
when the LDL is minimally oxidised by oxidative waste a pro-inflammatory activity can be seen, 
which can go unnoticed by macrophages 17. The minimally oxidised form of LDL stimulates the 
endothelial cells to produce pro-inflammatory adhesion molecules and growth factors which 
recruit circulating monocytes and lymphocytes to the vessel wall of the lesion 17. This 
interaction has also been attributed to the intimal calcification of atherosclerotic plaques, which 
can further reduce the elasticity of the vasculature 28. 
 
A number of adhesion molecules, including selectins, aid in the first process of migration though 
the endothelial surface by binding to the leukocytes and facilitating leukocyte rolling along the 
surface 17. The macrophages, as well as the endothelial cells and smooth muscle cells, express 
CD40 which produces inflammatory cytokines, adhesion molecules and proteases upon binding 
with its ligand, CD40L. This interaction is important for the production of ECM and for the 
migration and proliferation of smooth muscle cells 17. 
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Once through the endothelial cell barrier, the inflammatory cells and LDL migrate into the sub-
endothelial matrix 13. The transport and retention of LDL are increased in the areas that are 
vulnerable for plaque development, which is greater when the levels of circulating LDL are 
increased 17. Lipid accumulation in the plaque generates ROS which can lead to endothelial 
dysfunction and an increase in permeability, which in turn promotes more lipoprotein migration 
20. LDL can undergo modifications including oxidation, lipolysis, proteolysis and aggregation, 
which can all lead to increased local inflammation as well as to the formation of foam cells.  The 
foam cells form through interactions between the LDL and macrophage receptors 17.  
 
A necrotic core forms as the macrophages and foam cells begin to die, which contributes to 
further inflammation and stress of the plaque as well as proteolytic breakdown 29. The necrotic 
core gradually increases in size due to increased infiltration of foam cells and lipids from broken 
down erythrocytes 25. Smooth muscle cells from the media layer of the vessel wall, migrate to 
the necrotic core and secrete a collagen-rich matrix which covers the site with a fibrous cap 20. 
Cells and lipids continue to gather in the atheromatous plaque which enlarges and protrudes 
into the vessel lumen. As the process continues the fibrous cap thins and the endothelial 
surface starts to split and crack making it liable to rupture 17. When the plaque ruptures, a 
thrombus forms which if large enough can block the blood vessel. This leads to clinical events 
such as a heart attack or a stroke if this occurs in a coronary or cerebral artery, respectively 13. 
The thrombus forms when lipid fragments and cell debris from the plaque are released into the 
vessel lumen, exposing them to thrombogenic agents on the endothelial surface.   
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1.5 American Heart Association Classification 
 
The development of atherosclerotic plaques can be classified according to the American Heart 
Association (AHA) system 30. This system aims to categorise the stages of the lesion by the 
components and histology of the vessel. Trying to classify plaques into a numerical system can 
be a challenge as plaques are heterogeneous with respect to the amounts of their different 
components 18. Other systems have been developed which aim to characterise the plaques by 
their morphological features 31, but the AHA numerical classification is a widely accepted 
classification.  
 
The first stage of the development of the atherosclerotic plaque is the type I lesion, or initial 
lesion, which is when the lipid deposits first become microscopically and chemically detectable 
but are not visible by the naked eye. Macrophages and foam cells are the key cellular 
components of these lesions which are most frequent in infants and children. The lesions have 
been seen in adults that have minimal atherosclerosis or in locations that are resistant to lesion 
formation. The initial changes in the vessel intima are minimal with small isolated groups of 
foam cells infiltrating the intimal space (Fig. 4) 32.  
 
Type II lesions are when the lesion is first identifiable by yellow coloured streaks or spots on the 
intimal surface of the arteries. The lesion is not entirely defined by the fatty streak but also by 
its microscopic composition. They contain a greater amount of foam cells than the type I lesions 
which are arranged in layers rather than as isolated cells. As well as foam cells they also contain 
more macrophages and also smooth muscle cells containing lipids and T lymphocytes. Type II 
lesions are common in the aorta with 99% of children between the ages of 2 to 15 years having 
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these lesions 32. They have been noted to appear in coronary arteries around puberty whereby 
approximately 65% of children between 12 to 14 years of age have either type I or II lesions 33. 
 
Type III lesions are a stage that bridges the gap between type II lesions and atheromas, and are 
therefore often referred as intermediate lesions or preatheromas. There is identifiable adaptive 
intimal thickening and its histologically distinguishable features include extracellular pools of 
lipid droplets and particles which form among the layers of smooth muscle cells. The lipid pools 
lie below layers of macrophages and foam cells and push smooth muscle cell layers apart. Type 
III lesions can be distinguished from type II lesions by their increased free cholesterol, fatty acid 
and other lipid derivatives (Fig. 4) 32. 
 
Type IV lesions, or atheromas, contain a lipid core which is a dense build-up of extracellular 
lipids which occupies a large area of the intima 34. The type IV lesions are the first lesions that 
are classified as advanced lesions as they cause this disorganisation and thickening of the 
arterial wall. Although the vascular wall is thickened the lumen of the blood vessel is not always 
narrowed. The lipid core causes great intimal disorganisation with smooth muscle cells and 
intracellular matrix dispersing as well as being replaced by extracellular lipids. Calcification 
occurs in type IV lesions which can be seen to affect the smooth muscle cells as well as the lipid 
cores 34.  
 
Between the lipid core and the endothelial surface the intima contains macrophages, foam cells 
and smooth muscle cells. Around the periphery of the lipid core macrophages, foam cells and 
lymphocytes are commonly more densely packed, which make it more liable to rupture. The 
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death of macrophages which invade the lipid pool is responsible for the conversion of intimal 
thickening to the start of the fibroatheroma (Fig. 4) 25. 
 
The lesion can progress from a type IV lesion to a type V lesion with a marked increase in fibrous 
connective tissue formed. This lesion is known as a fibroatheroma due to the increased fibrous 
connective tissue infiltrating the atheroma and surrounding the lipid cores (Fig. 4) 34. This 
further distorts the normal cellular and intercellular matrix structure of the intima. The 
lymphocytes, foam cells and macrophages are no longer limited to the intima in type V lesions 
and start to migrate into the media and adventitia. Smooth muscle cells in the media are also 
affected and being lesser in number and disarranged.  
 
The clinical manifestations leading to morbidity and mortality from atherosclerosis are mainly 
due to type IV and type V lesions which have disruptions in the surface of the endothelium, or 
haemorrhage within the plaque. This leads to thrombogenic agents coming into contact with 
the plaque components, forming a thrombus and blocking the arteries 34. When this occurs the 
lesion is classified as a type VI, or complicated lesion. The defining features of type VI lesions are 
one or more, of a surface defect, haematoma, or thrombosis. This means that the type VI lesion 
may not necessarily progress from a type V but may develop straight from a type IV lesion 30. It 
is also noted that the lesions may themselves also block the vessel and produce a clinical event 
without developing into a type VI lesion (Fig. 4) 30 
 
  
 
Fig. 4 - The progression of the atheroma showing approximate AHA lesion stage and the components of the atherosclerotic plaque.  
Adapted from Servier Medical Art 4 
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1.6 Hypoxia in the Plaque  
 
Evidence has proved that hypoxia plays an important role in the pathogenesis of many major 
diseases, with increased roles seen in diseases such as, inflammatory diseases, heart disease, 
cancer and wound healing 35. It has also been shown that hypoxia is involved in endothelial 
dysfunction, typically in severe hypoxia 36.    
 
It has long been thought that hypoxia in the plaque has a key role in plaque progression. The 
luminal blood and the vasa vasorum of the adventitia provide the oxygen and nutrients for the 
intima and media of the artery wall 37. As the plaque progresses and thickens the diffusion of 
oxygen is impaired. Hypoxia occurs in vessel walls where the maximal oxygen diffusion limit 
exceeds 200µm 38. The intimal thickness alone of advanced atherosclerotic lesions have been 
found to be far greater than this limit which results in areas of the plaque becoming hypoxic 39. 
In most lesions there is a hypoxia-negative rim of around 100 to 250µm which borders the 
lumen of the vessel 39.  
 
It is not just the diffusion limit of oxygen which causes areas of the plaque to become hypoxic 
but the increased demand of oxygen from metabolically active inflammatory cells which 
accumulate in the core of the lesion 39. It is therefore commonly the macrophage and foam cell 
rich regions that show the highest levels of hypoxia 40. Although hypoxia is commonly present in 
macrophages and foam cells, not all of them are hypoxic. However some foam cells are hypoxic 
even though they lie within the oxygen diffusion capacity 39. Interestingly, the formation of 
foam cells and increased inflammation are promoted by hypoxia 37. 
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Metabolism in the plaque can result in the generation of ROS through the inefficient use of 
oxygen by the mitochondria during oxidative phosphorylation 41. These ROS cause cell 
dysfunction and death through oxidising cellular lipids, proteins and nucleic acids 42. As well as 
causing cell dysfunction, an increase in ROS under hypoxic conditions is required for the 
activation of the master regulator of oxygen homeostasis HIF (Hypoxia-inducible Factor) 42. 
 
1.7 Hypoxia-Inducible Factor  
 
The HIF complex of proteins were discovered in 1991 when studies on the erythropoietin gene 
lead to the identification of a transcriptional regulator in hypoxic conditions 43,44. Upon 
purification of the protein, it was discovered that HIF1 exists as a heterodimeric protein 
composed of two different subunits, a 120kDa HIF1α unit and a 91-94kDa HIF1β subunit 45. 
These proteins belong to the basic-loop-helix per-aryl hydrocarbon Sim protein nuclear 
translocator family 46. Interactions between the two basic-loop-helix domains leads to 
dimerization, which stabilises the protein and allows the units to bind to the hypoxia response 
element (HRE) (5’-RCGTG-3’) DNA consensus sequence 46. The HIF1β subunit is constitutively 
expressed and is not affected by hypoxia 47, but the HIF1α subunit is highly regulated by oxygen 
levels. HIF1α is continually synthesised but is rapidly degraded with a half-life of around 5 
minutes in normoxic conditions 48. If stabilised HIF1 is able to bind to other coactivators, p300 
and CBP, to form the HIF response complex.  The HIF response complex targets many biological 
processes and also upregulate the prolylhydroxylases (PHDs), acting as a negative feedback 
loop. This leads to the attenuation of HIF in prolonged hypoxic conditions and sets a new 
oxygen threshold for the activation of HIF 49.  
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In most adult tissues oxygen concentrations range from 3% to 5% and when any decrease is 
seen a graded response to the hypoxic conditions is observed 35. These concentrations are 
substantially less than the ambient air, 21% oxygen, and or in a main artery, ~13% 36.  The 
expression of HIF1α is only upregulated at the protein level by hypoxia as there is no effect of 
hypoxic conditions on HIF1α mRNA 50.  
 
There are other isoforms of HIF1α, HIF2α and HIF3α, which are able to compensate for each 
other in knock-down experimental conditions 51. The isoforms also have self-regulatory roles 
through either inhibiting or promoting the other isoforms expression, which can be shown by 
HIF1α expression increasing and HIF2α decreasing when HIF3α is silenced 52. 
 
HIF2α was discovered by searching for proteins that shared similar homology to HIF1α 53 and 
was shown to be upregulated in murine endothelial cells. Furthermore, it was seen to regulate 
VEGF, glycolytic enzymes and other proteins governed by the HRE sequence 53. HIF2α differs to 
HIF1α in its expression pattern, showing a more tissue specific pattern rather than the 
ubiquitous expression of HIF1α. HIF2α is primarily expressed in endothelial cells, kidney and 
lung epithelial cells, bone marrow macrophages, as well as cells derived from neural crest tissue 
during development 54. HIF2α expression is controlled by a similar oxygen gradient response 
involving FIH and the PHDs as HIF1α, although recent evidence has shown that an iron 
responsive element (IRE) is also present and controlled by an iron regulatory protein (IRP). 
Depending on the amount of cellular iron present, IRP can prevent HIF2α translation, which 
differs to the regulation seen in the other HIFs.  
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HIF3α was identified in 1998 through the cloning of a cDNA fragment that contained 61% 
homology to the hypoxic responsive domain of HIF1α 55. HIF3α shows marked differences to the 
other HIFs in the lack of a transactivation domain 55 and therefore does not form the active HIF 
transcription factor with HIF1β 56. Unlike the other HIFs, HIF3α has no known activation role and 
instead it is believed to be a negative regulator of HIF transcription 56. 
 
Although the different HIF isoforms are closely related they all have their own distinct roles in 
controlling gene expression. It is widely accepted however that HIF1α is the most important 
isoform for hypoxic control of genes 52.  
 
1.7.1 Hypoxia-Inducible Factor 1 Alpha 
 
 
HIF1α is a downstream activated molecule of the phosphatidylinositol 3-kinase (PI-3-kinase) 
pathway and is also known to be activated via the mitogen activated protein kinases (MAPKs). 
HIF1α is activated through phosphorylation by the p42 and p44 MAPKs  in response to hypoxia, 
which also enhance the transcriptional activity of HIF1 57.  Additionally, HIF1α is also 
upregulated by the PI-3-kinase pathway via a post-transcriptional mechanism 58.   
 
In normoxia there are two identified ways in which HIF1α is degraded using hydroxylation and 
ubiquitinylation 59. The first is the hydroxylation of HIF1α at two proline residues (Pro-402 and 
Pro-564) in the oxygen-dependent degradation domain. This promotes the interaction with the 
von Hippel-Lindau ubiquitin ligase complex (VHL) which polyubiquitinylates HIF1α and targets it 
for degradation by the proteasome (Fig. 5) 59. The second method involves β-hydroxylation of 
P a g e  | 34 
 
an asparagine residue (Asn-803) which inhibits the interaction of HIF1α with its co-activators 
p300 and CBP (Fig. 5). This hydroxylation of HIF1α is catalysed by factor inhibiting HIF (FIH) at 
the asparagine residue and by PHDs at the proline residues. The PHDs are termed the 
prolylhydroxylase domains enzymes (PHD1, PHD2 and PHD3) 59. Each of the PHDs acts to 
suppress HIF activity but PHD2 has been found to have more activity on HIF1α than the other 
PHDs 59. It has been found that the PHD enzymes bind the VHL complex through an interaction 
with the tumour suppressor LIMD1 which enables HIF1α to be effectively degraded 60.  
 
The prolyl hydroxylases are dependent on oxygen for their activation and therefore their action 
is reduced in hypoxic conditions 59. This permits the dimerisation of HIF1α with HIF1β which 
bind to their co-activators to form an active HIF response complex. The active HIF response 
complex locates to the promoter region of the gene of interest and increases its transcription 
(Fig. 5). 
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There are hundreds of genes that are upregulated by HIF1α, and they have vital roles in cell 
growth, apoptosis, cellular metabolism, and angiogenesis 61. HIF1α generates a response to 
hypoxia both at the cellular level, in changing to anaerobic metabolism, and at the tissue level, 
through the promotion of angiogenesis.  An imbalance of HIF1α can lead to disease and is 
known to have roles in the pathogenesis of cancer 62,  pulmonary hypertension 63 as well as 
atherosclerosis 39. Dysregulation of these genes is implicated in the progression of the plaque to 
a complicated lesion. Of interest, is the upregulation of angiogenic genes such as Vascular 
 
Fig. 5 – The regulatory pathway of HIF1α in hypoxia and normoxia. HIF1α is stablised 
and binds to the cofactors HIF1β, P300 and CBP in hypoxia to form the HIF response 
complex, but is targetted for degradation in normoxia by Prolyl Hydroxylases and FIH.  
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Endothelial Growth Factor (VEGF), Tie2 and Placental Growth Factor (PLGF) which promote 
neovascularisation into the plaque to provide nutrition to areas of hypoxia 64. Prolonged 
exposure of macrophages to hypoxic conditions has been shown to lead to an increased 
expression of genes involved in angiogenesis as well as transporter proteins 65. The large 
population of macrophages in atheroma can therefore be affected by the hypoxic conditions 
and HIF1α.     
 
Although hypoxia is known as the key upregulator of HIF1α there are other factors that can lead 
to its upregulation. Hormones such as insulin and heregulin have been shown to increase HIF1 
activation and HIF1α accumulation through the PI-3-kinase and rapamycin signalling pathway 66. 
In hypoxia, insulin increases HIF1α protein levels, binding to DNA, and increases HIF1α-
mediated gene activation. It does this not by decreasing degradation or increasing transcription, 
but through increasing HIF1α translation 66.   Glucose has also been shown to have an important 
role in the activation and regulation of HIF1 with glucose being required for HIF1 activation in 
hypoxic conditions 67.   
 
As well as being upregulated in hypoxia, HIF1 can also accumulate and activate during 
normoxia. This process is driven by cytokines, growth factors, hormones and ROS 68. Cytokines 
such as interleukin-1β and tumour necrosis factor-α have been shown to enhance the binding of 
HIF1 to DNA, as well as increase HIF1 accumulation 68,69. This has great importance with respect 
to inflammation as cytokines are upregulated during an inflammatory response, which in turn 
would increase intracellular levels of HIF1. These include immune responses which as well as 
promoting HIF1α expression also increase angiogenesis into the atheroma 70. 
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1.8 Neovascularisation in the Plaque  
 
In normoxic conditions, blood vessels are nourished by oxygen diffusing from either the lumen 
of the vessel or from the adventitial vasa vasorum. When hypoxic areas occur in the plaque and 
the diffusion is insufficient to meet the metabolic demands of newly formed tissue, new blood 
vessels are formed in order to supply the areas that are outside the usual capacity for oxygen 
diffusion. 
 
Neovascularisation is the process of generating new blood vessels from either pre-existing 
vasculature, via angiogenesis, or from endothelial precursor cells, termed vasculogenesis 1. 
Angiogenesis is the predominant form of neovascularisation in atherosclerosis and is mediated 
by endothelial cells sprouting primarily from the vasa vasorum 71 leading to the formation of 
new capillaries 72. This is stimulated when the intima thickens past the oxygen diffusion 
gradient, causing hypoxic areas to form, which upregulates HIF1α and in turn activates 
angiogenic response genes 35.  
 
Non-diseased coronary arteries do not contain vasculature in their intima or media 73, however 
most human atherosclerotic plaques do contain neovasculature 74. This indicates that the 
formation of the new microvessels is due to the progression of the plaque, rather than the 
neovascularisation being the cause of the atherosclerosis 72. 
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The process of angiogenesis begins with an increase in the permeability of the microvessels, 
through the upregulation of VEGF 75,76, and degradation of the matrix surrounding the 
vasculature. Endothelial cells then migrate and proliferate in the required direction governed by 
genes including angiogenin 77, tumour necrosis factor-α (TNFα) 78, and transforming growth 
factor-α (TGFα) 79.  This results in thin walled, permeable sprouts which are matured and 
maintained by cytokines including transforming growth factor-β (TGFβ) 80 and by the formation 
of the basement membrane. The new blood vessels are further enhanced by the recruitment of 
smooth muscle cells and pericytes 81. 
 
Neovascularisation in the atherosclerotic plaque is present in three regions, the adventitia, the 
intima-media border, and in the intraplaque region. The microvessels invade from the 
adventitial layer, through the medial elastic lamina and then break though into the plaque 81. As 
the plaque progresses the microvessel density increases, indicating that the new vessels play a 
role in the development of the plaque 82.  
 
The endothelial integrity of the new microvessels is severely compromised with incomplete 
inter-endothelial contact and an inadequate recruitment of mural cells. Moreover, detachment 
of the endothelial cells from the basement membrane is common. This leads to an increase in 
blood-derived inflammatory cell infiltration into the plaque, promoting necrotic core expansion 
and overall plaque progression 82. The leakage of the blood vessels is not the only reason for the 
increase in leukocytes. It has been seen that the neovasculature expresses the leukocyte 
adhesion molecules  E-selectin, ICAM-1 and VCAM-1 more abundantly than the lumen of the 
arterial endothelium, thus enhancing leukocyte accumulation in the plaque 74. 
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Early stage plaques show the presence of neovascularisation with microvessels observed in 
stage II plaques associated with macrophages and immature mast cells. The microvessels 
become more common in intermediate plaques, with either sparsely or densely packed 
microvessel accumulation. Build-ups of lipoproteins are observed to surround these vessels, 
suggesting that the lipids are using the new vasculature to invade the plaque 83. In the more 
advanced plaques, the vessels are more abundant with the more severe plaques tending to 
have a larger number of adventitial vessels 71 .  
 
Neovascularisation in atheromas is an important target for therapy as analysis of plaques has 
shown that unstable lesions are associated with a higher degree of neovascularisation 82. 
 
 
1.9 Plaque Instability 
 
It was initially thought that the increased plaque size leading to the narrowing of the blood 
vessel lumen was the primary cause of clinical events such as myocardial infarction and strokes. 
It is now known that, although this stenosis can obstruct the vessel, the most common cause of 
a clinical event is plaque rupture, which occurs in 75% of fatal coronary events 84.  A ruptured 
plaque leads to the formation of a thrombus due to either endothelial degradation or 
intraplaque haemorrhage 18. The thin fibrous cap contains slight openings and fissures in plaque 
ruptures which brings the circulating blood into direct contact with the thrombogenic 
components of the lipid core. This leads to the formation of the thrombus and potentially to 
clinical events 18. 
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Histological assessment has identified distinguishing characteristics which are associated with 
the vulnerability of the plaque to rupture, including size of the plaque 85, a large cholesterol and 
oxidised lipid-rich plaque core, a thin fibrous cap with weakened smooth muscle cell and 
collagen availability, inflammatory cell infiltration and increased neovascularisation 86.  
 
The increased neovascularisation of the atheroma plays an important role in the progression 
from a stable asymptomatic state into a high-risk unstable lesion 25. The new leaky vasculature 
provides new pathways for leukocytes, red blood cells, cholesterol and other molecules to enter 
the plaque. This leads to an increased necrotic core mass and inflammatory cell induced 
apoptosis 25.    
 
Localised mechanical shear stress forces can also cause the plaque to rupture through affecting 
its structural integrity.  Once the plaque ruptures, a thrombus forms around the exposed pro-
thrombogenic core, which can eventually occlude the vessel 20. Increased plaque disruption 
enhances the likelihood of an intraplaque thrombosis occurring 85. The majority of plaque 
ruptures occur at the shoulder regions of the atheromas, where the lipid depositions, and 
inflammatory cells are commonly located 87–89. This has been attributed to the mechanical stress 
of the plaque being shifted to this region where there is less structural integrity 87,88.  
 
Matrix metalloproteinases (MMPs) are proteolytic enzymes that degrade the ECM and are 
highly expressed in macrophage-rich areas of the atherosclerotic plaque, particularly at the 
shoulder regions of the cap. The MMPs may therefore promote the weakening of the cap and 
further destabilise the plaque leading to rupture 90. These will be discussed in detail in section 
1.12. 
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Research has looked into the potential of preventing neovascularisation in atherosclerotic 
plaques through the use of angiogenesis inhibitors, and thereby increasing plaque stability. It 
has been found that by using endothelium-specific angiogenesis inhibitors, such as the type 
XVIII collagen fragment endostatin and TNP-470, there is a decrease in plaque size of 85% and 
70%, respectively 91. Angiostatin treatment has also been shown to markedly reduce 
neovasculaturisation invading the atheroma from the vasa vasorum of murine models 92.  Other 
drugs including simvastatin have also shown beneficial effects on reducing angiogenesis in 
atherosclerotic plaques93.  
 
 
1.10 Statins 
 
Some of the most commonly prescribed drugs to prevent and treat cardiovascular disease are 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) which are the 
most important and most widely prescribed class of lipid and cholesterol lowering drugs 94,95.  
 
HMG-CoA reductase catalyses the rate-limiting step in the biosynthesis of cholesterol, and thus 
inhibition leads to a decrease in cholesterol and in a reduction in atherogenic events 94. The first 
statin drug, mevastatin, was discovered in the 1970s and was shown to inhibit hepatic 
cholesterol synthesis through inhibition of HMG-CoA reductase (Fig. 6) 96. 
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The first statin that was approved for clinical use was lovastatin which was approved by the U.S. 
Food and Drug Administration (FDA) in 1987 95. Since then there have been several more statins 
identified, with seven of them being approved for clinical application to date. These statin drugs 
can be classified by their origin, either from a natural source or obtained through chemical 
synthesis 95. Natural statins are commonly derived from fungal metabolites and include 
lovastatin, pravastatin and simvastatin 97. The newer synthetic compounds are markedly 
different in their chemical structure from the natural statins but they retain the HMG-CoA-like 
structure which is responsible for the HMG-CoA reductase inhibition 98.  
 
 
Fig. 6 – The mode of action of statins. This family of drugs competitively inhibit the 
conversion of 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate with an end reduction 
in cholesterol. 
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Statins function by competitively inhibiting HMG-CoA reductase which subsequently lowers 
cholesterol production 96. Statins have a much higher affinity for the active site of HMG-CoA 
reductase than its substrate HMG-CoA and therefore are potent inhibitors 99. As well as 
preferentially occupying the active site of HMG-CoA reductase, statins alter the conformation of 
the enzyme. This prevents HMG-CoA reductase from attaining a functional structure and further 
inhibits the pathway 100. 
 
Following the reduction in hepatocyte intracellular cholesterol concentration, there is an 
increase in the expression of hepatic LDL receptors. The increase in LDL receptors leads to 
enhanced clearing of LDL and its precursors from the circulation 95.  
 
Statins have also been shown to decrease VLDL synthesis through the inhibition of 
Apolipoprotein-B100 (Apo-B100) production. This is achieved by limited lipidation of Apo-B100, 
leading to increased degradation. Apo-B100 is involved in VLDL synthesis, alongside cholesterol 
esters, triglycerides and phospholipids, and thus a decrease in Apo-B100 leads to the inhibition 
of VLDL synthesis 101. A reduction in VLDL synthesis also leads to a reduction in triglycerides, 
which can be seen in patients treated with atorvastatin, cerivastatin, and pitavastatin 102.    
 
As well as having inhibitory effects on the formation of VLDL, LDL, triglycerides and cholesterol, 
statins have also shown upregulatory effects on HDL and apolipoprotein A-I 103. Interestingly 
statins are shown to increase apolipoprotein A-I through activation of its promoter and 
suppressing the Rho signalling pathway, through inhibiting the production of isoprenoid 
intermediates 102. Apolipoprotein A-I is the main component of HDL and therefore its 
upregulation leads to a higher concentration of HDL. The upregulation of HDL leads to another 
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key mechanism which is aided by statins. Reverse cholesterol transport whereby cholesterol is 
actively taken up by the liver via a multistep process from the plasma requires HDL and 
lecithin:cholesterol acyltransferase. These esterify the cholesterol so that it can be taken up by 
the liver and excreted into bile 104.  
 
Endothelial function is known to be improved by lowering cholesterol levels, as 
hypercholesterolemia reduces the production and increases the degradation of endothelial 
derived nitric oxide 105. Through lowering cholesterol levels statins cause an increase in nitric 
oxide levels which are important for proper endothelial function 106.  
 
In addition to having lipid and cholesterol lowering effects statins can also improve 
cardiovascular events through actions independent of cholesterol lowering. These actions are 
known as pleiotropic effects of statins and have provided new insights and potential treatments 
for a variety of diseases, including Alzheimer’s, rheumatoid arthritis and cancer 95. 
 
The pleiotropic effects are commonly mediated by statins inhibition of mevalonate synthesis, 
which blocks the synthesis of isoprenoid intermediates, such as farnesyl pyrophosphate (Fig. 6) 
107, and leading to accumulation of inactive GTP-binding proteins in the cytoplasm. These small 
GTP-binding proteins include Rho, Rac, Ras, Rap and Ral which are important substrates for the 
post-translational modification by prenylation 94 and have a vital role in cellular signalling events 
including controlling proliferation, migration, and apoptosis. As well as inhibition of mevalonate 
synthesis, statins have been found to alter other signalling pathways including the activation of 
Akt through phosphorylation. The exact mechanism of this has not been elucidated however it 
is known to be mediated by the PI-3-kinase pathway 108,109. The activation of AKT  has been 
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linked to an increase in endothelial nitric oxide synthase (eNOS) production, which can be 
attributed to a more healthy endothelium 109. 
 
Simvastatin and lovastatin have been shown to increase the transcriptional activation of eNOS 
gene in human endothelial cells in vitro 110 . This occurs through an increased polyadenylation of 
the eNOS mRNA transcript, leading to post-transcriptional stabilisation of the mRNA111. The 
increased polyadenylation is due to the inhibition of the Rho signalling pathway affecting the 
actin cytoskeleton 111. Statins have also been shown to activate the PI-3-kinase/Akt pathway, 
which also leads to an increase in eNOS expression. Statins also have post-translational 
upregulatory mechanisms for eNOS upregulation, commonly mediated through 
phosphorylation of serine and threonine residues 112. 
 
In addition to inhibiting the isoprenylation of the GTP-binding proteins, statins are also known 
to exert their pleiotropic effects through affecting the lipid rafts. Statins may disrupt or deplete 
lipid rafts, affecting further signal transduction 113.   
 
As well as increasing nitric oxide levels, statins are also able to reduce inflammatory cell 
infiltration into atherosclerotic lesions through inhibiting adhesion molecules such as ICAM-1 
114, VCAM-1 and E-selectin 115 which is an important step in preventing the progression of the 
plaque. 
 
The prevention of inflammatory cells from binding and infiltrating into the plaque is not the only 
mechanism of lowering inflammation. Statins can also alter the expression of chemokines, such 
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as interleukin-8 and monocyte chemoattractant protein-1 which control leukocyte migration to 
the plaque 116. 
 
Statins’ pleiotropic effects are not limited to affecting endothelial function as they also decrease 
vascular smooth muscle cell and macrophage proliferation 117,118, reduce the activity of platelets 
119, stabilise atherosclerotic plaques 120, and act as an antioxidant 121. Through inhibiting 
signalling through the Rho pathway, statins have been shown to have beneficial effects in 
inhibiting cardiac hypertrophy 122. Furthermore, their wide-ranging effects do not only impact 
cardiovascular health, but are able to also reduce MHC class II molecules via inhibiting their 
transcription 123. Recent evidence suggests that statins are able to increase the degradation of 
proteins, including HIF1α, through increasing their ubiquitination 124. This has implications for 
treatment of diseases such as atherosclerosis and cancer where HIF1α plays a role in their 
pathophysiology.  
 
The pleiotropic effects can be biphasic, whereby different concentrations of statins result in 
different effects. This is the case for atorvastatin, as cell migration and angiogenesis was 
increased with concentrations lower than 0.1µmol, but inhibited at higher concentrations 125. 
These complex pharmacokinetics of statins make them a subject of intense research and are, 
for the most part, still not well understood.  
 
The biphasic effects could be due to a switch mechanism whereby at low dose concentrations 
activation of genes occurs, but at higher doses an inhibition of the isoprenoid intermediates and 
other factors leads to a decrease in activity. This can be related to the process of angiogenesis 
whereby at low statin concentrations eNOS can be activated leading to increased angiogenesis, 
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but at high statin concentrations reduction of isoprenoid intermediates and other angiogenic 
proteins leads to inhibition of angiogenesis 126.  
 
The effects of statins have been assessed in clinical trials which have revealed some interesting 
effects in reducing the risk of coronary heart disease (CHD) events. The West of Scotland 
Coronary Prevention Study (WOSCOPS) and the Air Force/Texas Coronary Atherosclerosis 
Prevention Study (AFCAPS/TEXCAPS) evaluated the effects of statins in groups that had no 
previous evidence of CVD. These studies showed that statins reduce the risk of major CHD 
events in patients with high and normal LDL-cholesterol levels 95. The Scandinavian Simvastatin 
Survival Study (4S) shows a 42% reduction in total mortality amongst patients with coronary 
artery disease that were taking 20 or 40mg/day simvastatin as well as a 34% reduction in 
coronary events 127.  
 
1.11 Simvastatin 
 
Simvastatin was first produced by Merck using the name ZOCOR® and was approved by the U.S. 
FDA in 1998 128. In 2006, after the term of the patent expired simvastatin was added to the 
World Health Organisations (WHO) list of essential medicines 129 and since then it has become 
one of the most commonly prescribed statin drugs with 67% of statin prescriptions in the UK 
being for simvastatin in 2007 130.  
 
Simvastatin is a semi-synthetic compound as it is of fungal origin, but contains a chemical 
modification of the lovastatin side chain 98 whereby the 2-methylbutanoyl side chain is replaced 
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by a 2,2-dimethylbutanoyl side group (Fig. 7) 131. It is a hydrophobic statin and is able to pass 
through cell membranes non-specifically through a simple diffusion mechanism132. 
 
 
The average daily dose of simvastatin to treat cardiovascular diseases is 20-40mg with a 
maximal dose of 80mg 133. Simvastatin is administered as an oral dose in a pro-drug form, 
whereby the lactone ring undergoes reversible hydrolysis to form the active simvastatin acid 
(Fig. 7)  134. As with most drugs once administered, simvastatin is concentrated in the liver 
whereby it is metabolised by the cytochrome P450 3A4 pathway. The majority of simvastatin is 
retained in the liver and the circulating concentration is low, with only 5% of active simvastatin 
detected in the circulation 100. This is common for all of the statins but simvastatin and 
lovastatin have the lowest detectable concentration in the circulation 100.  
 
Fig. 7 – The chemical structure of simvastatin. The modified 2,2-dimethylbutanoyl side 
group shown in red and lactone ring in blue.  
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Simvastatin is known to greatly reduce cholesterol and to improve cardiovascular functioning 
127. It also has beneficial effects seen for other diseases whereby it has shown to prevent the 
growth of breast cancer 135, affect apoptosis in cancer cells 136 and reduce inflammatory arthritis 
137. It is therefore a statin that has been widely used in research. Although simvastatin has been 
shown to have beneficial effects in treating cardiovascular disease, it also has significant side 
effects with myalgia, jaundice and hypersensitivity being some of the listed complications of 
using the drug 133. Furthermore, simvastatin has been shown to have teratogenic effects when 
taken during the first trimester of pregnancy, with adverse effects seen in the migration, 
proliferation and apoptosis of trophoblastic cells 138.  
 
Simvastatin has been shown to affect angiogenesis whereby it can both promote angiogenesis 
in ischaemic myocardium, but also inhibit angiogenesis in the aortic arch 139. This in part has 
been attributed to a decrease in HIF1α levels of samples treated with simvastatin 139. Further 
studies on simvastatin’s effect on HIF1α have speculated that alongside other statins it is able to 
inhibit the binding of HIF1α to the HRE of platelet-derived growth factor B and endothelin-1 140.   
It is known that patients that take simvastatin are less liable to plaque rupture, which are 
plaques that are characteristically defined by having a thin fibrotic collagen cap. It has been 
shown that a mechanism for this is simvastatin’s ability to increase the expression of prolyl-4-
hydroxylase-1-α which is involved in collagen synthesis 141. Simvastatin has also been found to 
affect the expression of matrix metalloproteinases (MMPs) 142, which are key components of 
the plaque causing tissue degradation and potential instability. Key MMPs which have been 
identified as having their expression levels decreased by simvastatin are MMP3 143, MMP9 144,145 
and MMP14 146. This shows that simvastatin may have a role in increasing plaque stability 
through inhibiting the production of MMPs. 
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1.12 Matrix Metalloproteinases  
 
The matrix metalloproteinases (MMPs) are a family of at least 23 secreted or cell surface zinc-
dependent enzymes that are capable of degrading ECM proteins, clotting factors, cell adhesion 
molecules, lipoproteins and growth factors 147 and seem to influence almost every aspect of 
mammalian biology 148. Also known as matrixins, the MMPs have 24 identified genes in man, 
but there is a duplicated MMP23 gene. Some MMPs are excluded from the nomenclature list as 
they were shown to be identical to other identified MMPs 149.  
 
Most MMPs generally have low activity levels in normal steady-state tissues 149, with their 
expression primarily regulated at the transcriptional level by a variety of growth factors, 
chemical inducers, physical stress, inflammatory cytokines, hormones, cell-to-cell, and cell-to-
matrix interactions 149,150. MMPs are mainly secreted or membrane bound proteins, commonly 
activated extracellularly, but there is evidence that some MMPs are activated intracellularly 
where they can interact with other intracellular proteins 151. 
 
The majority of MMPs are not constitutively expressed and instead are induced according to 
their physiological or pathophysiological roles. Transcriptional regulation is an important 
regulatory step in controlling MMP expression. The regulation can occur via histone acetylation 
and deacetylation 152, DNA methylation 153, as well as by transcription factors binding to specific 
cis-regulatory elements within the promoter region of the genes 154.  
 
The binding of transcription factors to relevant cis elements is a main regulatory step of 
transcriptional control of MMPs. MMPs contain several cis-regulatory elements in their 
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promoter regions which allow regulation by activators such as, Sp-1, AP-1, PEA3, β-catenin, and 
NF-kB 154. The MMPs can be split into three groups according to the cis-elements contained in 
the gene promoter region. Most of the MMPs contain both a TATA box and an AP-1 binding site 
and are classified into the first group. The second group includes MMP8, MMP11, and MMP21, 
which contain a TATA box but do not have the AP-1 binding site 154. The final group does not 
contain a TATA box and includes MMP2, MMP14 and MMP28. This group is mainly regulated by 
the SP-1 family of transcription factors as well as containing other cis-elements such as HRE’s 
and AP-2 sites 154.  
 
Histone acetylation is another method of gene regulation used to control MMP expression. This 
process involves the reversible unravelling of DNA binding to histone proteins. This allows the 
transcription factors to access the DNA regulatory elements more easily. The acetylation 
process is controlled by the histone acetyltransferases (HATs) whilst deacetylation is controlled 
by the histone deacetylase (HDACs). Histone deacetylation is an inhibitory step which binds the 
DNA back to the histones, preventing the genes from being activated 152. It has been shown that 
the use of HDAC inhibitors can either repress or activate the expression of different MMPs at 
both the mRNA and protein level 155.  
 
Some MMPs undergo DNA methylation in order to control their gene expression. DNA 
methylation occurs at CpG islands within the promoter regions of genes and is governed by DNA 
methyltransferases. The methylation occurs at cytosine residues and further prevents the 
binding of DNA transcription factors to gene regulatory elements. MMP9 has been shown to be 
affected by DNA methylation in lymphoma cells with increased DNA methylation being inversely 
correlated with the gene’s expression in these cells 153. As well as MMP9 it has also been seen 
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that MMP3 is controlled by methyltransferases with  the knockout of methyltransferases 
increasing MMP3 expression in colon cancer cells156. 
 
In addition to the transcriptional regulation of MMPs, there is also a wealth of factors that 
regulate them at the post-transcriptional level. These include activation and inhibition by other 
proteins, such as α2-macroglobulin and tissue inhibitors of MMPs (TIMP), and miRNA, such as 
microRNA-146b which has been shown to downregulate MMP16 in glioma 157. The activity of 
MMPs is also dependent on temporal and tissue specific cleavage of MMP zymogens 158. Most 
MMPs are synthesized as zymogens with the capability of being activated by other MMPs. Some 
MMPs, particularly the membrane type MMPs, have a furin activation domain 149. This area is 
targeted by a furin molecule which cleaves the MMP and removes the pro-peptide.  There are 
also other less specific inhibitors of MMPs including the more general protease inhibitor α2-
macroglobulin, the membrane bound glycoprotein RECK 159, as well as thrombospondin 160.  
Other synthetic inhibitors of MMPs, such as tetracycline, prevent the zinc cofactor from binding 
and are non-selective inhibitors of MMPs 161.  
 
As well as being regulated by activation, MMPs are also influenced by TIMPs which inhibit 
activated MMPs and are their key regulators and inhibitors at the protein level 147. So far, there 
have been four TIMPs identified and shown to affect MMPs with different affinities. Like MMPs, 
TIMPs are regulated at the level of transcription by growth factors, cytokine and chemokines 
and also respond to stimuli at the transcription level 155.  
 
The four TIMPs are in general broad-spectrum inhibitors of MMP activity but there are some 
notable differences in specificity between them. It has been seen that TIMP1 has more of a 
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restricted inhibition range than the other TIMPs with a low affinity for the MT-MMPs and 
MMP19 162. As well as this there are some differences in the affinities of other TIMPs with 
MMPs, such as TIMP2 and TIMP3 which are weaker inhibitors than TIMP1 for MMP7 163. 
 
The mechanism of TIMP inhibition of MMPs has been discovered by the use of crystallography 
where it has been seen that the TIMPs overall structure is “wedge-like” which is able to interact 
with active site of the MMPs by forming a non-covalent 1:1 stoichiometric complex 149. The 
inhibition is reversible but is resistant to heat denaturation and proteolytic degradation 164.  
TIMPS are therefore key regulators of the MMPs but they have also been shown to have 
important roles in MMP activation, such as TIMP2 which is an important cofactor in the 
activation of MMP2 by MMP14 155. 
 
The roles of TIMPs alongside MMPs are well characterised but they are also known to have 
biological activities that are independent of MMPs. TIMPs are able to modulate cell 
proliferation, cell migration, apoptosis and invasion whilst also exerting anti-angiogenesis 
abilities. These activities may be partly due to MMP inhibition but many of them have been 
shown to be independent of MMP inhibition, such as interacting directly with cell specific 
receptors in order to induce cellular responses 162. 
 
More specifically it has been shown that TIMP1 promotes cell growth in keratinocytes and 
fibroblasts 165,166. It has also been found that TIMP1 and TIMP2 increase the expression of Ras-
GTP utilising different signalling pathways. TIMP1 activates the MAPK pathway and TIMP2 can 
signal via the PI3K pathway 167. 
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 It is well established that TIMPs are able to attenuate angiogenesis through the inhibition of 
pro-angiogenic MMPs, such as MMP9 and MMP14. However, TIMP2 and TIMP3 have been 
found to exert anti-angiogenic activity independent of their MMP inhibitory activities, thus 
enhancing their importance for diseases such as cancer and atherosclerosis 168. 
 
The importance of TIMPs in cardiovascular disease has been shown through analysis of patients 
plasma following acute myocardial infarction whereby elevated TIMP1, TIMP2 and TIMP4 levels 
were noted 164.  Studies on mice have shown that both TIMP1 and TIMP3 deficiency lead to 
cardiovascular disease progression. Mice that lack TIMP1 expression have smaller atheromas 
but have increased aneurysm formation 169. As well as this it has been shown that TIMP3 
deficiency in mice leads to disrupted matrix homeostasis with spontaneous left ventricular 
dilation, cardiomyocyte hypertrophy and contractile dysfunction 170.  The balance between 
MMPs and TIMPs is critical for the ECM remodelling and cellular functioning and therefore it is 
vital that these processes are tightly controlled 149.  
 
The identification of MMP structure has been achieved through the use of X-ray crystallography 
149. The MMPs have a common domain structure with a signal peptide, a propeptide of about 80 
amino acids, a catalytic metalloproteinase domain of about 170 amino acids, a hinge region of 
variable lengths and, a C-terminal haemopexin domain of around 200 amino acids (Fig. 8) 149,155. 
The catalytic metalloproteinase domain contains a zinc binding motif, HEXXHXXGXXH, which 
activates the MMP upon the co-factor’s binding. Preceding this site is a conserved methionine 
residue, which forms a “Met-turn”. This supports the active site structure around the zinc ion 
171. The propeptide domain contains a cysteine switch motif, PRCGXPD, which inhibits the 
binding of the catalytic zinc ion to the zinc binding motif through an unpaired cysteine residue. 
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This keeps the MMPs inactive by preventing a water molecule from binding to the zinc ion 
which is essential for catalysis 149. Activation of the MMP occurs when the cysteine-zinc linkage 
is disrupted through cleavage of the propeptide by proteolytic cleavage 148.  
 
The propeptide contains a proteolytic cleavage site which is used to activate the pro-MMP into 
an active MMP.  Serine proteases, opportunistic bacterial proteinases and other MMPs are able 
to enzymatically cleave the propeptide to form the active enzyme 149,172.  Partial cleavage of the 
propeptide is common and often requires completion by the MMP intermediate itself, or by 
other active MMPs. This process has been termed “stepwise activation” due to the incomplete 
nature of the first cleavage 149. Once the propeptide domain has been removed a 
conformational change occurs which exposes the catalytic domain to the ECM substrate 172. This 
catalytic domain is conserved with a high degree of homology between the MMPs and 
therefore does not play a role in substrate specificity 172. There is a substrate specific pocket, 
known as the S1’ pocket, which varies in depth and is located to the right of the zinc atom. This 
pocket is hydrophobic in nature and is one of the determining factors of substrate specificity in 
MMPs 149.  
 
In all of the MMP family members except MMP7, MMP23 and MMP26, a hinge region links the 
catalytic domain to the c-terminus haemopexin-like domain (Fig. 8) 155. The haemopexin domain 
structure has been identified as comprising of a four-blade-β-propeller 173.  This domain has a 
key role in substrate specificity, binding to ECM proteins on the basis of the sequence at the C-
terminus 155. It is also the region which is inactivated by the binding of TIMPs which locate to 
and competitively block the active site of the MMP 149.  
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The membrane type MMPs (MT-MMPs) contain a few distinct features which differ from the 
rest of the MMPS including the presence of a transmembrane spanning domain, or a 
glycosylphosphatidylinositol anchor, with a potential furin cleavage site located within the 
propeptide domain (Fig. 8). The furin cleavage site is a potential mechanism to activate the MT-
MMP prior to its secretion 155.   
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Fig. 8 – The structure of the MMPs categorised by their functional classification. 
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MMPs are traditionally subdivided into different groups, the collagenases, gelatinases, 
stromelysins, matrilysins and membrane-type, determined by substrate specificity, structure 
and cellular location 155. The collagenases cleave interstitial collagens I, II, and III three quarters 
of the way to the N-terminus providing two distinct fragments151. In addition, the collagenases 
are able to cleave some other ECM molecules and soluble proteins. The stromelysins have a 
similar structural arrangement to the collagenases but they are unable to cleave the interstitial 
collagens. As well as cleaving some ECM components the stromelysins also cleave and activate a 
number of pro-MMPs151. The gelatinases include MMP2 and MMP9 and are able to digest 
gelatins as well as other ECM molecules including type IV, V and XI collagens and laminin 149. 
They contain a distinct fibronectin repeat in their catalytic domain.  The matrilysins are easily 
identified as they lack the C-terminal haemopexin domain. Alongside the cleavage of ECM 
components the matrilysins are able to cleave cell surface molecules including E-cadherin, Fas-
ligand and pro-tumour necrosis factor a 149. The MT-MMPs are anchored to the membrane 
either through a transmembrane domain or a glycosylphosphatidylinositol anchor (Fig. 8). They 
are capable of activating other MMPs, such as MMP2, as well as cleaving the ECM 
components151.  
 
The MMPs were originally thought to be primarily involved in cleaving ECM substrates and in 
maintaining ECM homeostasis but it is now recognised that they have much more complex 
functions 155.  These include regulating cell growth, regulation of apoptosis, affecting cell 
proliferation, migration, invasion and metastasis, cleaving adhesion molecules, enhancing 
angiogenesis and vascular permeability and modulating inflammation and immunity 174.  Some 
of these functions are due to MMPs role in ECM homeostasis which alters other interactions. 
The breakdown of ECM molecules and cell surface molecules alters cell-matrix and cell-cell 
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interactions. The breakdown of the ECM releases bound growth factors allowing receptors to be 
activated 149.  More recently however, there has been evidence that as well as extracellular 
targeting, MMPs may also have an intracellular role, with some MMPs also containing a nuclear 
localisation signal 175. As well as this, a number of non-ECM molecules are also substrates for 
MMPs, including other MMPs, which can lead to further signalling cascades. Many of these 
substrates are important for MMPs’ mediating functions such as cell migration, differentiation, 
angiogenesis and inflammation 149. 
 
Similarly, due to their function in the aforementioned processes, MMPs have been associated 
with disease progression. Research into the role of MMPs in cancer has been ongoing with the 
identification that MMPs are important in many processes involved in the progression of cancer 
including cell metastasis 176, invasion 177, and angiogenesis 178. MMPs were therefore identified 
as a potential target for therapy due to their ability to prevent progression of cancer. MMP 
therapeutics however were unsuccessful in clinical trials as some MMPs have contradictory 
effects at different stages of cancer progression 179 with some MMPs leading to tumour 
progression, and others exerting anti-tumour functions 180. MMPs also act in a signalling cascade 
either by activating or inhibiting other MMPs, therefore targeting MMP activity and expression 
may lead to an imbalance of other MMPs.  
 
In addition to cancer, MMPs have been identified to be contributors to other disease processes 
including diseases of the central nervous system 181, asthma and chronic obstructive pulmonary 
disorder 182, and inflammatory conditions such as arthritis 183, and cardiovascular disease 147,149. 
It has become clear that MMPs play an important role in the progression of atherosclerosis with 
all of the classes of MMPs as well as TIMPs being expressed in areas of atheromas 90. 
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Observational studies have shown both the mRNA and enzymatic forms of the MMPs to be 
present in the atheromas, with a potential role in plaque disruption suggested 18.  
 
The collagenases play a predominant role in the atherosclerotic plaque with all three of the 
collagenases showing expression. MMP1 has been shown to be expressed in the fibrous cap and 
shoulder regions of the atherosclerotic regions 90,184. MMP13 expression is localised to 
endothelial and smooth muscle cells within the lesion itself 185. MMP8 has also been shown to 
be expressed in atheromas, predominantly at the fibrous cap where there is a rich abundance of 
collagen I and III 186.  This may suggest that the collagenases are associated with plaque 
vulnerability through degradation of the fibrous plaque. The collagenases, however, are not just 
associated with lesion instability. Research shows that MMP8 has an active role in 
atherosclerosis progression. This has been seen in MMP8 null mice, having a reduced amount of 
atheromas containing a denser proportion of collagen when MMP8 is knocked out187. MMP8 
has also been attributed to increasing angiogenesis and therefore may provide a potential 
mechanism for neovessels to form in the atherosclerotic plaque 188.   
 
The gelatinases are amongst the most researched of the MMPs in relation to atherosclerosis 
and are known to be highly expressed in the fatty streaks and shoulders of the plaque 90,189. The 
identification of the gelatinases in the fatty streaks suggests that they may be involved in the 
formation of the atheroma 189.  
 
The stromelysins, represented in the atherosclerotic plaque by MMP3, have been shown to be 
present in smooth muscle cells and macrophages within the atheroma. MMP3 is therefore 
suggested to be involved in the growth of the plaque as well as their destabilisation 190.  
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MMP7 expression has been demonstrated in atherosclerotic lesions, particularly associating 
with macrophages, and is suggested that it may cleave proteoglycans and destabilise the cap 191. 
Studies of MMP7 knockout mice showed little effect on atheroma development and stability, 
but there was an increase of smooth muscle cells within lesions as well as an increased rate of 
apoptosis 192. This suggests that MMP7 has an important role in vascular smooth muscle cell 
recruitment and necrotic core development.  
 
An interesting finding was that plaques that have a thinner cap tend to have higher levels of 
MMP1, MMP3, MMP7 and MMP12 mRNA. As well as this plaques that have ruptured have a 
much higher level of MMP12 193. It is also interesting that hypoxia has been shown to 
upregulate several MMPs, including MMP7 and MMP14 194,195.  
 
MMP14 can be detected in both normal and atherosclerotic arteries, with a particularly high 
expression seen in macrophages, foam cells and in vascular smooth muscle cells of 
atherosclerotic lesions 196,197. The high expression in of this protein these cells may cause plaque 
disruption when activated by pro-inflammatory mediators 196,197.   
 
MMP14 is of increasing interest in relation to atherosclerosis as it has been found to be able to 
promote angiogenesis 198,199, activate other MMPs within the atherosclerotic plaque 200–202 and 
lead to plaque instability. These findings show that MMP14 is an important molecule in the 
pathogenesis of atherosclerosis.  
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1.13 Matrix Metalloproteinase 14  
 
MMP14 was first identified in 1994 by Sato et al and was the first known member of the 
membrane type metalloproteinases, also known as MT1-MMP. It was shown to activate MMP2 
and have a potential role in tumour invasiveness 200. MMP14 was found to be a protein of 582 
amino acids in length and to encode a protein of 63-66kDa 200. Further studies of the human 
genome has led to MMP14s gene being mapped to chromosome 14q11-q12 203–205, which is 
similar to that of the mouse genome 206.  
 
Many studies on the transcriptional control of MMP14 have been investigated in the context of 
cancer. These studies have shown that MMP14 is transcriptionally controlled by Krüppel-like 
factor 8 207. It is also shown that the MMP14 promoter is under Sp1 transcriptional regulation 
and also contains HRE sites which are activated by HIF2α 208.  In endothelial cells it has been 
shown that MMP14 is regulated by Egr1 and Sp1, which bind to a GC-rich sequence at position -
288 to -275 from the start of transcription 209,210.   
 
MMP14 is expressed on the surface of many cell types including macrophages, endothelial cells, 
smooth muscle cells, cardiac myocytes and epithelial cells 211. Like the other MT-MMPs, MMP14 
contains a furin cleavage site, characterised by the conserved Arg-Arg-Lys-Arg-Arg sequence 
between the pro-peptide and catalytic domains 212 (Fig. 8).  MMP14 is activated by furin which 
cleaves the pro-peptide and the catalytic domains between an Arg111 and Tyr112 resulting in the 
pro-peptide and the activated MMP14 protein 212. It has been shown that the activation of 
MMP14 by furin occurs intracellularly after its release from the golgi apparatus 213.  Another 
regulator of MMP14 is cell-ECM interactions whereby it has been shown that stretched cardiac 
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fibroblasts have an increase in MMP14 expression at both the mRNA and protein levels 214.  
Activated MMP14 can homodimerise on the cell surface through the haemopexin domain 215. It 
is found that this homodimerisation and activation is between the β-Blades IV and I 216. 
 
TIMPs are known to inhibit MMPs and have been seen to do so with different affinities. TIMP1 
is the only TIMP so far identified to be a poor inhibitor of all the MT-MMPs 217,218. As well as 
playing a role in the inhibition of MMP14, TIMP2 is able to complex with MMP14 to activate 
pro-MMP2. MMP14 is functionally associated with MMP2 in that MMP14 is able to activate the 
pro-MMP2 zymogen to form the fully functional MMP2, which is important for cell invasion and 
growth 200. 
 
MMP14 acts as a cell surface receptor for TIMP2, which forms a complex that binds to pro-
MMP2 219. TIMP2 binds to the catalytic site of MMP14 using its inhibitory N-terminal domain 220. 
The pro-MMP2 molecule then binds to the C-terminal domain of TIMP2 via the haemopexin 
domain. In order to be activated another MMP14 molecule needs to be in close proximity to 
this complex and be free of a TIMP2 molecule, which is facilitated by the ability of MMP14 to 
homodimerise through the haemopexin domain 215. 
 
The MMP14-TIMP2-pro-MMP2 complex is only able to process the pro-MMP2 into an 
intermediate protein. In order to become fully activated the pro-MMP2 molecule has to 
undergo self-autolytic cleavage 221. In order for the activation of MMP2 to be effective there has 
to be a fine balance in the concentration of TIMP2. Excessive levels of TIMP2 results in an 
inhibitory effect as the activator complex cannot be formed 221,222.  
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As well as activating MMP2 there are other MMPs that MMP14 is able to activate, such as 
MMP8 and MMP13, either on its own, or in a cascade involving MMP2 201,202. MMP14 also has a 
broad ECM substrate specificity with important roles in degrading components including type I, 
II, and III collagens as well as fibronectin, gelatin, proteoglycan, vitronectin, laminin-1, and fibrin 
223,224. 
 
MMP14 knockout mice have been developed to characterise more clearly the function of 
MMP14. It has been shown that the MMP14 knockout mice display skeletal abnormalities and 
defective vasculature which can be detected 3-5 days after birth 199,225. The skeletal 
abnormalities include dwarfism, arthritis, craniofacial dysmorphism, osteopaenia, and fibrosis of 
soft tissues. This has been attributed to the lack of collagenolytic activity which is necessary for 
the modelling of skeletal and connective tissues 225. The knockout mice commonly die 
approximately 3 weeks after birth when their body weight is 30-40% of their wild-type litter 
mates199. MMP14 is expressed in the osteoclasts 226, highlighting its importance in the bone 
development 227. MMP14 is also highly expressed in developing vascular tissues, kidney cells 
and muscle tissue in the developing mouse embryo 206.  
  
MMP14 is located on the surface of cell membranes which means that it is able to directly clear 
ECM components in the path of the cell. However, its role in cell migration is not just limited to 
remodelling the ECM, but also by releasing growth factors in the ECM 228, processing cell 
adhesion molecules 229 and activating other MMPs. It has been found that MMP14 is important 
in the lung development, where it is a downstream signalling molecule of EGFR 230. The 
epithelial branch formation within the lungs is also incomplete when MMP14 is knocked out 
which has been attributed to a lack of ECM cleavage for the formation of the branches 230. 
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MMP14 was first identified as being involved in tumour cell invasion 200 but it is now clear that 
MMP14 has roles in many diseases as diverse as asthma 231, obesity 232 and arthritis 233. As well 
as this, MMP14 has been found to be an inducer of angiogenesis 234. 
 
The defective vasculature seen in MMP14 knockout mice showed that MMP14 has a vital role in 
vasculogenesis and indicated a role in angiogenesis 199. One of the ways in which MMP14 can 
promote angiogenesis is through increasing the expression of VEGF 234. VEGF is not the only 
factor that MMP14 exerts an effect on to increase angiogenesis. Semaphorin 4D is a ligand that 
when processed can bind to plexin-B1 and promote tubulogenesis. MMP14 is able to process 
inactive semaphorin 4D into its soluble form, and promote angiogenesis 235.  MMP14 is also able 
to cleave ECM components allowing a path for invasion of new tubules 198.  
 
MMP14 expression has been detected in the atherosclerotic plaque with high expression seen 
in smooth muscle cells, macrophages and endothelial cells 196,236. This expression is markedly 
increased in hypoxic conditions, which has been shown in hepatoma cells 195, and in choroid 
retinal endothelial cells of monkeys 237. It has also been shown that HIF1α increases MMP14 
expression in cancer cells, whereby siRNA targeting HIF1α caused a marked decrease in MMP14 
expression  238,239. 
 
As discussed previously, atheromas develop hypoxic areas as their size and necrosis increases, 
leading to an increase in MMP14 levels. The MMP14 gene contains two putative HRE’s in the 
promoter region showing that hypoxia is a likely regulator of its expression 208. An increase in 
MMP14 expression leads to an increase in VEGF expression 234,237 and, subsequently, 
neovascularisation of the plaque. As well as leading to increased neovascularisation, enhanced 
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MMP14 expression can destabilise the atheromas through the ECM cleaving properties of 
MMP14. Vulnerable plaques show a marked increase in MMP14 expression compared to stable 
plaques which shows the importance of MMP14 in the pathogenesis of atherosclerosis 240.  
 
1.14 Summary 
 
With atherosclerosis being a major contributor to worldwide morbidity and mortality, and 
predicted to increase further still, there is an ever growing need to understand the molecular 
mechanism governing the development of atheromas. Simvastatin is commonly prescribed to 
patients with cardiovascular disease and is known to stabilise atheromas through preventing 
rupture and neovascularisation by decreasing HIF1α and levels of certain MMPs 139,142. With 
MMP14 expression being located in atherosclerotic plaques, and having increased expression 
through hypoxic activity, a role for simvastatin could be to reduce MMP14 activity either 
directly, or through inhibition of HIF1α. MMP14 expression is known to be reduced by 
simvastatin treatment 146 but a link with hypoxia and HIF1α has not been established. 
Elucidating these links may provide valuable insights into improved drug targeting strategies. 
 
My project involves identifying a potential regulation of MMP14 expression by HIF1α in vascular 
endothelial cells. In particular, the effects of simvastatin on angiogenesis via HIF1α and MMP14 
activity using in vitro, ex vivo and in vivo models will be explored. This will provide new insights 
into MMP14 gene regulation in angiogenesis and atherosclerosis and further knowledge into 
the beneficial effects of simvastatin treatment, whilst offering new opportunities for drug 
development.  
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1.15 Hypothesis 
 
HIF1α binds to the MMP14 promoter in hypoxic conditions upregulating MMP14 activity, which 
is attenuated by simvastatin. HIF1α depletion and simvastatin will attenuate angiogenesis 
through inhibiting MMP14 in a HIF1α-dependent manner.   
 
1.16 Project aims 
 
1. To characterise HIF and MMP14 co-localisation in blood vessels in atheromas   
2. To study the role of the HIF-response elements in the MMP14 gene promoter region 
3. To assess the effect of HIF on MMP14 expression in endothelial cells 
4. To study the effects of statins on hypoxia-induced MMP14 expression and angiogenesis 
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2. Materials and Methods 
 
For the formulation list of the buffers used in the method section please see Appendix I. 
 
2.1 Ethical Clearance 
All experiments involving human tissue were carried out under the relevant ethical clearance 
number 08/H0704/140, approved by the East London & The City REC Alpha. 
 
2.2 Cell Culture 
 
To maintain sterility all cell work was conducted in a laminar flow hood which was disinfected 
regularly with 70% ethanol and sterilised using an ultraviolet light. The work on human cells was 
approved by the responsible ethics committee.  
 
2.2.1 HUVEC Supplements 
 
A cocktail of supplements proven to aid the growth of HUVECs when added to the culture 
media 241 were used. The HUVEC supplements were made by dissolving heparin sodium salt, 
thymidine, endothelial cell growth supplement and β-endothelial human cell growth factor 
(Sigma Aldrich, UK) in Medium 199 (Sigma Aldrich, UK) to a 100X stock solution in a 1ml aliquot. 
Thymidine and heparin sodium salt were dissolved in double distilled water to stock solutions 
with concentrations of 50mg/ml and 10,000 units per ml, respectively.  A thymidine and heparin 
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sodium salt solution was prepared by sterile filtering 500µl of thymidine and 10ml of heparin 
sodium salt stock solutions through a 0.22µM membrane, producing final concentrations of 
25mg per ml of thymidine and 10,000 units per ml of heparin sodium salt. Three 15mg vials of 
endothelial cell growth supplement and one vial 25mg β-endothelial human cell growth factor 
were dissolved in the thymidine and heparin solution to final concentrations of 4.5mg per ml 
and 2.5mg per ml respectively. Medium 199 was added to make the final volume of the 500X 
HUVEC supplement stock to 20ml, before aliquoting into 1ml aliquots and storing at -80°C until 
use. 
 
2.2.2 HUVEC Cell Culture 
 
Human umbilical vein endothelial cells (HUVEC) were used for the cell based experimental 
procedures. The cells were isolated by the Department of Biochemical Pharmacology at the 
William Harvey Research Institute, from umbilical cords donated by patients from the maternity 
ward at the Royal London Hospital, and commonly supplied at passage one. The cells were 
grown on 0.04% gelatin coated flasks in M199 Media (Sigma Aldrich, UK) supplemented with 
one aliquot of 500X HUVEC supplements, 100units per ml of penicillin, 0.1mg/ml streptomycin 
solution, 2mM of glutamine and 15% foetal bovine serum (FBS). The cells were incubated at 
37°C with 5% CO2 for optimal growth conditions. The cells were washed in sterile autoclaved 
phosphate buffered saline (PBS) 242 (Appendix I), and media was changed every two to three 
days. The cells were identified as endothelial by their characteristic cobblestone morphology. 
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2.2.3 Passaging of HUVECs 
 
When the HUVECs were 80% confluent the cells were passaged in a 1:4 or 1:6 ratio as described 
below. The HUVECs were washed with sterile PBS before the addition of 0.25% trypsin-EDTA 
solution (Sigma Aldrich, UK) to cover the monolayer of cells. The cells were incubated for 1 to 2 
minutes, or until the cells rounded and lifted from the bottom of the flask, before the addition 
of serum containing HUVEC media to inactivate the trypsin. If the cells required plating at a 
specific density the cells were counted using a haemocytometer (Hawksley, UK) and seeded 
onto new flasks, coated with 0.04% gelatin. All experiments were performed on HUVECs that 
were below passage 6. 
 
2.2.4 Cryopreservation of HUVECs 
 
HUVECs were washed with sterile PBS before 0.25% trypsin-EDTA solution (Sigma Aldrich, UK) 
was added to cover the monolayer of cells. The cells were incubated for 1 to 2 minutes at room 
temperature, or until the cells rounded and lifted from the bottom of the flask. HUVEC media 
was then added to the cells to inactivate the trypsin. The cell suspension was aliquoted into a 
15ml centrifuge tube and spun at 1,250rpm to form a pellet. The supernatant was removed and 
the cell pellet was resuspended in freezing media containing 10% dimethyl sulphoxide (Sigma 
Aldrich, UK), 70% FBS and 20% HUVEC media, which has shown to be effective at preserving 
cells for frozen storage 243. The solution was dispensed into 1.8ml cryovials (Thermo Scientific, 
UK) and placed in a cryopreservation container (Thermo Scientific, UK) filled with isopropanol 
for gradual freezing, 1°C per minute, and storing at -80°C. After two hours the cells were 
P a g e  | 71 
 
removed from the freezing container and placed in -80°C for mid-range storage or in liquid 
nitrogen, -196°C, for long term storage. 
 
2.2.5 Resuscitation of  Cryopreserved HUVECs 
 
HUVECs that had been frozen at -80°C or stored in liquid nitrogen were thawed rapidly in a 37°C 
water bath for 1 minute. The cell suspension was transferred into a 15ml centrifuge tube and 
resuspended slowly in serum free M199 media (Sigma Aldrich, UK) to prevent rapid changes in 
the DMSO gradient. The cells were centrifuged at 1,250rpm for 5 minutes to form a cell pellet. 
The cell pellet was resuspended in complete HUVEC media before transferring to the relevant 
cell culture flasks, pre coated in 0.04% gelatin. 
 
2.2.6 Preparation of Simvastatin Solution  
 
The preparation of simvastatin followed documented methods to ensure effective activation 
and storage 244,245. Simvastatin (5mg) (Sigma Aldrich, UK) was dissolved in 100µl of 100% ethanol 
and 150µl of 0.1N NaOH, which hydrolysed, opened and activated the lactone ring through 
incubating at 50°C for 2 hours. Subsequently, the pH was corrected to 7.0 by the addition of 1N 
HCl in a drop by drop manner. The solution was topped up by the addition of double distilled 
water to a final concentration of 5mM, then aliquoted into 500µl samples and stored at -80°C. A 
5µM working stock solution of simvastatin was made by diluting 50µl of the 5mM simvastatin 
solution in 49.95ml of HUVEC media. The working solution was then used in subsequent 
experiments to achieve a concentration of 0.1µM of simvastatin. The working solution was 
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stored at 4°C and discarded after 1 month’s use. A vehicle control equivalent was produced at 
the same time, in the same manner, but without the addition of simvastatin. Simvastatin, or the 
control, was added 24 hours before experiments commenced, if not stated otherwise. 
Simvastatin was used at a concentration of 0.1µM, unless otherwise stated, following a 
concentration panel analysis of HUVEC cultures. 
 
2.2.7 Hypoxic Conditions 
 
In order to obtain hypoxic conditions a hypoxic chamber (Stem Cell Technologies, UK) was used. 
This apparatus provides an enclosed environment which can be filled with gas to a required 
concentration. Published protocols were followed to ensure the accurate use of the hypoxic 
chamber 246.  
 
A petri dish filled with double distilled water was placed at the bottom of the hypoxic chamber 
to maintain a humidified environment. The cells were then placed on the shelf above the water 
bath and the hypoxic chamber was tightly sealed using the O-ring. The two valves were opened; 
one valve was connected to a flow meter (Stem Cell Technologies) and the other to an oxygen 
meter (Greisinger, Germany). The gas in the hypoxic chamber was replaced by flushing the 
chamber with nitrogen gas (BOC, UK) until the oxygen meter read <1% oxygen. A hypoxic gas 
containing 1% oxygen, 5% carbon dioxide, and nitrogen as a balance (BOC, UK) was used to 
obtain standard hypoxic conditions 247. The flow meter was connected to the hypoxic gas 
canister and filled with the gas until 1% O2 conditions was achieved. To prevent pressure 
increase inlet and outlet valves were used to allow the air to flow into and out of the chamber 
whilst the hypoxic conditions were achieved. Once the correct conditions were maintained the 
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valves were closed and the chamber was placed in a 37°C incubator for various time points, as 
specified. Normoxic cultures were maintained at 21% oxygen.  
 
2.3 In Vitro Assays 
 
2.3.1 Protein Extraction 
 
The cells were washed twice with ice cold PBS which was then totally drained from the cell 
culture flask. The cells were lysed directly by the addition of RIPA buffer 248 containing 1X 
protease inhibitors 249 (100µl per T25 flask) (Appendix I). HIF1α has a half-life of less than 5 
minutes in normoxia 250, so it was vital that all work in normoxia was performed quickly, until 
the cells were lysed in RIPA buffer containing protease inhibitors. Cell scrapers were then used 
to lift all of the cells and lysate into a corner of the flask before pipetting the lysate into a 500µl 
tube and incubating on ice. The lysate was mixed using a vortex mixer every 5 minutes for half 
an hour before centrifuging at 1,250rpm for 10 minutes at 4⁰C. The supernatant was transferred 
to a new 500µl tube and frozen at -80°C until quantification.   
 
2.3.2 Protein Quantification  
 
The bicinchoninic acid (BCA) protein assay reagent method (Thermo Scientific, UK) was used to 
quantify and standardise the protein lysates in a 1:2 dilution. The BCA method has proven 
effective at quantifying protein levels as a stable purple colour is produced upon the complex of 
BCA with copper ions (Cu+) produced when cupric sulphate is reduced by peptide bonds of 
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proteins 251. The amount of Cu+ produced is proportional to the amount of protein present in 
the solution. The colour increases proportionally with higher protein concentrations and 
preferentially absorbs light at a wavelength of 562nm 251, allowing quantification of protein 
using a plate reader. The technique has been adapted and there are now protocols that allow 
for the determination of proteins that are in samples containing high reducing agents such as β-
mercaptoethanol 252.  
 
A bovine serum albumin (BSA) standard was prepared in RIPA buffer with a range of 
concentrations between 0µg/ml to 2µg/ml. The BSA standard had 10µl of each concentration 
loaded into a 96 well plate in duplicate, and 5µl of the samples were dispensed into 
neighbouring wells in duplicate. The samples were diluted by the addition of 5µl of RIPA buffer. 
The BCA working reagent was prepared and 200µl was added to each of the standards and 
samples before incubating at 37°C for 30 minutes under normal CO2 conditions. The plate was 
allowed to cool to room temperature before analysing the protein concentrations using a plate 
reader (Dynex, MRX Revelation) at 562nm wavelength. The quantified proteins were assessed 
and concentrations were calculated from a calibration curve before using RIPA buffer to 
standardise the proteins to 1.25µg/µl. A 5X sodium dodecyl sulphate (SDS) loading dye 
(Appendix I) was added to the samples which were then frozen at -20°C until needed.  
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2.3.3 siRNA Nucleofection 
 
The use of short interfering RNA (siRNA) to knockdown mRNA and reduce the expression of 
proteins was first developed after the discovery of RNA interference (RNAi) in Caenorhabditis 
elegans 253. RNAi is mediated by siRNA which is generated from longer double stranded RNA by 
an RNase protein, Dicer. The resultant siRNA is around 22 nucleotides in length and is targeted 
to mRNA by the RNA-induced silencing complex (RISC) following RNA helicase activity to form a 
single stranded active siRNA. The siRNA binds to a complementary mRNA sequence, targeting it 
for cleavage 253. Transfection allows the delivery of foreign nucleic acid into cells and utilises 
liposomal, calcium phosphate, viral or electroporation delivery 254. In general, it has been easier 
to transfect immortalised cell lines compared with primary cells. The use of siRNA alongside 
transfection-based methods has allowed for the knockdown of specific proteins of interest in 
the laboratory. The use of the nucleofection technique allows for the introduction of nucleic 
acid via an electrical impulse, and has proved effective at transfecting primary cell lines 254.  
 
HUVECs were transfected using a Nucleofector II device (Lonza, UK) with either a HIF1α 
targeted siRNA or a control scrambled siRNA (Santa Cruz, USA). HUVECs were trypsinised and 
resuspended in HUVEC media and counted using a haemocytometer (Hawksley, UK). A maximal 
capacity of 1.5 million cells can be nucleofected at one time and therefore the correct quantity 
was aliquoted in a 50ml Falcon tube before centrifuging to form a pellet. All media was 
removed before resuspending the pellet in HEPES buffered saline (HBS) 255  and 400nM of the 
relevant siRNA. The cells were transferred to electroporation cuvettes (VWR, UK) and 
nucleofected using program U-001 as recommended by the manufacturer. Following 
nucleofection treatment the cells were resuspended in complete HUVEC media before seeding 
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onto the relevant culture flasks, pre-coated with 0.04% gelatin, with media replaced 24 hours 
later.  
 
2.3.4 Immunoblotting 
 
Western blot electrophoresis is a well-established semi-quantitative method for detection of 
protein types within cells and tissues. The immunoblotting protocol followed standard 
procedures and is described below. 
 
The SDS-PAGE acrylamide gels were prepared using the Mini-PROTEAN tetra cell casting module 
(Bio-Rad, UK) which was loaded with the specific concentration of acrylamide gel required. The 
concentration of acrylamide gel that was used for the western blots was 10%. The separating 
gel was prepared first and loaded into the casting module, the addition of 1ml of butanol to the 
gel before it had set made sure that the gels were level. Once the gels had set the butanol was 
removed and the gels were washed with distilled water, before drying using filter paper. The 
stacking gel was then added to the casting module to set above the running gel, the loading 
comb was added to the top of the gel and allowed to set. The formula for the 10% gel is shown 
below. 
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Table 1 - The formulation of the 10% running gel and 6% stacking gel used during SDS-PAGE 
immunoblotting 
Running Gel Stacking Gel 
Reagent Volume Reagent Volume 
Double Distilled Water 3.2 ml   Double Distilled Water 2.13 ml   
30% Acrylamide (Fisher Scientific) 2.67 ml   30% Acrylamide (Fisher Scientific) 0.8 ml   
1.5M Tris-HCl pH 8.8 2 ml   0.5M Tris-HCl pH 6.8 1 ml   
10% SDS 80 µl   10% SDS 40 µl   
10% APS  80 µl   10% APS  40 µl   
TEMED  5.33 µl   TEMED  2.67 µl   
 
 
The protein samples were denatured at 60°C for 4 minutes in SDS loading buffer (Appendix I), 
vortex-mixed and centrifuged, before loading into the wells. After setting up the Tetra-lock 
Mini-protean (Bio-Rad, UK) electrophoresis apparatus and 10% acrylamide gel, 25μg of each 
protein sample was loaded per well and 5µl of a colour plus pre-stained protein ladder (New 
England Biolabs, UK) was loaded into one well to act as a marker.  
 
The distance migrated through the gel was strictly dependent upon the molecular weight of the 
protein. The gel was run at 100V for 15 minutes in running buffer 242 (Appendix I) to allow the 
samples to migrate through the stacking gel. The voltage was then increased to 120V and run 
for a further 1 ½ hours. After the samples had migrated the required distance through the 
acrylamide gel it was placed into the transfer apparatus, as described below. The proteins were 
transferred onto polyvinylidene difluoride (PVDF) membranes (GE Healthcare, UK), pre-soaked 
in 100% methanol for 10 minutes, using the Mini Trans-Blot Module (Bio-Rad, UK).  Blotting 
pads and filter papers were pre-soaked in transfer buffer for 10 minutes and assembled as 
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described in (Fig. 9). The gel was removed from the running cassette and laid on top of the filter 
paper and blotting pad. The PVDF membrane was placed on top of the gel. Filter paper and 
blotting pads were then placed on top and any trapped air was removed using a roller (Fig. 9). 
The proteins were electro-transferred in transfer buffer 242 (Appendix I) for 2 ½ hours at 60V.  
 
 
 
 
 
 
Ponceau S staining solution (0.1% ponceau S in 5% acetic acid) (Sigma Aldrich, UK) was used to 
detect efficient transfer of proteins. The PVDF membrane was rinsed in the ponceau S staining 
solution for 10 minutes. The membrane was rinsed in distilled water to remove background 
staining. Any detectable proteins can be seen by a red stain in the location of the proteins. The 
ponceau S stain reversibly to the proteins and can therefore be completely removed by several 
washes with distilled water.  
 
 
Fig. 9 – Protein transfer assembly. The diagram shows the layers necessary for the transfer of 
separated proteins onto a membrane, in preparation for immunoblotting. 
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After the proteins had been transferred the PVDF membranes were cut at 80kDa. The 
membranes were then blocked in 5% non-fat skimmed milk (Marvel, UK) in Tris-Buffered Saline 
and Tween 20 (TBST) (Appendix I) for 1 hour on a plate rocker. Following blocking the 
membranes were rolled into a 15ml falcon tube containing the relevant antibody. The top 
section of the membrane, over 80KDa, was incubated with mouse-anti-HIF1α (1:750; BD 
Biosciences, UK) and the bottom section with the house keeping protein mouse-anti-β-actin 
(1:1000, Abcam, UK) made in 4.5ml of 5% non-fat skimmed milk in TBST. The membranes were 
then incubated overnight in the corresponding antibody overnight at 4°C on a slow rolling 
mixer.  
 
The following day the membranes were washed three times with TBST for 10 minutes on a plate 
rocker. The membranes were then incubated for 1 hour at room temperature in the horseradish 
peroxidase (HRP) conjugated secondary antibody anti-mouse IgG-HRP (1:3000; New England 
Biolabs, UK) made in 5% non-fat skimmed milk in TBST. After the secondary antibody incubation 
the membranes were washed three times with TBST for 10 minutes per wash to minimise non-
specific signal.  
 
The membranes were briefly dried before the addition of enhanced chemiluminescence (ECL) 
reagent (Appendix I) 256, which reacts with the HRP-conjugate emitting luminescence and can be 
detected using X-Ray film. The ECL was prepared by mixing equal volumes of ECL solution 1 and 
ECL solution 2 and keeping in the dark (Appendix I). ECL reagent was added to cover the 
membrane and allowed to incubate for 5 minutes before excess reagent was removed. They 
were then transferred to a film cassette to protect them from light and taken to a dark room. 
The membranes were exposed to CL-Xposure film (Thermo Scientific, UK) for 1-10 minutes, to 
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obtain the optimal signal which depends on the primary and secondary antibody affinity and 
the HRP conjugate reacting with the ECL to form the luminescence reaction. The film was then 
developed using a western blot film developing machine (Konica Minolta SRX-101A). 
 
Following the detection of the β-actin housekeeping protein the bottom section of the 
membranes were incubated in the western stripping buffer 242 for 30 minutes at 50°C. The 
membranes were then washed three times in TBST for 10 minutes each wash at room 
temperature before re-blocking of the membrane using 5% non-fat skimmed milk in TBST for 1 
hour. The membranes were re-rolled into 15ml centrifuge tubes containing rabbit-anti-MMP14 
(1:1000; Abcam, UK) made in 4.5ml of 5% non-fat skimmed milk in TBST. The membranes were 
then incubated overnight at 4°C on a slow rolling mixer. 
 
The following day the membrane was washed three times with TBST for 10 minutes on a plate 
rocker. The membrane was then incubated for 1 hour at room temperature in the horseradish 
peroxidase conjugated secondary antibody anti-rabbit IgG-HRP (1:3000; New England Biolabs, 
UK) made in 5% non-fat skimmed milk in TBST. After the secondary antibody incubation the 
membrane was washed three times with TBST for 10 minutes per wash. The membrane was 
briefly dried before being submerged in the ECL reagent for 5 minutes. The excess reagent was 
removed and the membrane transferred to a cassette to protect it from light and taken to a 
dark room where the membrane was exposed to CL-Xposure film (Thermo Scientific, UK) for 2 
minutes. The film was then developed using a western blot film developing machine (Konica 
Minolta SRX-101A). Data was collected by measuring the densitometry of the western blot 
bands and standardising these readings to a background control using FIJI software 257. 
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2.3.5 Flow Cytometry of HUVECs 
 
Flow cytometry is a technique that was developed in the late 1960s 258, and allows the analysis 
of size, granulation, internal complexity as well as cell markers  making use of fluorescent dyes 
or antibody conjugates259. A laser is targeted at the cell which scatters the light to be detected 
by relevant probes. The technique has been refined and improved drastically with a number of 
lasers and probes now available allowing for the detection of up to 20 parameters 260.  An 
addition benefit of using flow cytometry is that it allows for sorting of cells depending on their 
antigenic markers. This allows for selection of specific populations of cells which can then be 
analysed or cultured independently from other cell types.  
 
For flow cytometry analysis HUVECs, either transfected or untransfected, were seeded into 6 
well plates at a density of approximately 300,000 cells per well. Once the HUVECs were 80% 
confluent, 24 hours after seeding, wells were incubated in the presence of 0.1µM simvastatin or 
a vehicle control for 24 hours. The following day media was replaced. The cell cultures were 
incubated in either hypoxic (1% O2) or normoxic conditions for 12-16 hours. The cells were 
washed and detached from the gelatin coated flask using accutase solution (Sigma Aldrich, UK) 
and transferred to a 1.5ml centrifuge tube. The cells were centrifuged for 5 minutes at 
4,500rpm at room temperature to form a pellet, before resuspending in 1% BSA diluted in PBS 
and kept on ice. 
 
The cells were transferred to corresponding wells of a 96 well plate, ensuring that there was a 
mixed population of cells in two wells to act as controls, one for an unstained control, and one 
for a secondary only control. The plate was centrifuged at 2000rpm for 1 minute to form a 
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pellet and supernatant was discarded. The cell pellets were resuspended in IC fixation buffer 
(eBioscience) and incubated for 10 minutes at room temperature. Following incubation with 
fixation buffer 100µl of permeabilisation buffer (eBioscience) was added before centrifuging at 
2000rpm for 1 minute. Cell pellets were washed two times in permeabilisation buffer and cells 
were recovered from suspension by centrifugation at 2000rpm for 1 minute.  
 
After the last wash, MMP14 primary antibody (1:100; Abcam, UK) diluted in the 
permeabilisation buffer was added to the cells and incubated on ice for 30 minutes.  The cells 
were then centrifuged for 1 minute at 2000rpm before washing 3 times with permeabilisation 
buffer. Following the last wash the secondary antibody, either goat-anti rabbit IgG-Alexa-488 
(1:400; Invitrogen, UK) or donkey-anti rabbit IgG-Alexa-594 (1:1000; Abcam, UK) diluted in 
permeabilisation buffer, was added to the cell pellets and incubated on ice in the dark for 30 
minutes. The samples were washed three times in permeabilisation buffer before resuspending 
in 1% BSA in PBS. The samples were transferred to corresponding fluorescent activated cells 
sorting (FACS) tubes and kept in the dark at 4°C until analysis using a FACSCalibur or Fortessa 
flow cytometry machine (BD Biosciences, UK). 
 
The cells were gated to exclude any dead cells or debris, as well as to exclude any doublet cells 
that were collected (Fig. 10). The unstained control cells were used to determine the positively 
stained population and these cells were selected for.  
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2.3.6 Immunohistochemistry  
 
 
Immunohistochemical staining is a popular method for both research and diagnostic 
laboratories. The technique relies on the use of specific antibodies for detection of antigens, 
followed by either enzymatic or fluorescence visualisation 261. The use of immunostaining has 
allowed for the characterisation of cell surface structures, morphology and traceability of cells 
which is commonly used in the detection of cancer metastasis in histopathology laboratories 
261,262.  There are two methods for preparing tissues for staining once obtained. These are either 
paraffin embedding or cryosectioning 261.  
 
 
Fig. 10 – The gating logic used to analyse flow cytometry samples. A) Gating to exclude dead 
cells and debris determined through the analysis of the forward and side scatter plots. B) Gating 
to exclude doublet cells determined by the analysis of the forward scatter. 
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2.3.7 Paraffin embedded sections 
 
Carotid atherosclerotic plaque specimens were collected from the Vascular Surgery Department 
of Royal London Hospital. The atherosclerotic plaques were embedded in paraffin wax and were 
sliced to 5µm sections using a microtome before mounting on glass microscope slides. The 
sections were allowed to dry overnight before heating to 65°C to confirm attachment to the 
slide.  
 
The sections were deparaffinised and hydrated by washing twice with xylene, followed by 100% 
ethanol, 70% ethanol and distilled water for 5 minutes per wash. The sections were immersed 
into preheated antigen retrieval solution (10mM citrate pH 6.0) 263 in a water bath at 95°C for 30 
minutes. This breaks the crosslinks of the antigens and allows more efficient binding of the 
antibody. The sections were then allowed to cool at room temperature for 20 minutes before 
rinsing twice in PBS for 5 minutes.  
 
To prevent non-specific binding, the sections were blocked using 10% FBS diluted in PBS 
(blocking solution) for 30 minutes. The MMP14 primary antibody (1:150; Abcam, UK) diluted in 
10% FBS in PBS was added to the sections and incubated for 2 hours in a humidified chamber. 
Following this the sections were rinsed twice in PBS for 5 minutes before the addition of the 
goat-anti rabbit IgG-HRP secondary antibody (1:300; Santa Cruz, USA) and incubation for 1 hour 
in the humidified chamber. The sections were then washed in PBS twice for 5 minutes before 
the addition of the peroxidase substrate (DAB-Dako-K346). The sections were incubated with 
the 3,3'-diaminobenzidine (DAB) solution for 3 minutes at room temperature before washing 
with PBS twice for 5 minutes. The HIF1α antibody (1:50; BD Biosciences, UK) and VE-Cadherin 
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antibody (1:100; Abcam, UK) were diluted in 10% FBS in PBS, added to the sections, and 
incubated at 4°C overnight in the humidified chamber.  
 
The following day the sections were removed and washed twice with PBS for 5 minutes. The 
goat-anti mouse-alkaline phosphatase antibody (1:50; Abcam, UK) was prepared in 10% FBS in 
PBS and incubated on the sections for 2 hours at room temperature in the humidified chamber. 
The sections were washed twice with PBS for 5 minutes before incubating the sections for 6 
minutes with Fast Red solution. To stop the reaction the sections were rinsed with distilled 
water. A drop of haematoxylin was added to the sections and incubated for 2 minutes before 
rinsing with water for 10 minutes and drying the slides at 65°C. The sections were mounted with 
mounting medium and stored at room temperature before examination with the Axioplan 
microscope (Zeiss, UK).  
 
2.3.8 Frozen Sections 
 
The APOE knockout mouse model is an important animal model for atherosclerosis as they are 
known to form atherosclerotic lesions with similar morphology to humans 264. APOE knockout 
mice were fed a high fat diet to induce the formation of atherosclerosis.  
 
Atheroma tissue was collected, frozen and sectioned from APOE knockout mice in collaboration 
with Dr Qingzhong Xiao from the Clinical Pharmacology department at the William Harvey 
Research Institute. These were then fixed in cold acetone for 15 minutes. The sections were 
washed for 5 minutes three times in PBS. Following the washes, the sections were heated to 
75°C for 20 minutes, which inactivates the endogenous alkaline phosphatase (AKP)/HRP activity. 
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The sections were allowed to cool to room temperature before incubating with avidin blocking 
solution (Insight Biotechnology, UK) for 15 minutes, followed by Biotin blocking solution (Insight 
Biotechnology, UK) for 15 minutes. The sections were washed for 5 minutes in PBS before 
incubating with 3% H2O2 made in methanol solution (v/v) for 15 minutes to inactivate the 
peroxidases. The sections were then blocked with 5% FBS for 30 minutes before incubating with 
rat anti-endomucin (1:200; Santa Cruz, USA), rat-IgG control, rabbit-HIF1α (1:75; Novus 
Biologicals, UK) or rabbit-IgG control in 5% FBS overnight in 4°C.    
 
The following day the sections were washed three times for 5 minutes before incubating with 
the secondary antibody, goat-anti-rat-biotin (1:200; VectorLabs, UK) or  goat-anti-rabbit-HRP 
(1:200; Cell Signalling, UK), for 60 or 120 minutes at room temperature.  Sections that were 
biotinylated were washed twice in PBS for 5 minutes and incubated with ABC Vectastain 
(Vectorlabs, UK) for 30 minutes. PBS washes were repeated as before, and the sections were 
developed using DAB (Vectastain) until colour development was seen with the naked eye, 
usually 1-3 minutes. The sections were washed twice with PBS for 5 minutes to stop the 
reaction before incubating overnight with the second primary antibody at 4°C, rabbit-MMP14 
(1:75; Abcam, UK), rabbit-HIF1α (1:75; Novus Biologicals, UK), rat-F4/80 (1:50; Abcam, UK), rat-
endomucin (1:200; Santa Cruz, USA) or the relevant rat or rabbit controls.  
 
Following the second primary antibody incubations the sections were washed three times with 
PBS for 5 minutes before incubating with the secondary antibody, anti-rabbit-AP or anti-rat-AP 
(both 1:100; Sigma Aldrich, UK). The sections were washed twice for 5 minutes with PBS before 
incubating with Fast Red (Sigma Aldrich, UK) and developing for 5-15 minutes until colour 
development was detected.  The colour development was stopped by washing twice with PBS 
P a g e  | 87 
 
for 5 minutes before cleaning the sections and allowing to dry. Sections were counterstained 
with haematoxylin (Sigma Aldrich, UK) for 2 minutes before washing twice with PBS for 5 
minutes and drying for 10 minutes at 60°C. The sections were then mounted with mounting 
media (Sigma Aldrich, UK) and analysed with the Axioplan microscope (Zeiss, UK).  
 
2.3.9 Chromatin Immunoprecipitation Assay 
 
The Chromatin Immunoprecipitation (ChIP) assay is a technique that allows for the study of 
protein interactions with specific DNA sequences 265. The first ChIP assay was developed in 1984 
by Gilmour and Lis 266. The early technique involved using UV light to cross link the DNA to the 
protein irreversibly. In 1997 the ChIP assay was adapted so that it could be used for mammalian 
cells. The detection of DNA was also improved by using PCR analysis rather than Southern Blots 
267.  The ChIP assay can use a crosslinking method, such as formaldehyde treatment or UV 
radiation, to link the proteins to DNA. Following this the chromatin is sheared with a sonicator 
to reduce it reduce it to shorter fragments, between 100bp to 1000bp, that can be assessed. It 
is also possible to use nucleic acid digestion for proteins that bind to DNA with high affinity 265. 
The ChIP assay followed a modified protocol provided by Merck Millipore, UK. The details are 
outlined below.  
 
HUVECs were cultured in 10mls of HUVEC media in 8xT75 flasks, with each condition requiring 
two separate T75 flasks. The four conditions used were hypoxic, normoxic, hypoxic with 0.1µM 
simvastatin and normoxic with 0.1µM simvastatin. Simvastatin was added to the cells that 
required treatment for 24 hours prior to the ChIP experiment. Cells that required hypoxic 
incubation were placed in the hypoxic incubator for 6 hours at 37°C. Following treatment the 
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proteins were cross-linked to DNA by the addition of 16% formaldehyde (Thermo Scientific, UK), 
to a final concentration of 1%, and incubated at room temperature for 10 minutes (Merck 
Millipore, UK). The cells were washed twice with ice cold PBS to remove any excess solution. 
The cells were then scraped in 1ml of PBS containing 1x protease inhibitors before aliquoting 
evenly into two 1.5ml microcentrifuge tubes per condition. A cell pellet was obtained by 
centrifuging the collected samples at 2,500rpm for 4 minutes at 4°C, which was subsequently 
resuspended in 200µl of ChIP lysis buffer (Appendix I) 268 containing protease inhibitors and kept 
on ice for 10 minutes. To shear the chromatin to 200bp-1000bp fragments, a probe sonicator 
was used. Optimised conditions showed that the most effective shearing occurred at 30% 
frequency, with a microtip limit of 3, for 35 seconds. To prevent the samples from overheating 
the samples were kept on ice and only sonicated in bursts for a maximum duration of 10 
seconds.  
 
Following sonication, the samples were centrifuged at 13,000g for 10 minutes at 4°C and the 
supernatant was collected and transferred to a new 1.5ml microcentrifuge tube. The samples 
were then diluted to 1ml with the addition of ChIP dilution buffer  (Appendix I) 268, 20µl of each 
sample was taken as an input control and stored at -20°C. The sonicated lysates had 40µl 
protein G-agarose beads (Merck Millipore, UK) added and were rotated for 90 minutes at 4°C to 
reduce non-specific binding. The samples were centrifuged at 4000g for 1 minute to pellet the 
protein-G-agarose beads and the supernatant was collected and transferred to a new 1.5ml 
microcentrifuge tube. Five µl of the HIF1α immunoprecipitating antibody (Thermo Scientific, 
UK) were added to the supernatant before incubating at 4°C overnight on a roller.  
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The next day 60µl of protein G agarose/salmon sperm DNA (50% slurry) (Merck Millipore, UK) 
was added to the samples and incubated for 3 hours at 4°C on a roller, to pellet-down the 
antibody/DNA complex. The protein-G-agarose beads were pelleted by centrifuging the samples 
for 1 minute at 4000g. The supernatant was removed and the protein-G-agarose/antibody/DNA 
complexes were washed for 5 minutes by the addition of 1ml of each of four buffers, and 
centrifugation at 4000g to reform the pellet. The buffers were added in the following order; low 
salt buffer, high salt buffer, LiCl buffer and finally TE buffer (Appendix I) 268. The DNA/protein 
complex was eluted from the antibody by the addition of 100µl of ChIP elution buffer (Appendix 
I) (Merck Millipore, UK) to the pelleted protein-G-agarose/antibody/DNA complexes. The 
samples were mixed and placed on a rotating platform for 15 minutes at room temperature 
before centrifuging at 4,000g and collection of the supernatant. This elution step was repeated 
so that the final elution gave a total of 200µl. To the eluted samples 0.4M NaCl was added 
before heating overnight at 65°C to reverse the protein-DNA crosslinks. The input DNA was also 
included at this step, with the addition of 4M NaCl.  
 
The next day the DNA was extracted from the samples by the addition of 32µl of ChIP digestion 
buffer (Merck Millipore, UK) (Appendix I) and incubation for 1 hour at 45°C. The DNA was then 
recovered by using Wizard® SV Gel and PCR Clean-Up System (Promega, Southampton, UK), 
according to the manufacturers recommendations. Briefly 200µl of membrane dilution buffer 
was added to the samples which were then transferred to a DNA binding column, inside the 
collection tube. The samples were allowed to incubate for 1 minute at room temperature 
before centrifuging at 13,000g for 1 minute. The flow through was discarded and the filter was 
washed with 400µl of membrane wash solution, containing ethanol. The samples were 
centrifuged at 13,000g for a further minute before discarding the flow through and washing the 
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filter again with 400µl of membrane wash solution. The sample was centrifuged at 13,000g for 1 
minute with the flow through discarded. The filter was allowed to air dry for 10 minutes before 
transferring to a new collection tube and adding 30µl of nuclease free water to the filter. The 
sample was centrifuged for 2 minutes at 13,000g, the flow through was collected and the DNA 
concentration was analysed using a Nanodrop spectrophotometer (ND-1000).  
 
2.3.10 PCR of ChIP DNA 
 
The polymerase chain reaction (PCR) was used to evaluate the effectiveness of the ChIP assay. 
PCR is a widely used technique in biological research which amplifies a specific region of DNA 
using selected primers. In order to amplify the DNA, a heat stable polymerase, isolated from the 
Thermus aquaticus bacterium, is required (Taq Polymerase). The reason for a heat stable 
polymerase is due to the temperature required to denature the DNA. The denaturing step 
unravels the DNA allowing access for the primers to the target DNA. Denaturation commonly 
occurs around 95°C. Following denaturation, the primers anneal to the DNA with optimal 
annealing occurring around 60°C but this is dependent on the composition of the nucleotides in 
the primers. The final stage of PCR is the extension which is where the amplification of DNA 
occurs, which is optimal for Taq polymerase at 72°C.   
 
The PCR reaction for the ChIP assay amplified the MMP14 promoter around the potential HIF-
Binding site. The primers used were forward 5’-CAGCCTGCACCACAAAAAG-3’ and reverse 5’-
CTTCTCCCACAGCCTCTCCT-3’ with an expected amplicon size of 160bp. The PCR consisted of 
0.4µM of the forward and reverse primers, 200µM dNTPs (Bioline),  1.25 units of Taq 
polymerase (Sigma Aldrich, UK), 1x PCR Buffer, 2mM MgCl2, and 20ng of the sample DNA 
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topped up to 25µl with nuclease-free water for each PCR reaction. The samples were vortexed 
and briefly centrifuged before loading onto the PCR thermal cycler (MJ Research) and loading 
the relevant program (Table 2). 
 
Table 2 – Details of the ChIP assay PCR program optimised for amplification of the MMP14 
gene promoter region 
PCR Stage Temperature Time 
Hot Start 95°C 5 minutes 
Repeat Cycle 
35 times 
Denature 95°C 60 sec 
Anneal 57°C 60 sec 
Extend 72°C 30 sec 
Extension 72°C 10 minutes 
Hold 4°C ~ 
 
 
The PCR products were run on a 2% agarose gel, made in TBE (Sigma Aldrich, UK) with the 
addition of 0.0001% Gel Red (Biotium) to detect the DNA amplicons. Gel Red binds to the DNA 
through intercalation and electrostatic interaction and can be detected by emitting 
fluorescence under UV light (Biotium). Images were taken of the electrophoresis gels using a UV 
light viewer and UV reader software. Data was collected by measuring the densitometry of the 
PCR amplicon bands and standardising these readings to a background control using FIJI 
software 257. 
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2.3.11 Tube Formation Assay 
 
The in vitro tube formation assay allows the analysis of promoters and inhibitors of angiogenesis 
using endothelial cells seeded onto a matrigel matrix. Cells attach to the matrigel, migrate 
towards each other and form tube like structures in response to a stimulus 269. The technique 
allows for an analysis of multiple angiogenic parameters than other in vitro angiogenesis 
methods, that commonly only allow for the analysis of a single parameter 269.  
 
The tube formation protocol followed a standard procedure developed in our laboratory using 
growth factor reduced Matrigel (BD Biosciences, UK) 188. 
 
Matrigel (BD Biosciences, UK), 96 well plates and pipette tips were cooled to 4°C overnight, the 
day before the tube formation assay. The following day the 96 well plates were kept on ice in 
the culture hood and 30µl of Matrigel was used to coat the bottom of the tissue-culture wells, 
using the cooled pipette tips to prevent early Matrigel polymerisation. The plates were 
incubated in the 37°C incubator for 30 minutes to allow the Matrigel to polymerise. The cells 
that were to be used for the tube formation assay were washed and detached from their 
culture flasks using trypsin, before resuspending in complete HUVEC media and transferring to a 
1.5ml centrifuge tube. 
 
The cells were centrifuged at 1,250rpm for 5 minutes to form a cell pellet before resuspending 
in tube formation media (M199, 10ng/ml insulin, 1 % BSA, HUVEC supplements, 100units per ml 
of penicillin, 0.1mg/ml streptomycin solution, 2mM of glutamine), either with or without 
simvastatin supplementation. The cells were resuspended thoroughly to avoid clumping and 
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30µl aliquots were taken from each cell donor to be counted. The cells were counted using a 
haemocytometer (Hawksley, UK) and calculations were made to ensure that 15,000 cells 
(diluted to 100 cells/µl) were added to the relevant wells of a 96 well plate. The experiments 
were conducted with a hypoxic plate and a normoxic plate in parallel, with half of each plate 
being for simvastatin treated cells. The plates were incubated for 8 hours at 37°C in a 
humidified cell culture incubator.  
 
The plates were then imaged using a brightfield microscope (Nikon) at 4x magnification to 
assess the tube formation. After the images had been taken the media was removed from the 
96 well plates and 200µl of glutaraldehyde was added to fix the cells. The plates were stored at 
4°C overnight.  
 
The following day the glutaraldehyde was removed from the wells and 100µl of ice-cold acetone 
(-20oC) was added to the cells for 10 minutes. The acetone was removed and 10% FBS made in 
TBS was added and incubated with the cells for 30 minutes. The solution was removed and 50µl 
of the primary antibody, anti-MMP14 (1:100; Abcam, UK), made in 10% FBS in TBS was added to 
the wells and incubated for 1 hour. Following the primary antibody incubation the cells were 
washed three times with 10% FBS in TBS before adding 50µl of the secondary antibody, Goat-
anti-rabbit-FITC (1:200; Abcam, UK), for 1 hour. The cells were washed a further 3 times in 10% 
FBS in TBS before the addition of 4', 6-diamidino-2-phenylindole (DAPI) (Invitrogen, UK) and 
incubated for 30 minutes on ice in the dark.  
 
The 96 well plates were analysed using a fluorescent microscope (AMG Evos Fl Microscope) and 
digital images were recorded. The images were analysed using the FIJI software with an 
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angiogenesis analysis software plugin 257,270. The angiogenesis analysis software allows for 
effective measurement of several parameters including total branching length, number of 
junctions and number of nodes.  
 
2.3.12 MMP14 Neutralisation 
 
In order to assess MMP14 inhibition in several experiments an MMP14 antibody (Merck 
Millipore, UK) or a Rabbit IgG-control (Santa Cruz, USA) was added to cell cultures at previously 
published concentrations (2.12µg/ml) 271. The MMP14 antibody is targeted to the catalytic 
domain of MMP14 and has shown to be effective in neutralising MMP14 activity 271. The 
antibody was targeted at a conserved sequence in the catalytic domain of MMP14 between 
humans and mice and therefore was suitable for use in both human and murine studies.  
 
2.3.13 In vitro Scratch Migration Assay 
 
 
The in vitro scratch migration assay is a well-established method for analysing cell migration 
through the direct observation of cell migration in a cell monolayer culture across a cleared 
scratch 272,273. Although the technique is simple it provides several advantages to other methods 
for analysing cell migration as it takes into account the cell-cell and cell-ECM interactions, which 
are often disrupted in other methods 272.   
 
HUVECs were transfected with either HIF1α or scramble siRNA and seeded onto 12 well plates 
coated with 0.04% gelatin at a density of approximately 200,000 cells per well. The cells were 
cultured until they had achieved 80% confluency, in the presence or absence of 0.1µM 
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simvastatin. Subsequently, the cell monolayer was scratched using a p200 tip to introduce a 
wound. The cells were washed twice with PBS before replacing with HUVEC media with or 
without 0.1µM simvastatin and with an MMP14 neutralising antibody (2.12µg/ml) (Merck 
Millipore, UK) or a rabbit-IgG control (Santa Cruz, USA).  The addition of the MMP14 neutralising 
antibody allowed for the analysis of MMP14 inhibition on cell migration.  
 
The HUVECs were imaged at the 0 hour time point before placing in hypoxia. The HUVECS were 
then imaged after 6 hours and migration was assessed using FIJI analysis software 257. The 
migration was analysed by measuring the wound width at the 0 hour time point and the 6 hour 
time point. This measurement was then used to determine cell migration. In order to limit bias 
the images were coded and measured in a blinded fashion, with several measurements taken 
for each image to obtain an average. 
 
 
2.3.14 Bromodeoxyuridine Proliferation Assay 
 
5-Bromo-2’-deoxyuridine (BrdU) is a thymidine analogue that can be used as a substitute and 
traced to measure proliferation. The BrdU is incorporated into the DNA during the S-phase of 
cell division and therefore successive divisions and proliferations can be traced through 
detection of the incorporated BrdU, commonly using immunohistochemistry 274. 
  
The BrdU colorimetric cell proliferation ELISA kit (Roche) was used to assess the proliferation 
according to manufacturer’s recommendations. HUVECs transfected with either HIF1α siRNA or 
scramble siRNA were seeded onto a 96 well plate coated with 0.04% gelatin. Simvastatin or a 
vehicle control was added 24 hours post transfection.  BrdU was added to the cell cultures 
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before incubating in hypoxia for 12-16 hours with either 2.12µg/ml rabbit-IgG control or 
2.12µg/ml MMP14 neutralising antibody. A blank control was used whereby BrdU was added to 
wells that did not contain any cells. A background antibody control was also prepared at this 
stage through incubating some cells without BrdU. Following the hypoxic incubation the 
HUVECs were fixed with the supplied fixing and denaturing solution for 30 minutes. Following 
fixation the cells were incubated with the anti-BrdU-peroxidase antibody for 90 minutes. The 
cells were washed three times with PBS before adding the substrate solution. Once the 
substrate solution was added the colorimetric readings were read using a plate reader at 370nm 
wavelength, with reference wavelength at 490nm. The readings were analysed and the blank 
control values were subtracted from each experimental well reading.  
 
 
2.3.15 Apoptosis Assay 
 
Flow cytometry can be used to study cellular apoptosis because of its ability to differentiate cell 
size using forward light scatter. This can determine if the cell has shrunk and therefore 
apoptotic, or enlarged and therefore necrotic 275. Commonly however, more quantitative results 
are desired and therefore apoptotic marking antibodies and dyes, such as annexin V and 
propidium iodide (PI) can be used 276. This method of apoptosis detection allows for the 
distinction of cells that are viable, necrotic or apoptotic 276, due to changes in the plasma 
membrane permeability and integrity 275. Necrotic cells cannot exclude PI which intercalates 
with nuclear DNA in the nucleus emitting a red fluorescent signal. Apoptotic cells with an intact 
membrane are impermeable to PI and therefore no signal will be emitted 275. Annexin V binds to 
the phosphatidylserine, which is usually intracellular but translocates during early apoptosis to 
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be expressed on the exterior cell membrane 275. Utilising an annexin V-fluorochrome conjugated 
antibody alongside PI therefore allows for the detection and distinction of viable and non-viable 
cells as well as to differentiate between different stages of the apoptotic process.  
 
The apoptosis assay followed the annexin V staining protocol provided by eBioscience. HUVECs 
were transfected with either a HIF1α siRNA or scramble control siRNA and cultured on 0.04% 
gelatin for 48 hours. The media was then replaced with conditioned media containing either 
0.1µM simvastatin or vehicle, or 2.12µg/ml MMP14 inhibitory antibody or rabbit IgG control 
and grown for a further 24 hours, before placing in either hypoxic or normoxic incubation for 4 
hours. A control culture containing 10µM MG132 was used as a reference for apoptosis, as it is 
a known inducer of apoptosis 277. The cells were then removed from the culture dishes using 
accutase before pelleting, resuspending in 1% BSA in PBS solution and transferring to 
corresponding wells of a 96 well plate. The plate was centrifuged at 2000rpm for 1 minute to 
form a pellet, which was washed twice with 1% BSA in PBS. The cells were then washed once 
more with 1x binding buffer (eBioscience) before resuspending in 1x Binding buffer with 5µl of 
annexin V conjugated antibody (eBioscience). The cells were incubated at room temperature for 
15 minutes in the dark before washing a further time with 1x Binding buffer. The cells were 
resuspended in 200µl 1x Binding buffer and 5µl of PI was added. The cells were taken to the 
flow cytometry facility and analysed using the LSRFortessa machine (BD Biosciences, UK).  
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2.3.16 Electrophoretic Mobility Shift Assay (EMSA) 
 
The electrophoretic mobility shift assay (EMSA) is a technique used to discover protein and 
nucleic acid interactions. Initially, the technique was described by Eisinger in 1971 278 with 
further modifications of the methodology by Garner and Revzin in 1981 279. The technique 
involves mixing nucleic acid sequences with proteins before separating the proteins using a 
polyacrylamide or agarose gel under electrophoresis. If the proteins and nucleic acids interact, a 
complex is formed which will run slower through the gel. The nucleic acids are tagged with an 
enzyme or a radioisotype for easy detection of protein nucleic acid complexes 280.  
 
The EMSA was carried out by Dr Conrad Hodgkinson. The protocol involved the use of  
biotin-labelled, double-stranded oligonucleotide probes which were incubated with HIF1α and 
HIF1β proteins, synthesised using the TnT Quick Coupled Transcription/Translation System 
(Promega, Southampton, UK). The primer probe sequences that were used are displayed below 
(Table 3) and were annealed with their reverse complement sequences respectively.  
 
Table 3 – Primer probe sequences used in the EMSA 
Primer Probe Target Primer Sequence (5' - 3') 
MMP14 proximal HRE wildtype AAACAACCACGTCCCCAACCA 
MMP14 proximal HRE mutant AAACAACCTTTTCCCCAACCA 
MMP14 distal HRE wildtype ATGGTGGCACGTGTTTGTAGT 
MMP14 distal HRE mutant ATGGTGGCTCGTTTTTGTAGT 
 
The probe and protein mixture were incubated in EMSA binding buffer (Appendix I) for 30 
minutes on ice, before subjecting to non-denaturing polyacrylamide gel electrophoresis at 4°C. 
Free probes and probe-protein complex were detected using a LightShift Chemiluminescent 
EMSA kit (Pierce Biotechnology).  
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2.3.17 Luciferase Assay 
 
 
Luciferase reporter assays are used as indicators of gene expression changes. The technique 
involves the cloning of a DNA sequence of interest into a plasmid vector. The cloned DNA 
sequence should be upstream of the luciferase reporter gene which will act as an indicator of 
the transcriptional efficiency of the DNA sequence of interest. Luciferase is commonly used as it 
provides a bioluminescent signal that can be quantified using a luminometer281.  
 
The luciferase assays were carried out by Dr Conrad Hodgkinson. Cultured mouse yolk sac 
endothelial cells (C166) were transfected with an MMP14 gene promoter-firefly luciferase 
reporter gene construct, together with plasmids to overexpress HIF1β or HIF1α+HIF1β, and a 
plasmid containing the Renilla luciferase gene to serve as a reference for transfection efficiency. 
The transfected cells were exposed to hypoxia (1% oxygen) or maintained under normoxia for 
18 hours. MMP14 promoter activity was measured by dual-luciferase assays. Mutations were 
introduced in the MMP14 promoter sequence at the HRE positions and subjected to HIF1α 
overexpression.  Analysis was performed by dual luciferase assays. The transfected cells were 
cultured in the presence or absence of simvastatin (2µM), and exposed to hypoxia (1% oxygen) 
or maintained under normoxia for 18 hours. MMP14 promoter activity was measured by dual-
luciferase assays using the Glomax 20/20 system (Promega, Southampton, UK). 
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2.4 Murine Work 
 
2.4.1 Breed Plan  
 
A breed plan to produce HIF1α endothelial-specific knockout mice was created (Table 4) and 
utilised HIF1αfl/fl mice from The Jackson Laboratory (B6.129-Itm3Rsjo/J) and Tie1 Cre+ mice which 
would target the knockout specifically for endothelial cells. The generation of these mice utilises 
Cre-Lox technology. Cre-Lox technology involves the use of the cyclization recombinase (cre) 
gene of the bacteriophage P1 and is a site specific DNA recombinase. Cre specifically recognises 
a DNA sequence known as the locus of X-over of P1 (LoxP) site and excises the DNA between 
two of these sites. The use of the cre gene and the loxP site, incorporated into the mouse 
genome surrounding a gene of interest, allows for the excision of specific genes. When the cre 
gene is under the influence of a tissue specific promoter, such as that of Tie1, then the excision 
of the DNA flanked by the LoxP sites will only occur in tissues expressing this gene 282.  
 
In order to produce HIF1αfl/fl Cre+ and HIF1αfl/fl Cre- mice, 3 male HIF1αfl/fl mice from The Jackson 
Laboratory were purchased (B6.129-Itm3Rsjo/J) and crossed with female Tie1 Cre+ females, kindly 
supplied by Professor Hodivala-Dilke. This breeding pair produced four potential outcomes 
which could be used for the next stage cross. The second cross involved the use of either male 
or female HIF1αfl/wt; Tie1 Cre+ mice crossed with HIF1α fl/wt; Tie1 Cre- mice. This second stage 
cross had 12 possible outcomes, of which 4 genotypes could be used for the final breeding 
cross.  
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The final cross involved the use of either male or female HIF1αfl/fl Cre+ mice crossed with 
HIF1αfl/fl Cre- mice of opposite gender. This final cross would produce both the knockout model 
and the control which were used in subsequent in vivo and ex vivo experiments. 
 
Table 4 – Outline of the breed plan used to create HIF1α endothelial cell specific knockout 
mice 
1st Breed Pair 
Male HIF1αfl/fl X Female Tie1 Cre+ 
2nd Breed Pair 
Male or Female HIF1αfl/wt; Tie1 Cre+ X Female or Male HIF1α fl/wt ; Tie1 Cre- 
3rd Breed Pair 
Male or Female HIF1αfl/fl; Tie1Cre+ X Female or Male HIF1αfl/fl; Tie1Cre- 
 
 
 
2.4.2 DNA Extraction from Mouse Tissue 
 
Ear snips are commonly used as a DNA source from laboratory rodents as this method also 
allows for future identification of the mice. In order to obtain DNA from the ear tissue an 
extraction process is performed, which involves lysing of the cell, salt precipitation of proteins 
and finally ethanol precipitation of DNA 283.  
 
An ear snip was collected from 18-20 day old mice pups in a manner which would enable 
identification between the pups after they were genotyped. The DNA extraction followed a 
standard isopropanol / ethanol extraction protocol whereby the tissue was lysed in 700µl of 
DNA lysis buffer (Appendix I) 284 and 20µl of 20mg/ml Proteinase K before incubating in a water 
bath at 55°C overnight with several vortexes for the first three hours to disperse the tissue. The 
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following day the samples were removed from the water bath, vortex mixed, and 275µl of 5M 
NaCl was added. The samples were vortexed and then mixed on a rocker for 5 minutes at room 
temperature before centrifuging at 13,000rpm for 7 minutes. Following the centrifugation, the 
supernatant was transferred to a new 1.5ml microcentrifuge tube and 500µl of isopropanol was 
added. The sample was mixed on a rocker for 2 minutes before centrifuging at 13,000rpm for 5 
minutes. The supernatant was discarded and the DNA pellet was washed with 500µl of 70% 
ethanol and centrifuged at 13,000rpm for 2 minutes. As much of the supernatant as possible 
was removed without disturbing the DNA pellet and the sample was left to air dry. Once the 
sample had been air dried, 70µl of nuclease free water was added to the sample which was 
subsequently vortexed and burst centrifuged before measuring the DNA concentration using a 
Nanodrop spectrophotometer (ND-1000). The DNA concentrations were standardised to 5ng/µl 
before use for PCR analysis.  
 
2.4.3 Genotyping Mice 
 
The DNA collected from the mice had to be genotyped for expression of Cre Recombinase, 
specific to Tie1, and the floxed HIF1α gene. The Cre Recombinase gene would either be present 
or absent, whereas the floxed HIF1α gene could either be floxed-floxed, floxed-wildtype, or 
wildtype-wildtype. The PCR consisted of 0.4µM of the forward and reverse primers, 200µM 
dNTPs (Bioline), 1.25 units of Taq (Sigma Aldrich, UK), 1x PCR Buffer, and 20ng of the sample 
DNA. To the Cre Recombinase primers 2.5mM MgCl2 was added, and to the HIF1α primers 2mM 
MgCl2, was added before topping up to 25µl with nuclease free water for each PCR reaction. 
The samples were vortexed and briefly centrifuged before loading onto the PCR thermal cycler 
(MJ Research) and loading the relevant program (Tables 5 and 6). 
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The HIF1α genotype could be assessed through the position of the bands in relation to a 
marker. The floxed genotype has an extra 50 base pair sequence of DNA and therefore has a 
slower electrophoretic mobility compared to the wildtype on an agarose gel during 
electrophoresis (Fig. 11) (The Jackson Laboratory).  
 
 
Table 5 – Primer sequences and PCR conditions used to genotype mice for Cre Recombinase 
expression 
Primer Name Primer Sequence 
Cre Recombinase 285 
GCCTGCATTACCGGTCGATGCAACGA 
GTGGCAGATGGCGCGGCAACACCATT 
PCR Stage Temperature Time 
Hot Start 93°C  5 minutes 
Repeat 
Cycle 35 
times 
Denature 93°C  30 Sec 
Anneal 67°C  30 Sec 
Extend 72°C 45 Sec 
Extension 72°C 10 minutes 
Hold 4°C ~ 
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Table 6 – Primer sequences and PCR conditions used to genotype mice for HIF1α floxed 
expression 
Primer Name Primer Sequence 
HIF1α Genotype 
(The Jackson Laboratory) 
CGTGTGAGAAAACTTCTGGATG 
AAAAGTATTGTGTTGGGGCAGT 
PCR Stage Temperature Time 
Hot Start 94°C  5 minutes 
Repeat 
Cycle 35 
times 
Denature 94°C  30 Sec 
Anneal 57°C  30 Sec 
Extend 72°C  45 Sec 
Extension 72°C 10 minutes 
Hold 4°C ~ 
 
 
 
 
 
 
Fig. 11 – A representation of the different HIF1α genotypes after gel electrophoresis 
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2.4.4 Isolation of Primary Endothelial Cells from Mice Lungs 
 
The isolation of primary endothelial cells from mouse lung tissue was carried out using well 
established methods described by Reynolds and Hodivala-Dilke286. 
 
HIF1αfl/fl; Tie1Cre+ and HIF1αfl/fl; Tie1Cre- mice were sacrificed four to six weeks after birth. The 
mice were split according to genotype with four mice per endothelial cell preparation used to 
isolate the mouse lung endothelial cells (MLEC). The dissection was performed in sterile 
conditions using a class II culture hood to avoid contamination. Two sets of dissection 
equipment were used, one for the outside of the mouse and the other for inside the body 
cavity. 
 
Prior to dissection the mice were cleaned with 70% ethanol to surface disinfect the mice and 
limit the possibility of contamination. Each mouse was dissected by first making an incision in 
the abdomen and cutting the peritoneal muscle wall to open the body cavity. The ribcage was 
cut and opened to expose the lungs. The lungs were removed by using forceps to lift the lungs 
and using sharp scissors to cut away the heart and connecting tissues. The lungs were placed in 
a petri dish containing 12ml of HamF12 solution. The lungs were cleaned from excess tissues, 
such as the trachea, and blood clots before rinsing in 70% ethanol and transferring to complete 
MLEC medium (Appendix I) 286. Excess liquid was drained before mincing the lungs with scissors 
to form a paste. The minced lung was transferred to a 50ml tube containing preheated 0.1% 
collagenase made in PBS and incubated for 1 hour and 15 minutes at 37°C with occasional 
agitation.  
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Following collagenase treatment 10ml of MLEC medium was added before the tissue was 
further fragmented by mechanically disrupting the tissue through a 30ml syringe and a 19G 
needle several times. This was repeated using a 21½G needle to further break bigger clumps. 
The solution was filtered through a 70µm strainer before centrifuging at 1,200rpm for 3 
minutes. The pellet was resuspended in 10ml of MLEC medium before dispensing in a T75 
coated with 0.1% Gelatin, 10µg/ml fibronectin and 30µg/ml PureCol (Advanced Biometrix).   
 
The following day the monocytes from the preparation were removed using magnetic sorting. 
The media was aspirated and washed three times with PBS before adding 6ml MLEC media and 
incubating at 4°C for 20 minutes. The media was aspirated and cells were washed with PBS 
before adding 3ml of rat-anti-FcyRII/III antibody at 1:1000 dilution, made in PBS, and placing at 
4°C for 30 minutes. The flask was washed once with PBS before 3mls of MLEC supplemented 
with 10µl of anti-rat IgG-Dynabeads (Life Technologies) were added to the flask and incubated 
at 4°C with occasional agitation. The media was aspirated and cells were rinsed twice with PBS 
before detaching the cells from the flask using trypsin. Once the cells were detached they were 
resuspended in MLEC media before dispensing into a 15ml centrifuge tube and placing in a 
magnetic rack. The solution was left for 5 minutes for the magnetic beads to settle before the 
solution was removed and dispensed into a T75 coated with 0.1% gelatin, 10µg/ml fibronectin 
and 30µg/ml PureCol (Advanced Biomatrix) and incubated at 37°C with 5% CO2 for 72 hours.  
 
Following monocyte removal, endothelial cells were positively selected using a similar method. 
Endothelial cells were identified by their clustering together and cobblestone appearance. The 
media was aspirated and washed with PBS before adding 6ml MLEC Media and incubating at 
4°C for 20 minutes. The media was aspirated and cells were washed with PBS before adding 3ml 
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of rat anti-CD102 antibody at 1:1000 dilution, made in PBS, and placing at 4°C for 30 minutes. 
The flask was washed once with PBS before 3mls of MLEC supplemented with 10µl of anti-rat 
IgG-Dynabeads (Life Technologies) were added to the flask and incubated at 4°C with occasional 
agitation. The media was aspirated and cells were rinsed twice with PBS before detaching the 
cells from the flask using trypsin. Once the cells were detached they were resuspended in MLEC 
media before dispensing into a 15ml centrifuge tube and placing in a magnetic rack. The 
solution was left for 5 minutes for the magnetic beads to settle before the solution was 
discarded. The beads were rinsed with MLEC media before dispensing in a T75 coated with 0.1% 
gelatin, 10µg/ml fibronectin and 30µg/ml PureCol (Advanced Biomatrix). 
 
The cells were maintained by replacing the media every other day and passaging once the cells 
had reached 70-80% confluency. 
 
2.4.5 Flow Cytometry of MLECs 
 
MLEC cells were seeded onto four T25s per genotype. Once the MLEC cells were 80% confluent 
two of the T25s were incubated in the presence of 0.1µM simvastatin for 24 hours. The 
following day the media, with or without 0.1µM simvastatin, was replaced in all four of the 
culture flasks. The cell cultures were incubated in either hypoxic (1% O2) or normoxic conditions 
for 12-16 hours. The cells were washed and detached from the T25 using accutase solution 
(Sigma Aldrich, UK) and transferred to a 1.5ml centrifuge tube. The cells were centrifuged for 5 
minutes at 4,500rpm to form a pellet, before resuspending in 200µl of 1% BSA made in PBS and 
kept on ice. 
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A 96 well plate had 150µl of cells transferred to a well corresponding to each condition. The 
remaining cell solution was combined and aliquoted into 2 wells of the 96 well plate to act as 
controls, one for an unstained control, and one for a secondary only control. The plate was 
centrifuged at 2000rpm for 1 minute to form a pellet and supernatant was discarded. The cell 
pellets were resuspended in IC fixation buffer (eBioscience) and incubated for 10 minutes at 
room temperature. Following incubation with fixation buffer, permeabilisation buffer 
(eBioscience) was added before centrifuging at 2000rpm for 1 minute. The cell pellets were 
washed another two times in permeabilisation buffer with a centrifuge at 2000rpm between 
each wash.  
 
After the last wash the rabbit-anti-MMP14 primary antibody and mouse anti-VE-CAD primary 
antibody (1:100 and 1:75; both Abcam, UK) made in the permeabilisation buffer were added to 
the cells and incubated on ice for 30 minutes.  The cells were then centrifuged for 1 minute at 
2000rpm before washing 3 times with permeabilisation buffer. Following the last wash the 
secondary antibodies, donkey-anti rabbit IgG-Alexa-594 and goat-anti mouse IgG-Alexa-488      
(Both 1:2000; Abcam, UK), made in permeabilisation buffer were added to the cell pellets and 
incubated on ice in the dark for 30 minutes. The samples were washed three times in 
permeabilisation buffer before resuspending in 200µl of 1% BSA in PBS. The samples were 
transferred to corresponding fluorescent activated cells sorting (FACS) tubes and kept in the 
dark at 4°C until analysis using a Fortessa flow cytometry machine (BD Biosciences, UK).  
 
The cells were gated to exclude any dead cells or debris, as well as to exclude any doublet cells 
that were collected. The unstained control cells were used to determine the positively stained 
population and these cells were selected for. To ensure that only endothelial cells were 
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analysed a final gate was added to analyse only cells that were positively stained for VE-
Cadherin.    
 
2.4.6 Aortic Ring Assay 
 
In 1990 the ex vivo rat aortic ring assay was developed which aimed to bridge the gap between 
in vivo and in vitro assays for the study of angiogenesis 287. The in vitro assays do not mimic the 
true in vivo environment and their information is usually seen as preliminary data which needs 
to be confirmed using more costly and demanding in vivo assays 288.  The use of ex vivo assays is 
more realistic than in vitro assays but less expensive and demanding than in vivo assays. This 
technique has been advanced and other animal models, such as mice, have been utilized for use 
in aortic ring assays. 
 
The aortic ring assay was performed according to the protocol which has been optimised and 
established in my supervisor’s laboratory and published by Baker et al. 289 
 
HIF1αfl/fl; Tie1Cre+ and HIF1αfl/fl; Tie1Cre- mice that were 4 weeks old were culled by a clean 
break in the neck, to avoid stretching of the aorta and formation of a thrombus which can affect 
sprouting 289. The mice were split according to genotype and kept separate throughout the 
assay. The dissection was performed in a sterile environment to avoid bacterial contamination 
with two pairs of dissection instruments used, one for outside the mouse and one for within the 
body cavity. Prior to dissection the mice were disinfected with 70% ethanol to further limit 
potential contamination.  
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The mice were dissected by first making an incision in the lower abdomen, slicing up to the 
shoulders, and pealing back the skin to allow access to the body cavity. An incision was made in 
the peritoneal wall, the ribcage was cut and opened to allow access to the lungs, heart and 
aorta. The lungs were removed to allow easy access to the aorta. The aorta was located and 
using a fine pair of forceps was lifted and separated from the connective tissue. The aorta was 
sliced at the base and top and transferred to a petri dish containing Opti-MEM media (Life 
Technologies) supplemented with penicillin and streptomycin.  
 
The aorta was cleaned from adventitial tissue, fat and sprouting blood vessels using a dissection 
microscope before thin 1mm sections were cut using a scalpel. The sections of the aorta were 
separated before transferring into a clean dish of Opti-MEM and incubated overnight at 37°C in 
5% CO2.  
 
Aortic rings were embedded on a collagen matrix within a 96 well plate. Separating rings for 
hypoxia or normoxia and with or without simvastatin treatment. Briefly collagen was diluted in 
DMEM media, to 1mg/ml, and neutralising the pH to a slightly basic pH, as indicated by the 
phenol red turning pink, with sodium hydroxide. The 96 well plate was tilted slightly before 
adding 50µl of the collagen solution to the wells. The collagen solution was added a few wells at 
a time to limit the chance of polymerisation before an aortic ring was added. Once the collagen 
was added to the well, an aortic ring was quickly added to the well and left to set by incubation 
at 37°C for 1 hour.  
 
Opti-MEM solution containing 2.5% FBS and 30ng/ml VEGF was added to the aortic rings either 
with 0.1µM simvastatin or the PBS controlled equivalent. The aortic rings we then incubated for 
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three days at 37°C in either hypoxic (1% O2) or normoxic conditions. The media was 
subsequently replaced every two days before ceasing the experiment on the sixth day after 
embedding. On the sixth day the amount of new vessels sprouting from the aorta were counted 
and quantified.  
 
Aortas that were scheduled for immunofluorescence staining had their culture media removed 
and were washed with PBS. Following this 4% formalin was added to the aortas and left to 
incubate at room temperature for 30 minutes. The aortas were then washed three times for 15 
minutes with permeabilisation buffer (PBS + 0.25% Triton-X100). The permeabilisation buffer 
was removed and the aortas were incubated with DAKO-Protein block (DAKO, UK) for 30 
minutes at 37°C. During the incubation the antibody solution was prepared. FITC-probe tagged 
MMP14 antibody (BIOSS Antibodies, USA) was used at a concentration of 1:150. The BS1-Lectin-
TRITC stain (Sigma Aldrich, UK) was used at a concentration of 1:1000. The antibodies were 
diluted in PBLEC buffer at their desired concentration and added to the aortas following the 
incubation with DAKO-Protein Block and incubated in the dark overnight at 4°C.  
 
The following day the aortas were washed three times for 15 minute washes with PBS + 0.1% 
Triton-X100 before a 15 minute wash with distilled water. The aortas were mounted on a 
microscope slide with ProLong® Gold Antifade reagent with DAPI (Invitrogen, UK) and left to set 
in the dark overnight at room temperature.  
 
Images of the aortas were taken using the Axioplan microscope (Zeiss, UK) using the same 
exposures for each condition. FIJI software 257 was used for analysis of the images. The 
fluorescence analysis consisted of outlining a blood vessel sprout in the green colour channel 
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(MMP14). The outlined sprout was then analysed using the mean grey value, which corresponds 
to the degree of fluorescence per pixel.  
 
2.4.7 Sponge Angiogenesis Assay 
 
There are several in vivo assays that measure angiogenesis including the corneal pocket assay 
and the chick chorioallantoic membrane assay, but often these methods lack an effective 
quantification method 290. The rat sponge assay technique was developed in 1987 and aimed to 
provide an angiogenic model that was easily quantifiable 290. This assay allows for the measure 
of blood flow, using radioactive clearance measurements, as well as new blood vessel 
infiltration by histological methods 291. The sponge assay has been adapted to be used in mice 
292 and also substituted in the use of Matrigel instead of sponge, so that parameters such as 
haemoglobin concentration can be measured 293. 
 
The sponge angiogenesis assay followed the published protocol developed in Professor 
Hodivala-Dilke’s laboratory 292. HIF1αfl/fl; Tie1Cre+ and HIF1αfl/fl; Tie1Cre- mice that were 4 to 6 
weeks old were selected for this assay. The mice were subcutaneously injected with either 
10mg/kg of simvastatin (Abcam, UK), dissolved in PBS and prepared as described previously, 
(Merck Millipore, UK) or a PBS control for 28 days.   
 
On the 13th day of injections the mice were shaved along their flanks under isoflurane 
anaesthetic. The following day a sterile polyether sponge (approximately 1 x 0.5 x 0.8cm3) 
(Caligen Foam, UK) was inserted subcutaneously into the flanks of the mice. The mice were 
firstly anaesthetised using isoflurane before injecting Carprieve 5.0% w/v in their scruff. 
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Following this a small incision was made on the lower back and a cavity was produced using 
forceps before inserting a trocar containing the sponge into the cavity. The sponge was 
implanted and the wound was then closed using a wound clip. The sponges were injected every 
other day with 100µl of 10ng/ml VEGF or 100µl of PBS as a negative control, producing a total of 
8 distinct experimental groups (Table 7). 
 
Table 7 – Experimental group design for the sponge angiogenesis assay 
 
Genotype 
Injection Site 
Subcutaneous Sponge 
HIF1α WT 
PBS PBS 
PBS VEGF 
Simvastatin PBS 
Simvastatin VEGF 
HIF1α KO 
PBS PBS 
PBS VEGF 
Simvastatin PBS 
Simvastatin VEGF 
 
After 14 days post implantation the mice were sacrificed and sponges removed and fixed in 4% 
formalin overnight at 4°C.  The next day, the sponges were sliced longitudinally and transferred 
to 70% ethanol before paraffin embedding by the Barts Cancer Institute Pathology department. 
 
Blood vessel infiltration was assessed by immunohistochemistry, as previously described 
(Section 2.2.7.), using 6µm sections which were stained for rat anti-endomucin (1:200; Santa 
Cruz, USA). The sections were also stained for MMP14 (1:75; Abcam, UK) in order to detect 
differences between the differently treated groups. The difference with the previously 
described immunohistochemistry staining technique involved the use of 1% NGS buffer in PBS 
for blocking antigens and preparing the endomucin and MMP14 antibody. The rat anti-
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endomucin antibody also required an anti-rat IgG-biotin and Vectastain (Vector Labs) tertiary 
antibody system to enhance the signal. The number of endomucin positive vessels was assessed 
and counted using the Axioplan microscope (Zeiss, UK) at multiple 20x optical fields.  
 
2.5 Statistical Analysis 
 
All statistical analyses were carried out using GraphPad Prism 5.00 (CA, USA) and IBM SPSS 
Statistics 22 (NY, USA) software. The data is presented as mean + standard error of the mean, 
unless otherwise stated. Statistical significance was determined using parametric statistical tests 
such as one-way analysis of variance (ANOVA), and t-tests as well as non-parametric statistical 
tests such as Kruskall-Wallis ANOVA. P-values less than 0.05 were considered statistically 
significant. 
 
2.6 Experimental Design 
 
 
Experiments were conducted on separate cell references for each experimental group. 
Therefore no same cell reference was used more than once for each experiment. In order to 
limit experimental bias, assays were analysed in a blinded fashion where appropriate.   
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3. Optimisation and Preliminary Results 
 
3.1 Optimisation Results 
 
 
3.1.1 Optimisation of Immunoblots 
 
Immunoblotting is a key technique for protein expression analysis that had to be optimised to 
ensure the correct antibodies and concentrations were used for future experiments. As well as 
this, the harvesting of the protein itself needed to be optimised to ensure that there was 
minimal HIF1α degradation which occurs rapidly when samples are exposed to normoxic 
conditions.  
 
It was important that the correct housekeeping antibody was selected which is not affected by 
hypoxic conditions. After a literature search it was found that common housekeeping genes, 
such as GAPDH 294, are affected by hypoxia. In order to ensure the control normalisation was 
effective β-Actin was selected as the housekeeping gene as it is not affected by hypoxic 
conditions 295.  
 
Protein extraction began with enzymatic cell detachment and pellet formation. This pellet was 
then disrupted and lysed in RIPA buffer to extract the protein from the lysate. This technique 
was successful for detecting MMP14 (Fig. 12A) levels on western blots but was not as successful 
at detecting HIF1α levels (Fig. 12B). It was therefore decided that a new technique for protein 
extraction was required with direct addition of RIPA buffer added to the cell culture flasks being 
the accepted method. This technique provided good detection of MMP14 (Fig. 12C) and gave 
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better results for detection of HIF1α (Fig. 12D) and the housekeeping protein β-Actin (Fig. 12E). 
This is likely due to less opportunity for HIF1α degradation as well as direct lysis of the cells 
providing a greater amount of cells for protein extraction. 
 
The first antibody that was used to detect HIF1α expression (Abcam, UK) contained a strong 
signal at a non-specific band at 60-65kDa (Fig. 12B). Upon contacting the manufacturer of the 
antibody it was confirmed that the non-specific band was unknown. The non-specific band was 
of high intensity making it difficult to assess HIF1α levels. Therefore, it was decided that a new 
antibody should be used (BD Biosciences, UK) which did not detect any non-specific bands (Fig. 
12D).  
 
As the research progressed an antibody that would be able to detect HIF1α in mice was 
required. To test the new antibody MLEC cultures were grown in hypoxia before lysing the cells 
in RIPA buffer to extract the protein. The new antibody was raised in a rabbit host (Pierce) and 
produced a specific band for HIF1α at the expected size of 110kDa (Fig. 12F).  
 
HIF2α was also assayed in order to see if a different expression was seen in subsequent HIF1α 
knockdown experiments. This antibody (Abcam, UK) showed weaker expression compared to 
the other antibodies (Fig. 12G). This may be due to the need to strip the membrane of the 
HIF1α antibody expression before re-probing with anti-HIF2α. The HIF2α antibody also showed 
two non-specific bands at approximately 80kDa (Fig. 12G). 
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Fig. 12 – Immunoblot optimisation results. A) MMP14 expression following protein 
extraction from a cell pellet. B) Immunoblot result after using Abcam antibody for HIF1α 
showing non-specific bands. C) MMP14 expression after protein extraction using direct 
RIPA buffer. D) HIF1α expression after protein extraction of HUVECs using direct RIPA 
method as detected by BD Biosciences antibody. E) β-actin expression used as a 
housekeeping gene. F) HIF1α expression in MLECs detected by Pierce antibody after 
direct RIPA protein extraction. G) HIF2α expression in MLECs detected by Abcam 
antibody following direct RIPA protein extraction and PVDF membrane stripping after 
previous antibody detection. 
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3.1.2 Optimisation of Simvastatin Concentration 
 
It was important to ensure that the concentration of simvastatin used was within a range that 
was not harmful to the HUVECs whilst still exerting an effect which was possible to detect. To 
make sure that the correct concentration of simvastatin was used a search of literature was 
conducted to assess the ranges commonly used. Following this endeavour, HUVECs were 
cultured in 6 well plates and differing concentrations of simvastatin were added to each of the 
wells. The cells were cultured in normoxic conditions over 48 hours and the HUVEC morphology 
was assessed (Fig. 13). 
 
The simvastatin concentration panel shows that as the concentration of simvastatin increases 
there is more cell death. It is also clear that increasing simvastatin concentrations leads to 
morphological changes in the HUVECs which obtain a more spindle like appearance (Fig. 13). 
The simvastatin concentration panel made it clear that the optimal concentration of simvastatin 
to use in subsequent experiments was 0.1µM. 
 
Using 0.1µM simvastatin as the selected concentration is more pharmacologically relevant as it 
is a relatively low dose of simvastatin 125 and more similar to  concentrations in the blood 
stream, where concentrations are less than 0.02µM 134.  
 
The luciferase assays however were conducted at 2µM as decided by Dr Conrad Hodgkinson.  
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Fig. 13 – The effects of increasing simvastatin concentrations on HUVECs 
morphology over 48 hours.  
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3.1.3 Ethanol Vehicle Test  
 
Simvastatin was dissolved in ethanol and therefore it was important to make sure that ethanol 
was not having an effect on protein expression. As the final concentration of ethanol added to 
the cell media was less than 1:50,000, an effect is unlikely. An immunoblot was conducted on 
whole-cell lysates of HUVECs cultured without any additive, with simvastatin, or with a 
matching ethanol vehicle control. The results showed that the use of ethanol had no clear effect 
on the expression of proteins of interest (Fig. 14).  
 
 
 
 
 
Fig. 14 – Ethanol vehicle test. Immunoblots were performed on cells grown without an additive, 
with 0.1µM simvastatin, or with an equal amount of ethanol. It was shown that there was not a 
large difference in protein expression. The trend that is shown by the addition of ethanol shows 
the reverse to that of simvastatin treatment. The results shown are standardised to the β-actin 
as a loading control. 
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3.1.4 Hypoxia Time Course 
 
Once the correct antibodies had been chosen and conditions for the immunoblots were 
optimised, it was vital that HIF1α expression was measured at their highest level, as well as 
MMP14. A hypoxic time course was therefore set up whereby protein was extracted and 
assessed at intervals to ensure that the optimal time was chosen for subsequent studies.   
 
The cells were cultured in hypoxia, with or without 0.1µM simvastatin over a range of time 
points. The chosen time points were 0 hours, 2 hours, 4 hours, 8 hours, 16 hours and 24 hours. 
It was seen that both HIF1α and MMP14 levels were highest expressed at 4 hours in both 
simvastatin and untreated media, with HIF1α protein levels increasing sharply at 4 hours before 
falling sharply to expression levels that matched those of the normoxic condition levels at 8 
hours for untreated media (Fig. 15A). The simvastatin treated media also had peak HIF1α 
expression at 4 hours but maintained expression through until the 8 hour time point (Fig. 15B).  
 
The MMP14 levels were fairly constant throughout the time course however, there was a peak 
seen at 4 hours with a slight decline in expression after the 4 hour time point in untreated cells 
(Fig. 15C). Simvastatin treatment did not appear to effect MMP14 protein expression over the 
time course (Fig. 15D).  
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Fig. 15 – Immunoblot results of HUVECs undergoing a hypoxic time course in untreated or 
0.1µM simvastatin treated media. The time course densitometry analysis results of A) HIF1α 
immunoblot in untreated media, B) HIF1α immunoblot in simvastatin media, C) MMP14 
expression in untreated media, and D) MMP14 in simvastatin media. E) A set of representative 
immunoblots. All results shown are standardised as the % of normoxia expression normalised to 
the β-actin loading control. Bar charts are representative of mean + SEM from 4 separate 
experiments. 
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3.1.5 ChIP Optimisation 
 
The chromatin immunoprecipitation assay needed to be optimised as laboratory-made reagents 
were used alongside a protocol designed for a kit. As well as this, ChIP assays need to be 
optimised for cell type and equipment used to ensure optimal shearing of the chromatin. The 
first optimisation step included the test of two sonication time points which would shear the 
chromatin to different sizes and provide an indication of the optimal time to shear chromatin 
between 200-800 base pairs. Optimal shearing occurred at 40 seconds at 30% duty cycle for 
HUVECs (Fig. 16A).  
 
The following step was to minimise the presence of non-specific DNA, preventing it from 
interacting with the immunoprecipitation step. Different amounts of Protein-G agarose beads 
were used to clear non-specific DNA. The effectiveness of DNA clearance was assessed by a PCR 
reaction using the DNA obtained from this clearing step. It was seen that decreasing volumes of 
Protein-G agarose increased the yield of target DNA (168bp) whilst there was no considerable 
change in non-specific DNA. It was therefore decided that the optimal conditions involved the 
use of 40µl of Protein-G agarose to clear non-specific DNA (Fig. 16B). 
 
Once the optimisation of clearing non-specific DNA was complete the actual 
immunoprecipitation step needed to be optimized to ensure that the Protein-G-agarose-
antibody-antigen complex had enough incubation time to complex together. The 
immunoprecipitation incubation was suggested to only take 1 hour in order to precipitate out 
the required ab-antigen complex and so initially this time point was used. The 
immunoprecipitation efficacy was determined using end point PCR at three separate stages, 
before clearing, after clearing and a waste fraction that would usually be discarded. It was seen 
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that the most specific fraction was the waste fraction and showed that normally the target DNA 
would be discarded (Fig. 16C). It was decided that the immunoprecipitation incubation time 
should therefore be increased and was therefore tested at 2 hour and 3 hour time points. The 
results show that by increasing the incubation time to three hours there was better specificity 
with minimal DNA loss in the waste fraction (Fig. 16D). 
 
Differing protocols suggested using either high NaCl concentrations, or low NaCl concentrations 
for the elution of DNA. Addition of both the higher (8M) and lower (0.4M) concentration were 
analysed alongside each other. It was found that the higher concentration of NaCl drastically 
reduced the amount of DNA eluted as seen by the decreased intensity of the specific band at 
16µbp (Fig. 16E). Therefore, it was decided that the lower concentration of NaCl should be 
used.  
 
Finally it was confirmed that the optimal conditions for subsequent experiments would include 
sonication for 40 seconds at 30% frequency, pre-clearing of the non-specific DNA using 40µl of 
protein-G-agarose, and to immunoprecipitate for 3 hours. In order to elute the DNA the lower 
concentration of 0.4M NaCl was used.  
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Fig. 16 – The stages of HUVEC ChIP optimisation. A) A gel electrophoresis image of the 
shearing of chromatin by a probe sonicator showing that the optimal conditions of 
shearing occur at 40 seconds. B) Pre-clearing of non-specific DNA with increasing 
volumes of protein-G-agarose beads from left to right of the electrophoresis image. C) 
Testing the efficacy of the immunoprecipitation incubation showing the pre-clearing 
DNA, post-clearing DNA and waste DNA PCR reactions. D) Optimisation gel 
electrophoresis image of immunoprecipitation. E) DNA elution optimisation using low 
NaCl concentrations and high concentrations of NaCl respectively. 
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3.1.6 siRNA Optimisation  
 
HUVECs, like most primary cell lines, are known to be difficult to transfect 296 and therefore a 
number of different techniques were tested in order to optimise the knockdown of HIF1α in 
HUVECs. The first method involved the use of endoribonuclease-prepared siRNAs (esiRNA) 
which are formed by cleaving longer double strands of RNA with an endonuclease. This 
produces siRNA which are similar to those generated by Dicer in vivo. Validated knockdown of 
HIF1α was not achieved by using this technique however and so it was decided to move to more 
traditional siRNA. 
 
HUVECs were transfected with the relevant siRNA or a nuclease free water control. The cells 
were allowed to proliferate for 72 hours to allow the siRNA to inhibit mRNA translation into 
protein and any remaining protein to degrade. The HUVECs were then placed in hypoxia or 
normoxia for 4 hours before collecting the protein lysate. The effect of transfection was 
assessed by using immunoblotting. Unfortunately using this method the results are not clear as 
there is no specific pattern of HIF1α knockdown and subsequent effect on MMP14 expression 
activity seen (Fig. 17). 
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Following the failure of detecting knock-down of HIF1α using a lipid based transfection method 
it was decided to try to introduce the siRNA into the HUVECs using electroporation. 
Electroporation involves the use of high voltage to permeabilise the cell membrane of the target 
cell, which allows siRNA in the surrounding buffer to enter the cell. Every cell type requires 
different electroporation conditions and therefore it is important to optimise 297.   
 
The electroporator used was the Nucleofector II device (Lonza, UK) which recommends HUVECs 
should be electroporated using either of two pre-set programmes (A-034 or U-001) 298. The 
commercial kit recommends using their own buffer, however the relevant literature 255 and 
comments from the scientific community, indicated that HEPES buffered saline (HBS) could be 
used as an alternative. A panel was set up using the two different recommended programmes, 
either HBS or PBS, and a green fluorescent protein (GFP) plasmid reporter to show transfection 
 
Fig. 17 – Immunoblots of the optimisation of HIF1α siRNA transfection.  No clear pattern of 
HIF1α knockdown between the two different cell types and conditions can be seen.  
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efficiency. Potential cell death and transfection efficiency were assessed using fluorescence 
microscopy (Fig. 18A). Flow cytometry of these cells was then used to test for actual 
transfection efficiency, measuring for GFP as a marker of plasmid uptake (Fig. 18B and C). 
 
It was seen that the optimal condition was programme U-001 with the electroporation being 
performed in HBS (Fig. 18). This showed a transfection efficiency of over 60% whilst also 
showing less cell death (Fig. 18). The PBS buffer and also programme A-034 were less effective 
than the HBS buffer and programme U-001 and therefore these conditions were not pursued.  It 
was therefore decided that this programme would be the most appropriate to use. Although a 
plasmid rather than siRNA was used for the transfection optimisation, in theory the transfection 
efficiency should be similar as the electroporation would permeabilise the membrane allowing 
uptake of either plasmid or siRNA. 
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Fig. 18 – The optimisation of siRNA nucleofection into HUVECs. A) Immunofluorescence 
microscopy of HUVECs transfected with GFP undergoing different nucleofection and reagent 
conditions. B) Flow cytometry analysis of HUVECs, using GFP as a marker of plasmid uptake, 
nucleofected in HEPES buffered saline buffer with differing nucleofection programs. C) Flow 
cytometry analysis of HUVECs GFP uptake into cells nucleofected in PBS nucleofection buffer 
with differing nucleofection programs. 
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3.1.7 Tube Formation Assay Optimisation 
 
A simple time course, for in vitro tube formation assays, was set up in order to make sure that 
the optimal time for tube formation is used in subsequent experiments. This was partly due to 
the requirement of hypoxic treatment and the inability to visualise the tube formation process 
under these conditions. Therefore, a time course was set up using normoxic conditions to 
observe the opportune time to analyse my results. It was seen that tube formation occurred at 
6 hours, but the tubes were more sparse and not completely formed (Fig. 19). At the 8 hour 
time point, however, complete, well defined, stable tubes could be observed (Fig. 19). The 8 
hour time point was therefore selected for subsequent tube formation experiments.  
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Fig. 19 – Tube formation assay time course of HUVECs seeded on reduced growth factor 
Matrigel. HUVECs were seeded on reduced growth factor Matrigel and observed every 2 
hours for a total of 8 hours. It can be seen that tube formation begins at 4 hours in the 
normoxic condition. Well defined tubes are seen at 8 hours.  
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3.1.8 Aortic Ring Assays 
 
In order to effectively evaluate the effects of experimental treatments using the aortic ring 
assay it was important to optimise the assay for the optimal sprouting duration. As with tube 
formation assays, aortic rings require hypoxic incubation, making it unviable to remove the 
cultures from hypoxia for daily analysis, as this will affect the hypoxic response. Due to high 
variation of sprouting observed in mice of different backgrounds, age and gender it is important 
before starting the final experiments that a time-course is set up to ensure that the sprouts are 
evaluated on the correct day and the effects of hypoxia are accounted for, whilst controlling for 
other variables.  
 
The time-course indicated that the optimal day for assessing sprouting was observed on day 6 
(Fig. 20). This is because the majority of the conditions have the highest amount of sprouting at 
this time point, only the hypoxic vehicle condition had a decrease in sprout numbers (Fig. 20). 
Therefore the 6 day time point was chosen for sprout evaluation. 
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Fig. 20 – Aortic Ring assay time course on Tie1 Cre+ HIF1αfl/fl and wildtype mice.  The chart 
shows the number of sprouts produced by the different conditions over a period of 10 days, 
representative of mean + SEM from at least 6 aortic rings per group from 10 mice in total. 
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3.1.9 Aortic Ring Staining Optimisation 
 
In order to see the effects of simvastatin, hypoxia, MMP14 neutralisation and endothelial HIF1α 
KO on MMP14 expression in the new blood vessels it was important to optimise staining for 
MMP14.  
 
The staining of aortic rings is a simple process as all of the staining reactions can occur within 
the wells that the aortic rings are cultured in. However, the removal of aortic rings from the 
wells can be difficult and can often cause vessels to tear so it was important to practice 
beforehand.  
 
Once the aortic rings had been cultured and sprouts counted they were fixed using 4% formalin 
and permeabilised with permeabilisation buffer. The aortic rings were blocked with DAKO-
Protein block (DAKO, UK) before incubating with the MMP14 primary antibody (Abcam, UK) 
diluted in PBLEC Buffer (Appendix I). Three different concentrations of the primary antibody 
were used (1:100, 1:150, 1:200) in order to find the best staining conditions to provide a strong 
signal with low background noise.  
 
Following the overnight antibody incubation the aortas were washed thrice for 15 minute 
periods with PBS + 0.1% Triton X-100. The secondary antibody anti-rabbit-IgG-FITC (1:750; 
Abcam, UK) and BS1-Lectin-TRITC stain (1:1000; Sigma Aldrich, UK) diluted in PBLEC buffer, were 
added to the aortic rings and incubated for three hours. The aortic rings were washed again 
with PBS + 0.1% Triton X-100 for three 15 minute washes before rinsing in distilled water. 
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Once the staining was completed, the aortic rings needed to be mounted onto a microscope 
slide. This involved scraping around the edge of the well with a needle and picking up the 
collagen surrounding the aortic ring carefully using forceps. It was important at this stage to 
limit instrument contact with aortic rings to minimise any breakage of the vessels.  Once on a 
microscope slide a drop of ProLONG Gold Anti-Fade with DAPI (Life Technologies) was added 
and a coverslip placed on the slide. The slides were allowed to dry for 24 hours before imaging. 
 
Neovessel formation from the aortic ring was observed at high magnification using the Axioplan 
microscope (Zeiss, UK). It was seen that there was high background noise for MMP14, even at 
the 1:200 dilution (Fig. 21C). Unfortunately, at the 1:200 dilution the staining of the vessels was 
quite weak and therefore diluting the antibody further was not an option (Fig. 21C). The high 
background could be due to the collagen trapping either the anti MMP14 antibody or the anti-
rabbit-IgG-FITC antibody. However, staining with BS1-Lectin and DAPI was effective.  As such, 
these conditions were adopted for future experiments (Fig. 21A and E).  
 
It was decided that to reduce background noise a conjugated primary anti MMP14-FITC 
antibody (BIOSS Antibodies, UK) would be used at a concentration of 1:150. This would be more 
specific, require less washes, and remove the need for secondary antibodies and its non-specific 
matches. Upon viewing the newly stained aortic rings with the conjugated antibody it was seen 
that there was less background noise and good staining of MMP14 in the neovessels (Fig. 21D).   
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Fig. 21 – Optimisation MMP14 staining of aortic rings from Tie1 Cre+ HIF1αfl/fl and wildtype 
mice. The left side of the image shows the unconjugated MMP14 antibody, with a separate 
FITC secondary antibody, producing high background. The right side of the image shows the 
conjugated MMP14-FITC antibody with less background staining. Arrows indicate clear defined 
sprouts. 
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3.1.10 Confirmation of HIF1α Endothelial Cell-Specific Knockout Mice 
 
 
It was important to ensure that the Tie1 Cre+ HIF1αfl/fl that were generated were actually 
endothelial cell-specific knockouts for HIF1α.  For this, sponge sections were used from the in 
vivo angiogenesis experiment. The sponge sections were stained according to the previously 
mentioned protocol using a rabbit anti-HIF1α antibody (1:75; Novus Biologicals, UK).  
 
Upon analysis of the sections it was seen that vessels from the Tie1 Cre+ HIF1αfl/fl mice did not 
have a strong brown border, indicative of HIF1α, in compared to the wildtype littermates (Fig. 
22A and B). This therefore showed that the Tie1 Cre+ HIF1αfl/fl mice were successfully bred and 
had no HIF1α expression in endothelial cells. 
 
 
 
 
 
Fig. 22 – IHC staining of sponge with neovascularisation for confirmation of endothelial cell 
HIF1α knockout. A) HIF1α wildtype mice neovessel staining showing a thick brown border 
around the blood vessel. B) HIF1α endothelial cell specific knockout mice neovessel staining 
showing a weak border around the vessel. C) Isotype control stain showing no HIF1α staining.  
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3.2 Preliminary Results 
 
3.2.1 Flow Cytometry for Apoptosis Assay 
 
In order to define the cell viability of cells undergoing the different oxygen and drug treatments 
it was decided that flow cytometry would be used. This incorporated the detection of PI and 
annexin V.  
 
Upon testing the cell viability it was seen that there was not much difference between the 
different cell conditions (Fig. 23). This could be due to weaker staining which meant a majority 
of the cells were classed as live as they were not identified via annexin V or PI. Another factor 
could be due to the siRNA transfection adversely affecting the cells or possibly due to there not 
being a difference in the viability of the cells. 
 
This may also be due to apoptosis potentially not being a confounding variable in angiogenesis 
being affected by simvastatin’s inhibition of HIF1α regulation of MMP14. As there was not a 
clear difference seen apoptosis assays were not used any further.  
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Fig. 23 – Apoptosis analysis using flow cytometry. A) The gating for the population of 
HUVECS. B) The analysis of unstained cells. C) The analysis of annexin V stained cells. D) The 
analysis of PI stained cells. E) An example of a flow cytometry readout of an analysed cell 
population. The proportion of cells that are F) classed as alive and viable, G) Annexin V positive 
and therefore apoptotic, H) PI positive and therefore necrotic, and I) Dead and unviable with 
no trend seen. Bar charts are representative of mean + SEM from 3 separate experiments. 
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3.2.2 Tube Formation Assays 
 
 
Tube formation assays were used to observe effects of simvastatin and hypoxia on angiogenesis 
in vitro.  
 
HUVECs were cultured on reduced growth factor Matrigel in hypoxic or normoxic conditions 
and in the presence or absence of 0.1µM simvastatin. The effect on tube formation can be 
analysed more quantitatively by looking at the total branching length, number of new nodes, 
and number of new junctions. It was seen that simvastatin reduced in vitro tube formation in 
both normoxic and hypoxic conditions with a significant decrease in total branching length (Fig. 
24). There was slightly increased tube formation seen in hypoxic conditions compared to 
normoxic conditions (Fig. 24) which is potentially  due to the upregulation of HIF1α which would 
activate angiogenesis promoting genes 64. Addition of simvastatin significantly reduced new 
junctions and nodes formed in hypoxic conditions, but this effect was not observed in normoxic 
conditions (Fig. 24).  
 
Following the incubation allowing for tube formation, the structures were stained for MMP14 
expression. DAPI stain was used to identify the nuclei. Based on rough nuclei counts, 
simvastatin cultures appeared to have less nuclear stains which suggested that there may be 
more cell death in cultures that were exposed to simvastatin (Fig. 24E). This was also seen in 
cells that were exposed to hypoxia (Fig. 24E).   
 
As the differences that were seen consisted of only a small change between the conditions it 
was decided that different angiogenesis methods should be used to further the work. This was 
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also partly due to the reasoning that angiogenesis is a multifactorial process that occurs by 
incorporating a number of different cells and stroma to form neovessels. The tube formation 
assay could be seen as being more a cell rearrangement or migration assay. Therefore more 
stringent ex vivo and in vivo assays took preference.  
 
Further to this the project required testing of the effects of HIF1α knockdown or knockout on 
tube formation and angiogenesis. HUVECs nucleofected with their specific siRNA were not 
viable after 8 hours of the tube formation assay. Therefore a different method was required to 
assess HIF1α knockdown or knockout on angiogenesis. It was decided that the aortic ring assay 
would be a proficient technique to do this.  
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Fig. 24 – Tube formation results of HUVECs cultured on reduced growth factor 142Matrigel in 
hypoxic or normoxic conditions, in the presence of 0.1µM simvastatin or vehicle. A) 
Representative images of the four conditions from showing normoxic, normoxic and simvastatin, 
hypoxic, and hypoxic and simvastatin from left to right. B) The total branching length of the tubes. 
C) The new number of nodes formed by the HUVECS seeded in Matrigel. D) The new junctions 
formed by HUVECs in Matrigel in the different conditions. E) A panel of representative MMP14 
(Green) and DAPI (Blue) stains performed on the formed tubes from the different conditions.  Bar 
charts are representative of mean + SEM from 5 separate experiments. Statistical analysis was 
conducted using One Way ANOVA with Neuman-Keuls post testing. * = P<0.05 
 
 
 
P a g e  | 143 
 
4. Results 
 
4.1 HIF1α Regulation of MMP14 and its Effect on Endothelial Function 
 
 
MMP14 had been identified to have HRE in the promoter region and regulated by HIF2α 208 but 
there was also evidence showing depleted HIF1α levels lead to diminished MMP14 levels 238. My 
project sought to identify a regulation of MMP14 by HIF1α and then observe effects of this 
relationship on endothelial function.   
 
 
4.1.1 HIF1α and MMP14 are Located in Atherosclerotic Plaques with Protein Colocalisation 
Observed Within Endothelial Cells and Macrophages 
 
 
To observe HIF1α and MMP14 expression in atherosclerotic plaques, immunohistochemical 
analysis of atheroma tissue was conducted by Dr Feng Zhang. The atheromas were sourced 
from various hospitals around the country and were obtained following endarterectomy. It was 
seen that in adjacent sections of human atheromas both HIF1α and MMP14 were expressed in 
the neovessels of the atheromas, with apparent co-localisation of HIF1α and MMP14 (Fig. 25). 
This identified that MMP14 and HIF1α are expressed in the same location and therefore a 
potential interaction of HIF1α with MMP14 could occur. 
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As well as staining human atherosclerotic tissue mouse atheroma tissue was stained for HIF1α, 
MMP14 and the macrophage marker F4/80. APOE knockout mice were fed a high fat diet in 
order to produce atherosclerotic lesions. Following this the tissue was harvested and 
cryosectioned. 
  
The mouse atheroma tissue was stained for an endothelial cell marker (endomucin) alongside 
HIF1α or MMP14 and for a macrophage marker (F4/80) alongside HIF1α. It was seen that both 
HIF1α and MMP14 colocalised with the endothelial cell marker in mouse atheromas (Fig. 26A 
and B). Furthermore, HIF1α colocalisation was observed with macrophage marker in the same 
tissue (Fig. 26C).  
 
Fig. 25 – HIF1α and MMP14 showed colocalisation in the neovessels of atheromas. 
Immunohistochemical staining with black arrows indicating the staining of neovessels for HIF1α 
(left panel) and MMP14 (right panel) at 20x magnification. (Courtesy of Dr Feng Zhang). 
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Fig. 26 – HIF1α and MMP14 colocalise with endothelial cells, and macrophages, in APOE 
knockout mouse atheromas. A) HIF1α (brown) colocalises with endomucin (red) in mouse 
atheroma tissue. B) MMP14 (red) colocalises with endomucin (brown) in mouse atheroma 
tissue. C) HIF1α (brown) colocalises with F4/80 (red) in mouse atherosclerotic tissue. D) Isotype 
control utilising species isotypes for the primary antibodies. 
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4.1.2 HIF1α Binds to the MMP14 Promoter in Hypoxia but this is Attenuated by Simvastatin 
Treatment 
 
 
To investigate the regulation of MMP14 by HIF1α a search of the MMP14 promoter for HREs 
was conducted. It was found that MMP14 contains two putative HREs in the gene promoter 
region at positions -125 to -129 and from -3568 to -3572, respectively, relative to the start of 
transcription. Additionally, another HRE after the start of transcription at position +144 to +148 
is noted 208. This suggested that MMP14 expression may be transcriptionally regulated by HIF1α. 
 
EMSAs were conducted by Dr Conrad Hodgkinson utilising synthetic HIF1α and HIF1β cultured 
alongside biotin-labelled double stranded oligonucleotides. Short nucleotide sequences 
containing an enzyme tag corresponding to HRE sites in the proximal (-125 to -129) and distal    
(-3568 to -3572) promoter regions of MMP14 were incubated with the protein extract from 
C166 endothelial cells.  
 
It was seen that when the biotin-labelled double stranded oligonucleotides were incubated with 
HIF1α and HIF1β together there was a shift in mobility and a distinct band was seen, showing 
that a protein complex had formed and bound to the relevant nucleotide tag. This was seen in 
both the distal and proximal HRE sites (Fig. 27B lanes 5) thus providing evidence that HIF1α 
binds to the MMP14 promoter.    
 
When either HIF1α or HIF1β were absent there was no binding of the nucleotide probe to the 
proteins (Fig. 27B lanes 1-4). This showed that the fully functional HIF response complex needed 
to form in order for interaction with the HRE of MMP14.  
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To confirm the interaction of HIF1α with the MMP14 promoter ChIP assays were also 
conducted. Chromatin immunoprecipitation assays were performed on cultured HUVECs either 
in hypoxia (1% O2) or normoxia, with 0.1µM simvastatin or vehicle control to assess HIF1α 
interaction with the MMP14 promoter and the effect of simvastatin on this. The chromatin was 
immunoprecipitated using a HIF1α antibody before PCR analysis using primers corresponding to 
the MMP14 promoter proximal HRE site.  
 
Fig. 27 – HIF binds to the MMP14 promoter at both the distal and proximal HRE. 
Electromagnetic shift assay of MMP14 HRE sites in the presence or absence of synthetic HIF1α 
and HIF1β. A) A diagram indicating the positions of the distal and proximal HRE in the MMP14 
promoter. B) A clear band is seen in both the distal (left side) and proximal (right side) HRE sites 
when both HIF1α and HIF1β are present (lane 5), however when either HIF1α or HIF1β are 
absent there is no band seen (lanes 1-4). The results are representative of 3 independent 
experiments. (Courtesy of Dr Conrad Hodgkinson).  
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The ChIP assays showed that HIF1α binds to the MMP14 gene promoter but that this was 
significantly attenuated by simvastatin treatment (Fig. 28). There was still some interaction of 
the HIF response complex with the MMP14 promoter in hypoxic conditions treated with 
simvastatin, however this was markedly decreased (Fig. 28). There was no HIF1α and MMP14 
interaction in cells that were cultured in normoxic conditions (Fig. 28). 
 
 
 
Fig. 28 – HIF1α binding to the MMP14 promoter in HUVECs occurs in hypoxic conditions and 
is attenuated by simvastatin treatment. The graph shows results of HUVEC chromatin 
immunoprecipitation assay. HUVECs were cultured in normoxia or hypoxia, with or without 
0.1µM simvastatin and immunoprecipitated for HIF1α before analysing for the MMP14 
promoter. A) Bar chart representing observed results whereby hypoxia increased the 
localisation of HIF1α to the MMP14 promoter while the addition of simvastatin reduced this 
affect.  B) Representative gel image of the ChIP assay. Bar chart is representative of mean + 
SEM from 3 independent experiments. Statistical significance was analysed by One Way 
ANOVA with Neuman-Keuls post test. * = P<0.05. 
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4.1.3 Simvastatin Attenuates HIF1α Upregulated MMP14 Promoter Activity  
 
The EMSA and ChIP assays had shown that HIF1α binds to the MMP14 promoter. In order to 
analyse the effect that this had on the activity of the promoter, luciferase reporter assays were 
carried out. The luciferase reporter assays were conducted by Dr Conrad Hodgkinson. C166 
endothelial cells were transfected with a human MMP14 gene promoter-firefly luciferase 
reporter gene construct, together with plasmids to overexpress HIF1α and HIF1β, HIF1β on its 
own, or an empty vector. Following successful transfection the cells were analysed using 
luciferase reporter assays.  
 
The luciferase assays showed that MMP14 promoter activity was increased when endothelial 
cells were overexpressing HIF1α and HIF1β in hypoxic conditions. This showed that HIF1α can 
upregulate MMP14 when the stable HIF1 complex was formed (Fig. 29A). Additionally only a 
small effect was seen when HIF1β was present on its own, showing a need for HIF1α in the 
formation of the stable HIF response complex.  As well as this we have shown an attenuation of 
MMP14 promoter activity when mutations were introduced into the HRE, primarily at the 
proximal site, in both normoxic and hypoxic conditions (Fig. 29B). This showed that the 
upregulation of MMP14 activity was due to the HRE. The distal HRE mutation showed a smaller 
attenuating effect than that of the proximal HRE mutation, whereby mutating the distal HRE 
alone showed only a minimal change in MMP14 promoter activity (Fig. 29B), showing that the 
proximal HRE is the primary HRE for MMP14 activity promotion. A cumulative diminishing effect 
was observed when both of the HRE were mutated in normoxia, although this was not seen in 
hypoxia (Fig. 29B).  
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MMP14 promoter activity was significantly increased in hypoxic conditions but the addition of 
simvastatin attenuated this effect (Fig. 29C).  Mutations of the HRE in the MMP14 promoter 
showed no change in response to hypoxia or simvastatin treatment (Fig. 29C).  
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Fig. 29 – MMP14 gene promoter activity is increased by HIF in hypoxic conditions and attenuated 
by simvastatin. Luciferase reporter assays of MMP14 gene promoter activity. Cultured endothelial 
cells (C166) were transfected with an MMP14 gene promoter-firefly luciferase reporter gene 
construct, together with experimental plasmids and a plasmid containing the Renilla luciferase gene. 
Transfected cells were exposed to hypoxia (1% O2) or normoxia for 18 hours. MMP14 promoter 
activity was measured by dual-luciferase assays. A) Relative MMP14 promoter activity after 
transfection with plasmids to overexpress HIF1β, or HIF1α + HIF1β. Transfection with HIF1α + HIF1β 
increased MMP14 promoter expression. B) Relative MMP14 promoter activity after transfection with 
plasmids containing mutations in the MMP14 promoter HREs. Mutations of HREs in the MMP14 
promoter significantly attenuated MMP14 activity. C) Relative MMP14 promoter activity after 
transfection with the MMP14 gene promoter-firefly luciferase reporter gene and the Renilla 
luciferase gene in either hypoxia or normoxia, with simvastatin (2µM) or vehicle control. Simvastatin 
significantly attenuated MMP14 activity in hypoxia, but had no effect when the HRE sites were 
mutated.  Data shown are mean +SEM of relative MMP14 promoter activity in three independent 
experiments * and Ϯ= P<0.05 (Courtesy of Dr Conrad Hodgkinson) 
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4.1.4 Simvastatin Inhibits MMP14 in a HIF1α-dependent Manner 
 
 
As it was shown that the MMP14 promoter was regulated by HIF1α and its activity was 
decreased by simvastatin an investigation of the molecular mechanisms of this effect on 
MMP14 protein expression was conducted.  
 
HUVECs were transfected, using nucleofection, with either a HIF1α specific siRNA (Santa Cruz, 
USA), a scramble control siRNA (Santa Cruz, USA) or a water control. Simvastatin (0.1µM) or a 
vehicle control was added to the cells in culture 24 hours prior to protein harvest. The protein 
was extracted and analysed using immunoblotting. 
 
The knockdown of HIF1α was shown to be effective as HIF1α expression in the HIF1α siRNA 
targeted cells was reduced by approximately 50% as compared to the scramble control (Fig. 
30A). MMP14 expression in hypoxia was reduced by 30% in the HIF1α knockdown cells 
compared to scramble control showing that MMP14 is under HIF1α control in hypoxic 
conditions (Fig. 30B). This was not seen however in normoxic conditions (Fig. 30C). 
 
The addition of simvastatin significantly attenuated HIF1α and MMP14 activity in hypoxic 
conditions to a similar extent as HIF1α knockdown showed (Fig. 30A and B), however there was 
no effect seen in the normoxic MMP14 condition.  
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Fig. 30 – HIF1α knockdown and simvastatin decrease MMP14 expression in HUVECs in hypoxic 
conditions. Immunoblot analysis of HUVECs nucleofected with HIF1α siRNA, scramble siRNA, or 
water control, cultured in either hypoxic or normoxic conditions, with or without 0.1µM 
Simvastatin. A) Analysis of HIF1α expression in hypoxic conditions showing HIF1α knockdown 
was effective and simvastatin significantly reduced HIF1α expression. B) Analysis of MMP14 
expression in hypoxic conditions showing MMP14 expression is significantly attenuated by HIF1α 
knockdown and simvastatin. C) Analysis of MMP14 expression in normoxic conditions showing 
there is no effect of HIF1α knockdown and simvastatin in normoxic conditions. D) A 
representative film image of immunoblots analysis. Bar charts represent the protein expression 
densitometry mean + SEM from 5 independent paired experiments. Statistical analysis was 
conducted using One Way ANOVA with Neuman-Keuls post testing. * = P<0.05 
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In order to further analyse the effect of HIF1α knockdown, hypoxia and simvastatin treatment 
on MMP14, flow cytometry assays were used. This enabled a more quantitative approach to the 
analysis of MMP14 expression.  
 
For this experiment both HUVECs and MLECs were used in order to investigate any difference 
between the human cells and the murine cells. MLECs were isolated from the lungs of both the 
Tie1 Cre+ HIF1αfl/fl mice and wildtype littermates. HUVECs were transfected, using 
nucleofection, with either a HIF1α specific siRNA (Santa Cruz, USA), a scramble control siRNA 
(Santa Cruz, USA). Simvastatin (0.1µM) or a vehicle control was added to the cells in culture 24 
hours prior to cell fixation. The cells were detached from the culture plates, fixed, permeabilised 
and stained for MMP14 activity before analysis with a Fortessa flow cytometer (BD Biosciences, 
UK).  
 
The results showed that hypoxia increases MMP14 expression in the wildtype MLECs and the 
scramble control siRNA HUVECs by approximately 100%, but this is not the case for the HIF1α 
knockout and knockdown cells (Fig. 31A and B). Simvastatin significantly attenuated the hypoxic 
increase in MMP14 activity in the wildtype MLECs and control HUVECs, by approximately 40-
60%, but had no effect on HIF1α knockout and knockdown cells or normoxic cells (Fig. 31). It 
could therefore be seen that simvastatin’s inhibition of MMP14 was occurring in a HIF1α-
dependent manner.  
  
 
 
Fig. 31 – Simvastatin, HIF1α knockout and HIF1α knockdown inhibit hypoxic MMP14 expression.  Flow cytometry analysis of MMP14 in 
HUVECs A) and MLECs B) cultured in hypoxia or normoxia, with or without 0.1µM simvastatin. A) HUVECs cultured in hypoxic conditions have 
significantly increased MMP14 levels than HUVECs grown in normoxia. Simvastatin significantly diminishes MMP14 levels in hypoxic conditions. 
B) Tie1 Cre- HIF1α WT and Tie1 Cre+ HIF1α KO MLECs were isolated and cultured in the specified conditions. Hypoxia significantly increased 
MMP14 levels compared to normoxia in Tie1 Cre- HIF1α WT MLECs. Simvastatin significantly reduces MMP14 levels in Tie1 Cre- HIF1α WT 
hypoxic MLECs. Hypoxic Tie1 Cre- HIF1α WT MLECs have a significantly increased MMP14 expression in comparison to Tie1 Cre+ HIF1α KO 
MLECs. Bar charts demonstrate the mean median fluorescence intensity of MMP14 levels + SEM from A) 6 and B) 5 independent experiments. 
Statistical analysis was conducted using One Way ANOVA with Neuman-Keuls post testing. * = P<0.05 
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4.1.5 Simvastatin Inhibits Hypoxic Endothelial Cell Migration and Proliferation 
 
 
Given experimental evidence that both simvastatin and HIF1α had a role in regulating MMP14 
expression, it was decided to investigate the effect of this on cellular function, specifically in 
roles related to angiogenesis.  Therefore analysis of migration and proliferation of nucleofected 
HUVECs with simvastatin treatment was conducted.  
 
HUVECs were nucleofected with either a HIF1α siRNA or scramble control siRNA (Santa Cruz, 
USA) and seeded onto 12 well culture plates for migration and 96 well culture plates for 
proliferation. The migration plates were allowed to reach full confluency before the addition of 
0.1µM simvastatin, 24 hours prior to introducing a wound in the cell monolayer. The 
proliferation assay plates grew for 24 hours post-transfection before the addition of 0.1µM 
simvastatin.  
 
The migration assays showed that both 0.1µM simvastatin and HIF1α knockdown significantly 
attenuate hypoxic migration of HUVECs by roughly 60% and 40%, respectively (Fig. 32A and B). 
The addition of 0.1µM simvastatin to HIF1α knockdown cells showed no significant difference 
compared to the vehicle control (Fig. 32B), thus showing the inhibition of migration was due to 
a HIF1α-dependent effect.  
 
The proliferation assays showed a similar pattern with 0.1µM simvastatin and HIF1α knockdown 
significantly inhibiting the proliferation of HUVECs in hypoxia by around 50% and 40% 
respectively (Fig. 32C). In the HIF1α knockdown groups the addition of 0.1µM simvastatin also 
significantly decreased proliferation compared to the vehicle control (Fig. 32C).   
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Fig. 32 – Simvastatin inhibits hypoxic endothelial cell migration and proliferation. HUVECs 
were nucleofected with either HIF1α siRNA or scramble siRNA were cultured in hypoxic 
condition with or without 0.1µM simvastatin. A) A representative image set for the scratch 
migration experiments from the start of the migration assay until completion after 6 hours. B) A 
bar chart representing the scratch assays performed and analysed over 6 hours. The resultant 
migration was compared to the control scramble siRNA without simvastatin. The data shows 
simvastatin significantly reduces hypoxic migration in control cells, but has no effect on HIF1α 
knockdown cells. C) A bar chart representing the BrdU incorporation proliferation assay 
performed with relevant proliferation compared to the control scramble siRNA without 
simvastatin.  The data shows simvastatin significantly reduces hypoxic proliferation in both 
control and HIF1α knockout cells. The bar charts represent distance migrated and BrdU 
incorporation compared to controls + SEM (n=5 and n=6). Statistical analysis was conducted 
using One Way ANOVA with Neuman-Keuls post testing. * = P<0.05 
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4.1.6 MMP14 Inhibition Decreases Proliferation and Migration in Hypoxia 
 
 
It had been shown that simvastatin decreased both hypoxic migration and proliferation of 
HUVECs but this could not be specifically related to MMP14. Therefore in order to test the 
effect of MMP14 inhibition on migration and proliferation of HUVECs in hypoxia an MMP14 
inhibitory antibody (Merck Millipore, UK) or rabbit-IgG (Santa Cruz, USA) control antibody was 
added to the cultures.  
 
The results showed that the addition of the MMP14 inhibitory antibody significantly decreased 
the migration of the HUVECs treated with scramble siRNA in hypoxia (Fig. 33A and B).  The 
addition of simvastatin was again shown to significantly reduce migration of HUVECs in hypoxia 
but showed no extra inhibitory effect on both HIF1α knockdown and scramble control cells 
cultured with the MMP14 inhibitory antibody (Fig. 33A and B).  
 
The proliferative potential of the HUVECs in hypoxia was also affected in a similar pattern to 
that of migration. The MMP14 inhibitor significantly inhibited proliferation of the HUVECs in 
hypoxia (Fig. 33C) and also showed that simvastatin had no added inhibitory effect on the HIF1α 
knockdown and scramble control cells cultured with the MMP14 inhibitory antibody (Fig. 33C).  
 
  
Fig. 33 – MMP14 inhibition decreases proliferation and migration of HUVECs in hypoxia. HUVECs nucleofected with either HIF1α siRNA or scramble 
siRNA were cultured in hypoxic condition with or without 0.1µM simvastatin and an MMP14 neutralising antibody or rabbit IgG control. A) A 
representative image set of the migration assay experiment. B) A scratch assay was performed and analysed over 6 hours. The resultant migration was 
compared to the control scramble siRNA without simvastatin with rabbit IgG. MMP14 inhibition decreases migration in control cells but not HIF1α 
knockdown cells or cells treated with 0.1µM simvastatin. C) BrdU incorporation assay with proliferation compared to the control scramble siRNA 
without simvastatin with rabbit IgG.  MMP14 inhibition decreases scramble siRNA cells proliferation, but not the HIF1α knockdown cells. MMP14 
inhibition does not affect proliferation in cells treated with 0.1µM simvastatin.  The bar charts represent distance migrated and BrdU incorporation 
compared to controls + SEM (n=5 and n=6). Statistical analysis was conducted using One Way ANOVA with Neuman-Keuls post testing. * = P<0.05 
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4.2 HIF1α and Simvastatin Effect on MMP14 and Angiogenesis 
 
4.2.1 Simvastatin Reduces Angiogenesis in a HIF1α-dependent Manner 
 
 
HIF1α and simvastatin were shown to have a role in regulating MMP14 expression in vitro with 
a consequential functional effect on migration and proliferation. In order to see if this had a 
further effect on angiogenesis via HIF1α and MMP14 regulation aortic rings were used. 
 
Aortic rings were cultured from Tie1 Cre+ HIF1αfl/fl mice and their wildtype littermates. They 
were cultured for six days in either normoxic or hypoxic (1% O2) conditions with either 0.1µM 
simvastatin or a vehicle control. The results showed that hypoxia significantly increased new 
blood vessel sprouting in wildtype mice, but not the endothelial cell-specific HIF1α knockout 
mice (Fig. 34). Simvastatin decreased the hypoxia-induced blood vessel formation in the 
wildtype mice to levels that were similar to the normoxic results, with around a 25% decrease in 
sprouts formed (Fig. 34). However, simvastatin had no effect on the Tie1 Cre+ HIF1αfl/fl mice or 
in normoxic conditions (Fig. 34)  
  
Fig. 34 – Simvastatin reduces angiogenesis in a HIF1α-dependent manner. The ex vivo aortic ring assay with aortas isolated from Tie1 Cre+ 
HIF1α KO mice and wildtype littermates, cultured in a three dimensional collagen matrix in hypoxia or normoxia, with or without 0.1µM 
simvastatin. Microvessel growth was analysed 6 days post-embedding. Wildtype mice show impaired microvessel sprouting with the addition of 
0.1µM simvastatin in both normoxic and hypoxic conditions. Hypoxia significantly increased sprouting in wildtype mice compared to normoxia 
but this observation was not matched in the HIF1α knockout mice. Wildtype mice showed increased sprouting in hypoxic conditions in 
comparison to Tie1 Cre+ HIF1α KO mice. Yellow arrows indicate sprouts. The bar chart represents the mean number of microvessel sprouts per 
aortic ring mean + SEM (n=15). Statistical analysis was conducted using One Way ANOVA with Neuman-Keuls post testing. * = P<0.05 
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4.2.2 Simvastatin and HIF1α Knockout Reduce MMP14 Expression in Immature Endothelial Cells 
Perturbing Angiogenesis 
 
 
It had been shown that both endothelial cell-specific HIF1α knockout mice and simvastatin 
significantly reduce angiogenesis in aortic ring cultures. As well as this a role of HIF1α and 
simvastatin in regulating MMP14, a promoter of angiogenesis, had been elucidated. Therefore 
in order to see if the perturbed angiogenesis was due to diminished MMP14 expression 
immunofluorescent staining of aortic ring microvessels was conducted.  
 
Following the aortic ring culture the rings were fixed and stained for MMP14 using a FITC-
conjugated MMP14 antibody (BIOSS antibodies, UK). Once the aortic rings had been stained and 
transferred to a microscope slide they were imaged for their fluorescence intensity.  
 
The results showed higher expression of MMP14 in new blood vessels of wildtype hypoxic aortic 
ring cultures (Fig. 35). The addition of simvastatin significantly reduced the hypoxic upregulation 
of MMP14 in wildtype hypoxic aortic ring cultures (Fig. 35). Tie1 Cre+ HIF1αfl/fl showed less 
MMP14 expression than the wildtype littermates (Fig. 35).  
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Fig. 35 – Hypoxia-stimulated MMP14 expression of new vasculature is significantly decreased 
in HIF1α KO and simvastatin-treated mice. The ex vivo aortic ring assay with aortas isolated 
from Tie1 Cre- HIF1α WT and Tie1 Cre+ HIF1α KO mice, cultured in a three dimensional collagen 
matrix in hypoxia or normoxia, with or without 0.1µM simvastatin. Following 6 days of culture 
the aortas were fixed and stained for MMP14 (Green), BS1-Lectin (Red) and DAPI (Blue). 
Fluorescence of MMP14 was analysed using FIJI software of individual microvessels in the green 
channel at X20 optical zoom, with the mean grey value per pixel per vessel taken for 
fluorescence intensity of each microvessel. MMP14 expression is significantly increased in 
hypoxia without simvastatin treatment in wildtype mice. The bar chart represents the mean 
MMP14 fluorescence of sprouts mean + SEM (n=10). Statistical analysis was conducted using 
One Way ANOVA with Neuman-Keuls post testing. * = P<0.05 
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4.2.3 VEGF-induced Angiogenesis is attenuated by MMP14 inhibition in a HIF1α-dependent 
Manner 
 
 
To test the effect of MMP14 neutralisation on angiogenesis aortic rings of Tie1 Cre+ HIF1αfl/fl 
mice and their wildtype littermate controls were cultured with either an MMP14 inhibitory 
antibody (Merck Millipore, UK) or a rabbit isotype control, in the presence of either 0.1µM 
simvastatin or vehicle control in hypoxia (1% O2). The results showed that after 6 days of culture 
there was a significant decrease in new blood sprouts from the aortic rings in MMP14 inhibited 
cultures (Fig. 36). The wildtype mice aorta showed a significantly reduced angiogenesis when 
cultured with the MMP14 antibody, as opposed to those cultured with the antibody control 
(Fig. 36). This effect was not replicated in the Tie1 Cre+ HIF1αfl/fl mice thus showing the inhibition 
was HIF1α driven.  
 
It was shown that simvastatin reduced the amount of new blood vessel formation from the 
aortic rings, similar to the previous observations (Fig. 36). However, it was shown that 
simvastatin had no effect on MMP14 inhibited aortic rings (Fig. 36).  
  
Fig. 36 – MMP14 inhibition decreases angiogenesis in a HIF1α-dependent manner. The ex vivo aortic ring assay with aortas isolated from Tie1 
Cre- HIF1α WT and Tie1 Cre+ HIF1α KO mice, cultured in a three dimensional collagen matrix in 1% hypoxia, with or without 0.1µM simvastatin 
and MMP14 inhibitory antibody. Microvessel growth was analysed 6 days post embedding. The addition of an MMP14 antibody significantly 
reduced sprouting of Tie1 Cre- HIF1α WT mice. MMP14 inhibition has no effect on Tie1 Cre+ HIF1α KO mice. The bar chart represents the mean 
number of microvessel sprouts per aortic ring mean + SEM (n=8). Statistical analysis was conducted using One Way ANOVA with Neuman-Keuls 
post testing. * = P<0.05 
 
P
a
g
e
 | 1
65
 
P a g e  | 166 
 
4.3 HIF1α and Simvastatin Effect on in vivo Angiogenesis 
 
 
4.3.1 Simvastatin Reduces in vivo VEGF-induced Angiogenesis via a HIF1α-dependent 
Mechanism 
 
 
It had been shown that simvastatin and HIF1α reduced neovascularisation in ex vivo models. In 
order to see the effects of this in vivo the sponge angiogenesis assay was used. This 
incorporated the use of Tie1 Cre+ HIF1αfl/fl and their wildtype littermates which were injected 
subcutaneously with simvastatin or a PBS control for 4 weeks. On the 14th day a sponge was 
inserted into the flanks of the mice which were injected with VEGF or a PBS control on 
alternated days for the remaining 2 weeks.  The sponges were harvested, fixed and sectioned 
before staining for the blood vessel marker endomucin. 
 
It was shown that VEGF treatment significantly increased neovessel formation in wildtype mice, 
but not in their Tie1 Cre+ HIF1αfl/fl littermates (Fig. 37). The wildtype mice that were treated 
with simvastatin had significantly decreased neovascularisation compared to the PBS controls in 
the VEGF-treated groups (Fig. 37).   
  
Fig. 37 – Simvastatin reduces VEGF-induced angiogenesis in a HIF1α-dependent manner. The in vivo sponge angiogenesis assay utilising Tie1 Cre- 
HIF1α WT and Tie1 Cre+ HIF1α KO mice, with sponges inserted in flanks and injections of either simvastatin or PBS subcutaneously for 4 weeks and 
VEGF or PBS into the sponges for 2 weeks on alternate days. Neovessel formation was assessed using IHC staining for endomucin and microscopic 
analysis at x20 magnification following harvesting and sectioning of sponges. Neovessel formation was significantly increased in wildtype mice with 
VEGF injections compared to Tie1 Cre- HIF1α KO mice. Simvastatin significantly attenuated neovessels formation in the VEGF-treated wildtypes. Red 
arrows indicate stained endothelial cells. The bar chart represents the mean number of neovessels per X20 image field mean + SEM (n=8). Statistical 
analysis was conducted using One Way ANOVA with Neuman-Keuls post testing. * = P<0.05 
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5. Discussion 
 
The research presented here has shown that MMP14 is regulated by HIF1α which is, in turn, 
affected by simvastatin.  This has implications in atherosclerosis treatment as atheromas 
express both HIF1α and MMP14 (Figs. 25 and 26). More specifically, the results have shown that 
HIF1α binds to the MMP14 promoter through interaction with the two HREs (Figs. 27 and 28), 
HIF1α increases the gene activation and protein expression of MMP14 (Figs. 29, 30 and 31), 
simvastatin attenuates the upregulatory effect of HIF1α on MMP14 activity leading to functional 
effects including inhibition of angiogenesis. This indicates a role for simvastatin treatment in 
cardiovascular disease by inhibiting angiogenesis and therefore enhancing plaque stability. 
 
 
5.1 HIF1α and MMP14 are Expressed in Endothelial Cells of Atheromas 
 
 
Human atheroma sections  and APOE KO mice atheroma sections immunostained for HIF1α and 
MMP14 showed strong staining in endothelial cells (Figs. 25 and 26).  
 
Studies have shown that atheromas can contain hypoxic areas 40 as a result of both thickened 
intima and inflammation leading to increased oxygen demand 38. This would lead to an expected 
upregulation of HIF1α within the atheroma. HIF1α expression upregulates angiogenesis and, 
therefore, its increased expression in the endothelial cells of the neovasculature is an important 
finding. Endothelial cell expression of HIF1α within the atheroma has been indicated before 39 
but was not specifically stated. Here it has been confirmed that HIF1α is expressed in atheromas 
with specific localisation on endothelial cells and macrophages (Figs. 25A, 26A and 26C).  
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MMPs are known to be expressed in atheromas 90 where they are associated with the 
pathological development of atherosclerosis. MMP14 has been shown to be expressed in 
atheromas with commonly enhanced expression in the monocyte and macrophage populations 
299. As well as an increased expression in monocytes and macrophages, MMP14 has also shown 
to have increased expression in vascular smooth muscle cells and endothelial cells within the 
atheroma 236. Here it has been confirmed that MMP14 is located in the atheroma with 
enhanced expression seen in endothelial cells (Figs. 25B and 26B).  
  
With MMP14 and HIF1α showing expression in endothelial cells with apparent colocalisation it 
suggests that there may be a potential interaction between them. Coupled with the information 
that the MMP14 promoter contains putative HREs 208 a regulatory mechanism was researched.  
 
 
 
 
5.2 HIF1α Binding to the MMP14 Promoter in Hypoxia is Attenuated by Simvastatin 
Treatment 
 
 
To analyse the regulation of MMP14 by HIF1α a bioinformatics search of MMP14s promoter 
region using TRANSFAC database for HREs was conducted. It was found that MMP14 contains 
two putative HREs in the upstream gene promoter region at positions -125 to -129 208 and from 
-3568 to -3572, respectively, relative to the start of transcription. As well as this, there is 
another HRE after the start of transcription at position +144 to +148 208. This suggests that 
MMP14 expression may be transcriptionally regulated by HIF1α.  
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The use of EMSA and ChIP assays has identified a binding of HIF1α to both the distal and 
proximal HREs at positions -3568 to 3571 and -125 to -129 in hypoxic conditions (Figs. 27 and 
28). It has been shown that the MMP14 promoter contains HREs and can interact with HIF2α 208, 
but this is the first time that an interaction of HIF1α with the MMP14 promoter has been 
demonstrated.   
 
It is also shown that low dose of simvastatin inhibits the interaction of HIF1α with the MMP14 
promoter, however the results show this may be due to reduced HIF1α availability (Fig. 30A). 
Simvastatin is known to affect binding of HIF1α to the promoter regions of other genes 
including those of platelet-derived growth factor B and endothelin-1 140. The hypoxia-induced 
attenuation detected in this study reinforces a role for simvastatin in affecting the functioning 
of the HIF response complex. 
 
There is no interaction of HIF1α and the MMP14 promoter region in normoxic conditions (Fig. 
28). This could be due to HIF1α being rapidly degraded in normoxic conditions 48 and therefore 
a stable HIF response complex is not formed to target the MMP14 gene. 
 
 
5.3 Simvastatin Attenuates HIF1α-upregulated MMP14 Promoter Activity  
 
 
The results of EMSA and ChIP assays showed that HIF1α interacts with the MMP14 promoter at 
the HREs (Figs. 27 and 28). Although this shows an interaction it provided no information on 
how this can affect the activity of the MMP14 gene.  Luciferase assays were used to establish if 
the interaction of HIF1α with the MMP14 promoter had a regulatory affect.  
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Several other studies have shown that MMP14 expression is increased in hypoxic conditions, 
but have not shown a mechanism for this upregulation 237,300. The research presented here 
shows a mechanism for the increase in MMP14 expression through an increase in MMP14 gene 
activation. The results showed that in the presence of HIF1α and HIF1β MMP14 gene activation 
is increased (Fig. 29A), but not with HIF1β alone. This showed that HIF1α was responsible for 
the upregulation of MMP14 expression with the formation of stable HIF1 complexes with HIF1β. 
 
In order to confirm that the increase of MMP14 activity was due to the interaction of the HIF 
response complex with the HREs, mutations were introduced into the HRE sequences of the 
reporter plasmid MMP14 promoter sequence. The results showed that mutating the HREs at 
the proximal site, distal site, and both of the sites together significantly decreased the activity of 
MMP14 in normoxic conditions (Fig. 29B). This shows that there may be some interaction and 
therefore upregulation of MMP14 in normoxic conditions by the HIF response complex. 
However, this was not observed via the ChIP assay (Fig. 28). Interestingly, in hypoxic conditions 
it is shown that the proximal HRE is of great importance in the upregulation of MMP14 
promoter activity, as evidenced by the proximal HRE mutations which diminish MMP14 
promoter activity (Fig. 29B). This HRE site was also specified in another study to have an 
important role in the interaction of HIF2α in renal carcinoma cells, leading to an increase in 
tumourigenesis 208. This shows that the proximal HRE is the dominant HRE in the activation of 
MMP14 by the HIF response complex. When the distal HRE is mutated there is not a reduction 
in MMP14 promoter activity seen in hypoxic conditions. This indicates that the distal HRE is of 
less importance in the activation of the MMP14 promoter by the HIF response complex.  
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Simvastatin had been shown to limit the interaction of HIF1α with the MMP14 promoter in 
hypoxic conditions (Fig. 28). The luciferase assays have also shown that simvastatin significantly 
attenuates MMP14 promoter activity in hypoxic conditions (Fig. 29C). Taking the EMSA and ChIP 
assays together, it is shown that the addition of simvastatin affects binding of HIF1α to the 
MMP14 promoter which, in turn, affects the usual hypoxic upregulation on MMP14 activity.   
 
The inhibitory effect of simvastatin was not seen when the HREs were mutated, or in normoxic 
conditions, thus indicating the inhibition of MMP14 promoter activity is HIF-dependent (Fig. 
29C). A previous study has shown that the addition of 0.1µM simvastatin significantly inhibits 
the expression of MMP14 mRNA and protein in B16 melanoma cells 146. This research was 
conducted in normoxic conditions but it is known that melanoma cells express an increased 
level of HIF1α 301, therefore HIF1α is likely to still have an effect here as very high levels of HIF1α 
may resist degradation. The research presented here shows that the inhibition of MMP14 
expression and activity is likely to occur at the gene regulatory level in the prevention of HIF1α 
interaction and activation of the MMP14 promoter. The decrease in MMP14 activity due to 
simvastatin may be linked to less HIF1α being available to interact with the MMP14 promoter as 
we have shown that simvastatin reduces HIF1α expression.  
 
Previous research has shown that MMP14 transcription in endothelial cells is regulated by the 
transcription factors Egr-1 and Sp-1, through binding to GC-rich sequences at -288  to -275 
relative to the start of transcription 209,210.  My research presents a new mechanism for the 
control of MMP14 expression in endothelial cells with a further regulation by HIF1α through the 
interaction with HRE in the MMP14 promoter.  
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5.4 Simvastatin Inhibits MMP14 Protein Expression in a HIF1α-dependent Manner 
 
HIF1α is known to be reduced by simvastatin, and hypoxia has been shown to upregulate 
several MMPs in a HIF1α-dependent manner 139,194,195. However, the role of simvastatin in 
controlling MMP14 expression via a HIF1α-controlled mechanism has not been elucidated. Here 
the research has shown that MMP14 is inhibited by simvastatin in hypoxic conditions in a 
HIF1α-dependent mechanism.  
 
The immunoblots show that under hypoxic conditions, both HIF1α and MMP14 expression are 
upregulated (Fig. 30A and B). However, the addition of simvastatin significantly reduces the 
hypoxia-driven increase in expression of both HIF1α and MMP14. It has been shown before that 
statins increase the degradation of HIF1α through increasing polyubiquitination, targeting it 
towards the proteosome 124. It has also been shown that simvastatin is able to upregulate the 
expression of vHL which is an important cofactor for HIF1α degradation 302. Here I have 
confirmed that the addition of simvastatin significantly reduces HIF1α protein levels, although 
whether this is due to decreased transcription, decreased translation or increased degradation 
cannot be elucidated (Fig. 30A).  
 
MMP14 protein and mRNA levels being reduced as a consequence of simvastatin has previously 
been reported with the same concentration, 0.1µM 146. Here we show however that the 
reduction of MMP14 expression is due to a HIF1α-dependent effect, as in normoxia there is no 
attenuation of MMP14 expression (Fig. 30C and 31). The use of siRNA targeting HIF1α in 
HUVECs and the use of HIF1α endothelial cell knockout mice showed that simvastatin only 
reduced MMP14 expression in hypoxic conditions when HIF1α was present (Fig. 30B and 31). 
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This shows that simvastatin inhibits MMP14 in a HIF1α-dependent manner in both human and 
mice endothelial cells.   
 
MMP14 is not the first of the MMPs shown to be affected by statin treatment. There is evidence 
that statins inhibited the secretion of MMP1, MMP2, MMP3 and MMP9 from vascular smooth 
muscle cells and macrophages in rabbits that were fed a high cholesterol diet 142. As well as an 
effect on MMPs, statins have also been shown to inhibit TIMPs, which would have a subsequent 
effect on MMP expression 303. Statins are able to modulate expression of MMPs in a wide 
variety of cell types important in atheroma development including macrophages, vascular 
smooth muscle cells, fibroblasts and endothelial cells 142,303–305. Here the research has confirmed 
a further inhibition of MMP14 with low-dose simvastatin treatment.  
 
The trends of flow cytometry and immunoblotting on MMP14 expressions are similar with both 
low-dose simvastatin and HIF1α knockdown attenuating hypoxic MMP14 expression (Figs. 30 
and 31). The flow cytometry results show a much more significant difference in MMP14 levels 
changing throughout the four conditions (Fig. 31) than immunoblotting is able to illustrate (Fig. 
30). This is likely due to the more sensitive detection that flow cytometry allows whereby each 
single cell can be counted for MMP14 expression, rather than the whole cell lysates 306. Flow 
cytometry is also a more quantitative method than immunoblotting as the fluorescence 
intensity can be measured and quantified between groups. Immunoblotting on the other hand 
is only semi quantitative and relies on the difference in saturation of a film to be analysed by 
densitometry software in order to compare groups.  
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5.5 Simvastatin Inhibits Hypoxic Endothelial Cell Migration and Proliferation 
 
MMP14 is known to have an important role in cell migration as well as angiogenesis 235. The 
immunostaining for both MMP14 and HIF1α showed that within atheromas their expression 
was particularly located in the neovasculature, which is indicative of a role in angiogenesis (Figs 
25, 26A and 26B). 
 
The investigations on the functional effects of MMP14 showed that hypoxic endothelial cell 
migration and proliferation are attenuated with HIF1α knockdown or simvastatin treatment. 
The results further showed that the attenuation of migration and proliferation by simvastatin is 
via a HIF1α-dependent effect (Fig. 32).    
 
Simvastatin inhibition of HIF1α-induced MMP14 expression was shown to significantly 
attenuate hypoxic migration and proliferation of endothelial cells (Fig. 32). This both supports 
and conflicts with previous studies  on the effect of simvastatin on migration and proliferation 
302. The use of 0.1µM simvastatin has previously been reported to significantly attenuate 
migration in melanoma cells 146, which is a similar finding to the research presented here. My 
research confirms that the inhibition of hypoxic migration occurs in a HIF1α-dependent manner 
(Fig. 32B).  
 
Simvastatin has been shown to significantly attenuate atrial myofibroblast proliferation at 
concentrations ranging from 0.1-1µM 307. This is in line with this study whereby I have shown an 
attenuation of proliferation by 0.1µM simvastatin (Fig. 32C).  However, it has also been shown 
that simvastatin use on HUVECs at concentrations from 1µM has no effect on the proliferation 
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capacity 302. This contradicts the current findings presented here.  It is known that statins are 
pleiotropic and exert different effects at different concentrations, therefore the discrepancy in 
results may be due to the increased simvastatin dosage used. Also the use of the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to measure proliferation 
instead of the BrdU assay may have led to differences in observations as it is a different 
technique used which measures metabolic rate rather than DNA synthesis 308.   
 
5.6 MMP14 Inhibition Decreases Proliferation and Migration in Hypoxia 
 
It is well known that the matrix metalloproteinases have vital roles in migration and 
proliferation 309. Our migration assays incorporating the MMP14 inhibitory antibody have shown 
that inhibiting MMP14 significantly reduces hypoxic cell migration and proliferation in our 
scramble-controlled cells (Fig. 33). This confirms that MMP14 has an important role in cell 
migration 216. This effect is not seen in our HIF1α knockdown cells and therefore shows MMP14-
driven hypoxic migration is governed by HIF1α.  
 
MMP14 inhibition experiments have also shown that the inhibition of HIF1α-dependent 
migration by simvastatin is driven through MMP14. This is due to the cells grown with 0.1µM 
simvastatin and the MMP14 inhibitor having no effect in comparison to the cells grown in the 
presence of the MMP14 inhibitor alone (Fig. 33B).  
 
Previous research has shown that MMP14 plays an important role in proliferation as when 
MMP14 is silenced there is a marked reduction in proliferation of glioma cells 310. Here, I have 
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also shown that the inhibition of MMP14 can significantly attenuate proliferation in endothelial 
cells (Fig. 33C).  
 
MMP14 is known to be heavily involved in cancer cell migration through the ECM during 
metastasis 216 . MMP14 is located on the leading edge of the invadopodia during cell migration. 
This allows for MMP14 to drive migration whilst also degrading the ECM to create a path for the 
cell to migrate through 311. As well as cleaving the ECM, MMP14 is able to promote migration 
through the activation of cell surface molecules such as CD44, integrin alpha v integrins and 
tissue transglutaminase 312. The effects of inhibiting MMP14 on migration has been shown 
before in endothelial cells where it was shown that siRNA targeted towards MMP14 disrupted 
migration and eventual tubulogenesis.  
 
The use of the MMP14 inhibitory antibody, rather than an MMP inhibitor, was used to ensure a 
specific inhibition of MMP14 only. Many MMP inhibitors are broad MMP inhibitors which 
therefore would have off target effects what were unwanted for this research. There has been a 
specific inhibitor developed for MMP14, peptide G, which has shown promise in inhibiting 
cancer cell migration an invasion in vitro at high concentrations 313.  My research however, used 
an antibody as an inhibitor of MMP14 to specifically target the catalytic domain which had 
proved effective in previous publications 271.  
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5.7 Simvastatin Reduces Angiogenesis in a HIF1α-dependent Manner 
 
The inhibition of migration and proliferation by simvastatin indicated that there may be a more 
important physiological role in the inhibition of angiogenesis. Here the ex vivo aortic ring assay 
has shown that the addition of 0.1µM simvastatin inhibits hypoxia-induced angiogenesis in a 
HIF1α dependent manner, decreasing sprout formation by around 25% (Fig. 34).  
 
This finding is of importance, as atheromas contain hypoxic regions which lead to the 
upregulation of HIF1α and, in turn, angiogenesis. The new vasculature leads to plaque 
disruption and therefore increases the likelihood of plaque rupture. Statins have been known to 
stabilise atheromas and prevent neovascularisation 314. My research has shown that this may be 
due to an inhibition of HIF1α and, therefore, angiogenesis.  
  
Previous research has shown that in vitro assays with statins increase angiogenesis at 
concentrations ranging from 1-10µM. However in a similar finding to us when the statins are 
added to aortic ring cultures there is an inhibition of angiogenesis seen 315. It is suggested that 
this may be due to a modification of the junction proteins that interact between endothelial 
cells, whereby they are upregulated in ex vivo assays preventing sprouting from intact cells but 
promote tube formation in vitro by encouraging cell-cell interaction 315. The findings that are 
produced here complement the previous research showing that in ex vivo angiogenesis assays 
simvastatin inhibits sprouting of endothelial cells.  
 
Interestingly, it has also been found that statins are able to promote angiogenesis in vivo 316, 
which has been suggested to be due to activation of the Rho and Akt pathways, as well as 
through increasing endothelial progenitor cell mobilisation 317.  There are disparate findings 
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with the use of statins and their role in angiogenesis. Statins have been shown to have biphasic 
effects on angiogenesis whereby at lower concentrations, less than 0.1µM, they promote 
angiogenesis and at concentrations greater than 0.1µM they inhibit angiogenesis 126. This falls in 
line with data presented here where concentrations of 0.1µM have shown that simvastatin is 
able to inhibit angiogenesis (Fig. 34).  
 
The disparate findings with the use of statins also seem to be related to the experimental 
conditions with either hypoxia, normoxia or other stimuli used and the type of assay that is 
performed 302,315. The same concentrations of statins have been shown to promote tube 
formation in vitro whereas they inhibit angiogenesis ex vivo 315. In this study the aortic ring ex 
vivo angiogenesis assay has been used and shown that 0.1µM simvastatin inhibits angiogenesis 
in hypoxia via a HIF1α dependent method.  
 
5.8 Simvastatin and HIF1α Knockout Reduce MMP14 Expression in Immature Endothelial 
Cells Perturbing Angiogenesis 
 
The effect of both 0.1µM simvastatin and HIF1α knockdown have shown to inhibit the 
expression of MMP14 on new microvessels (Fig. 35). As well as this, it has been shown that 
aortic ring cultures from HIF1α knockout mice, and wildtype controls, incubated with 0.1µM 
simvastatin have perturbed sprouting. On imaging the aortic ring sprouts which were stained 
for MMP14 it has become clear that hypoxia leads to an increase in MMP14 levels of sprouts in 
wildtype mice. However, this is attenuated in HIF1α knockout mice and wildtype aortas treated 
with 0.1µM simvastatin (Fig. 35). This result shows that the increased angiogenesis is due to 
increased MMP14 levels as compared with normoxia, simvastatin-treated and in KO mice. 
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Furthermore, this shows that the MMP14 increase is due to HIF1α upregulation which is 
perturbed by simvastatin. 
 
MMP14 is known to promote angiogenesis and may have an important role in promoting 
neovascularisation into the atheromatous plaque 198,199,234,235. MMPs have been studied in 
relation to angiogenesis using aortic ring cultures before. It has been found that MMP2 and 
MMP9 are important MMPs in mediating this process and, interestingly, it has been shown that 
MMP9 is specifically located in the microvessel sprouts 318. As well as MMP2 and MMP9 other 
MMPs including MMP3, MMP10, MMP11, MMP13 and MMP14 have also been shown to be 
produced in aortic ring cultures 319. However not all of these MMPs have a direct role on 
angiogenesis, such as MMP11 which has no effect on vessel sprouting 320.  
 
MMP14 is known to be an inducer of angiogenesis via both ECM degradation and growth factor 
activation 234,235. With defective angiogenesis seen in MMP14 knockout mice, the importance of 
MMP14 in inducing angiogenesis is paramount 199. The aortic rings presented here have shown 
that reduced MMP14 expression by simvastatin and HIF1α knockout reduces 
neovascularisation. This adds extra emphasis to the importance of MMP14 in inducing 
angiogenesis.  
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5.9 MMP14 Inhibition Attenuates VEGF-induced Angiogenesis in a HIF1α-dependent 
Manner 
 
The inhibition of MMP14 expression in aortic ring cultures has confirmed that MMP14 is 
required for sprout formation in hypoxic conditions (Fig. 36). Interestingly the addition of 
simvastatin to aortic ring cultures grown with the MMP14 inhibitor did not affect sprout 
formation in comparison to those without the MMP14 inhibitor (Fig. 36). This shows that 
simvastatin decreases the formation of new blood vessels through inhibition of MMP14. With 
the antibody-based inhibition of MMP14, any upstream inhibition of simvastatin on MMP14 
expression would not have an additive effect on inhibiting neovascularisation. If a decrease was 
seen however then it would suggest that simvastatin is acting in other mechanisms.  
 
The defective vasculature seen in MMP14 knockout mice, leading to premature death, confirms 
that MMP14 is vital in neovascularisation 199. The use of broad spectrum MMP inhibitors such as 
batimastat and marimastat have been shown before to block the angiogenic potential of aortic 
rings in collagen gel cultures 318. More specifically, the use of MMP14-null mice aortic rings have 
shown a complete attenuation of sprout formation198. In relation to this finding, other research 
has found that MMP14 is required for migration through the collagen matrix due to its location 
at the invadopodia of migrating cells providing a path clearing mechanism 321. The inhibition of 
MMP14 though an inhibitory antibody, 0.1µM simvastatin, or HIF1α knockout leads to 
decreased sprout formation from aortic ring cultures, thus confirming the importance of 
MMP14 in hypoxic angiogenesis. 
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5.10 Simvastatin reduces in vivo VEGF-induced angiogenesis via  a HIF1α-dependent 
Mechanism 
 
The ex vivo angiogenesis models showed that simvastatin reduced neovascularisation in a HIF1α 
dependent mechanism through the inhibition of MMP14. In order to determine if these results 
were replicated in vivo, the sponge angiogenesis assay was performed. This showed that 
simvastatin significantly attenuated neovascularisation in a HIF1α-dependent manner (Fig. 37).  
 
This is in line with previous research whereby the use of simvastatin inhibited angiogenesis 
when used at the same concentration, 10mg/kg per day 322.  The use of simvastatin at this 
concentration has also showed beneficial effects in reducing the neointimal thickening of 
atherosclerosis 323. This is known as a relatively low dose of simvastatin and therefore falls in 
line with the rest of the research at the in vitro and ex vivo level.  
 
Perturbed wound healing and neovascularisation has been shown in endothelial cell specific 
HIF1α knockout mice. These mice used a Tie2 Cre+ system rather than Tie1 Cre+ but the same 
HIF1αfl/fl mice were used for the crossing as we have used here 324. This research falls in line with 
our research whereby reduced angiogenesis was seen in endothelial cell specific HIF1afl/fl mice. 
This shows the importance of endothelial HIF1α in the promotion of angiogenesis.  
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5.11 Future Work 
 
Although my study has shown that simvastatin has a beneficial effect on the prevention of 
angiogenesis there would need to be further work in order to relate this to clinical findings. A 
potential difficulty in the recommendation for the use of simvastatin to stabilise atheromas is 
that there is a great deal of variability in the responses of individuals to statins. This can be 
linked to pharmacogenetics whereby genome wide association studies have shown that SNPs in 
the APOE and LPA genes correlate with differing cholesterol-lowering response to statins 325.  
 
Simvastatin is unlikely to exert its effects directly on HIF1α and is likely to affect upstream 
proteins and genes which subsequently effect HIF1α expression. A possible mechanism of 
action could involve eNOS, which is known to be upregulated by simvastatin 95, and 
subsequently an increase in nitric oxide production. The increase of nitric oxide upregulates 
PHD2 expression, by affecting random oxygen species production 326, which will in turn inhibit 
HIF1α. Thus, it could be this pathway that simvastatin is utilising to affect HIF1α regulation of 
MMP14 (Fig. 38). 
 
 
 
Fig. 38 – A possible mechanism for Simvastatin regulation of MMP14 via 
modulating HIF1α activity 
P a g e  | 184 
 
It would be of interest to see if the proposed pathway of simvastatin’s inhibition of MMP14 is 
correct (Fig. 38). Knockdown of eNOS would allow for the identification if simvastatin is working 
along the proposed pathway. If similar effects are seen as those with simvastatin treatment, 
then it would confirm that simvastatin is acting upon this pathway. If however different results 
are seen it would show that simvastatin is affecting MMP14 activity via modulating HIF1α in a 
different way.   
 
In order to confirm the inhibition by simvastatin is due to the inhibition of HMG-CoA reductase, 
and therefore isoprenoid intermediates, mevalonate rescue studies could be used. These 
experiments bypass the actions of simvastatin and should return HIF1α and MMP14 expression 
back to base-line levels if simvastatin is working through the blockage of isoprenoid 
intermediates.  
 
Other cell types, such as monocytes and smooth muscle cells, are known to express MMP14 
within the atherosclerotic plaque 196,236 and may also play a role in the promotion of 
angiogenesis via a MMP14 mediated response. My research has focussed on endothelial cells 
but I have also shown that HIF1α is expressed in macrophages. Therefore simvastatin may also 
play a role in dampening MMP14 levels in a HIF1α dependent manner in other cell types, thus 
creating a more stable atheroma. However simvastatin is known to have tissue-specific 139 and 
microenvironment-specific responses 302 and therefore the expression pattern seen could either 
correlate or contradict my findings with HUVECs.  
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There are other potential transcription factors that are known to increase MMP14 activity, 
including Sp-1 and Egr-1 209,210. It would be interesting to know whether there is any interaction 
between HIF1α and the other transcription factors in upregulating hypoxic MMP14 expression. 
Ways of identifying any interactions could include co-immunoprecipitations and luciferase 
assays incorporating mutations in Sp-1 and Egr-1 sites of the MMP14 promoter in conjunction 
with HIF1α expression plasmids.  
 
In order to assess simvastatin’s effects on angiogenesis in vivo another technique could be used 
which would also allow for detection of MMP14 levels, following immunostaining. The mouse 
injury angiogenesis model assesses wound repair of the aorta following a wire being passed 
through the blood vessels. Over a predetermined period, the vessel would be allowed to repair 
before analysis of the effects. The tissue could be sectioned and stained for their protein 
expression.  
   
Another study could utilise the crossing of the HIF1αfl/fl Tie1 Cre+ mice with APOE KO mice, 
which is a recommended model for the study of atherosclerosis in mice due to the lesions 
having similarities with humans 264. This would allow for the identification of neovascularisation 
in vivo within a developing atheroma and would also elucidate more clinically relevant 
information.  
 
 
 
 
P a g e  | 186 
 
6. Conclusion 
 
 
My research has shown that MMP14 protein expression is upregulated in hypoxic conditions 
through direct HIF1α interaction with the MMP14 promoter. The addition of simvastatin 
significantly attenuates this upregulation, possibly through increased degradation of HIF1α. This 
has further physiological implications in relation to angiogenesis which is perturbed by 
simvastatin through the downregulation of MMP14 via a HIF1α-dependent mechanism.  
 
This finding is of relevance to the use of statins in the treatment of atherosclerosis, which are 
known to stabilise atheromas 120.  The expression of MMPs varies between stable and 
vulnerable atheromas with the upregulation of some MMPs being characteristic of a vulnerable 
plaque 240. MMPs such as MMP9, MMP12 and MMP14 have been shown to have a significantly 
increased expression in the vulnerable plaques in comparison to stable plaques 240. As well as 
MMP levels, TIMPs have also been shown to have altered expression between stable and 
vulnerable atheromas with TIMP3 found to have a decreased expression in more vulnerable 
plaques 240.  This is important as TIMP3 is a MMP14 inhibitor, and TIMP3 knockout is known to 
intensify the formation of atherosclerosis through the increase in the formation of invasive 
foam cells 197.  Other research has also shown that microRNAs have roles in the formation of 
vulnerable plaques with mir-712 being shown to downregulate TIMP3 and therefore lead to an 
increase in MMP14 327. Taken with my research it would suggest that simvastatin downregulates 
MMP14 and could therefore be used to reduce the risk of progression to a vulnerable plaque.   
 
With the increased expression of several MMPs being related to the formation of vulnerable 
plaques, the use of MMP inhibitors could be worthwhile. MMP inhibitors, however, have had 
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mixed outcomes when used in clinical trials with some studies being stopped prematurely due 
to their use leading to poorer survival outcomes 328. New MMP inhibitors are being produced in 
order to counteract some of the issues seen with conventional MMP inhibitors, such as using 
different zinc binding domains to interact with the MMP catalytic site 329. However, there is no 
guarantee that these new inhibitors will pass clinical trials. Statins are already widely prescribed 
in order to treat cardiovascular diseases and, although they have side effects, they are approved 
by FDA. Therefore, simvastatin could potentially have a more important role in the inhibition of 
MMP14 in disease.    
 
In conclusion, I have shown a regulation of MMP14 by HIF1α with attenuation by simvastatin. 
The upregulation is mediated through direct binding of HIF1α to the MMP14 promoter HIF 
binding sites. The attenuation of MMP14 by simvastatin is via a HIF1α-dependent mechanism 
and has further implications in limiting angiogenesis. In relation to atherosclerosis this could 
potentially be a mechanism for the stabilisation of atheromas by simvastatin. Future research 
could utilise murine models of atherosclerosis to further identify the effects of simvastatin and 
relate this to clinical situations.  
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Appendix I 
 
Appendix I – A table of buffers used in the experiments showing their formulation and the 
application that they are used for. The buffers are presented in alphabetical order.  
Name of Buffer Formula Application Reference 
ChIP Digestion Buffer 0.15M EDTA, 0.6M Tris-HCl pH 6.5 
and 0.625mg/ml Proteinase K  
ChIP Assay Merck 
Millipore 
UK 
ChIP Dilution Buffer 0.01% SDS, 16.7mM Tris-HCl pH 
8.0, 1.2mM EDTA, 1.1% TritonX-
100, 150mM NaCl  
ChIP Assay 268 
ChIP Elution Buffer 1%SDS, 0.1M NaHCO3 ChIP Assay Merck 
Millipore 
UK 
ChIP Lysis Buffer 1% SDS, 10mM EDTA, 50mM Tris-
HCl pH8.0 
ChIP Assay 268 
DNA Lysis Buffer 1% SDS, 50mM Tris-HCl pH 8, 
100mM EDTA, 100mM NaCl 
DNA Extraction 284 
EMSA binding buffer 2% v/v glycerol, 0.5mM MgCl2, 
0.25mM EDTA, 25mM NaCl, 5mM 
Tris, pH7.5 
EMSA  
ECL 
Reagent 
Solution 
1 
100mM Tris–HCl, pH 8.5, 2.5mM 
luminol, 400μM p-coumaric acid 
Western Blot 256 
Solution 
2 
5.4mM H2O2, 100mMTris–HCl, pH 
8.5 
High Salt Buffer 0.1% SDS, 1% Triton X-100, 2mM 
EDTA, 20mM Tris-HCl pH8.0, 
500mM NaCl 
ChIP Assay 268 
HEPES Buffered 
Saline 
20mM HEPES, 137mM NaCl, 5mM 
KCl, 6mM D-Glucose, 0.7mM 
Na2HPO4, pH 7.4 
Nucleofection 255 
Immunoprecipitation 
Buffer 
0.9M Urea, 0.2% Triton-X100, 
0.1% Dithiothreitol, 10% Lithium 
Dodecylsulphate  
 
Immunoprecipitation 330 
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LiCl Buffer 0.25M LiCl, 1% NP-40, 1% SDC, 
1mM EDTA, 10mM Tris-HCl pH 8.0 
ChIP Assay 268 
Low Salt Buffer 0.1% SDS, 1% Triton X-100, 2mM 
EDTA, 20mM Tris-HCl pH8.0, 
150mM NaCl 
ChIP Assay 268 
MLEC Medium 200ml DMEM w Glutamax Low 
Glucose (Invitrogen, UK), 200ml 
Ham’s F12 w Glutamax 
(Invitrogen, UK), 50mg Heparin, 
250mg Penicillin and 
Streptomycin, 4mM L-Glutamine, 
25mg Endothelial mitogen (AbD 
Serotech, UK), 100ml heat-
inactivated FCS 
Mouse Lung Endothelial 
Cell Preparation 
286 
PBLEC PBS, 0.1µM MnCl2, 1% Tween-20 Aortic Ring Assay  
Staining 
289 
PBS (pH 7.4) 10mM Na2HPO4, 136mM NaCl, 
2.68mM KCl, 1.76mM KH2PO4 
Cell culture, Protein 
Extraction, ChIP Assay, 
Immunohistochemistry 
242 
10X PCR Loading 
Buffer 
50mM Tris-HCl pH 7.6, 0.025% 
Bromophenol Blue, 60% Glycerol 
PCR 242 
Permeabilisation 
Buffer 
PBS + 0.25% Triton-X100 Aortic Ring Assay Staining 289 
Protease Inhibitor 
Cocktail 
1mM PMSF, 1 µg/ml Leupeptin , 1 
µg/ml Aprotinin, 1 µg/ml 
Pepstatin 
ChIP Assay, Protein 
Extraction, Protein 
Quantification 
249 
Radio 
Immunoprecipitation 
Assay (RIPA)  Buffer 
0.1% SDS, 50mM Tris-HCl pH7.4, 
150mM NaCl,  0.5% sodium 
deoxycholate, 1% NP-40 
Protein Extraction, 
Protein Quantification 
248 
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TBST 50mM Tris-HCl pH 7.5, 150mM 
NaCl, 0.05% Tween 
Western Blot 242 
TE Buffer 20mM Tris-HCl pH 8.0, 1mM EDTA 
pH8.0 
ChIP Assay 268 
TNESV Buffer 50mM Tris-HCl pH 7.5, 1% v/v 
Nonidet P40, 2mM EDTA, 100mM 
NaCl, 10mM Sodium 
Orthovanadate, 1x Protease 
Inhibitors 
HIF1α Ubiquitination 
Assay 
331 
Western Blot Running 
Buffer 
0.1% SDS, 25mM Tris-HCl, 192mM 
Glycine 
Western Blot 242 
Western Blot 
Transfer Buffer 
25mM Tris-HCl, 192mM Glycine, 
20% Methanol 
Western Blot 242 
Western SDS Loading 
Buffer 
1% SDS, 31.25mM Tris-HCl pH 6.8, 
50% Glycerol, 5% β-
Mercaptoethanol, 0.05% 
Bromophenol Blue 
Western Blot 242 
Western Stripping 
Buffer 
2% SDS, 62.5mM Tris-HCl pH 6.8, 
100mM β-Mercaptoethanol 
Western Blot 242 
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Appendix II 
Appendix II – A Table of Primers and Procedures they were used for 
 
Primer Target Procedure Orientation Nucleotide Sequence 
MMP14 
Promoter 
ChIP Assay 
Forward CAGCCTGCACCACAAAAAG 
Reverse CTTCTCCCACAGCCTCTCCT 
Mouse HIF1α HIF1α Genotyping 
Forward CGTGTGAGAAAACTTCTGGATG 
Reverse AAAAGTATTGTGTTGGGGCAGT 
Cre 
Recombinase 
Cre Recombinase 
Genotyping 
Forward GCCTGCATTACCGGTCGATGCAACGA 
Reverse GTGGCAGATGGCGCGGCAACACCATT 
 
